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3Abstract
X-linked Severe Combined Immunodeficiency (SCID-X1) is an immunopathy caused by
a mutation of the common gamma chain (γc) gene, IL2RG, which results in a lack of T
cells, NK cells and with dysfunctional B cells. Current gene therapy methods involve the
addition of a correct γc gene via integrating viral vectors. However, these current non-
targeting gene addition strategies can result in transformation of the cell. A novel
solution to this problem is met by targeted gene correction via homologous
recombination stimulated by a site specific cleavage event caused by zinc finger
nucleases (ZFN) within the disease gene.
A γc deficient mouse has been created by replacing the murine il2rg locus with a
mutated human IL2RG containing a point mutation frequently seen in SCID-X1
patients. The mutant human IL2RG is transcribed and initial analysis of this new SCID-
X1 model has revealed a phenotype mirroring γc gene knockout mice. Lineage negative 
bone marrow cells from these mice, transduced with integrating lentiviral vector
encoding functional IL2RG can reconstitute the immune cells in the Rag2-/-γc-/- double
knockout SCID mouse model. Therefore the humanised mouse model of SCID-X1 can
be corrected and is an appropriate platform to assess the efficiency of various gene
targeting and correction strategies for the human mutation including ZFN induced
homologous recombination.
We have successfully achieved targeted homologous recombination in both a human T
cell SCID-X1 cell line model and the humanised mouse embryonic stem cells with IL2RG
specific ZFN.
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1 Introduction
This introduction outlines the cause of the genetic disorder X-linked severe combined
immunodeficiency and discusses treatment for the disease in the context of gene
therapy. This will lead to the potential for targeted gene correction strategies, in
particular, homologous recombination stimulated by zinc finger nucleases.
1.2 The common gamma chain and Severe Combined Immunodeficiency
X-linked severe combined immunodeficiency (SCID-X1) occurs as a result of the loss of
signalling by interleukins vital for immune system development. The affected
individuals are severely immuno-compromised with no T cells, no NK cells and
defective B cells. Consequently, the individual is not protected from infection and
prone to disease caused by common opportunistic pathogens (Buckley 2004). The
disease incidence could be up to 1 in 60000 births (Cavazzana-Calvo, Lagresle et al.
2005) and if left untreated, the patient will die at infancy (Fischer, Le Deist et al. 2005).
SCID-X1 is caused by dysfunctional common cytokine receptor gamma chain (γc) 
caused by mutations in its gene, IL2RG, resulting in an inherited disorder which follows
an X-linked recessive pattern occurring in males.
1.2.1 IL2RG
Linkage analysis revealed the gene for the transmembrane protein, γc, to be located 
on chromosome Xq13.1 (de Saint Basile, Arveiler et al. 1987; Noguchi, Yi et al. 1993;
Puck, Deschenes et al. 1993) and consist of 8 exons. The extracellular domain contains
two pairs of conserved cysteine residues shared between exon 2 and 3 and a
conserved WSXWS motif located in exon 5. Both motifs are typically found in the
cytokine receptor super family. Exon 6 encodes the transmembrane domain and the
cytoplasmic tail is encoded by exons 7 and 8 (Noguchi, Adelstein et al. 1993).
γc was first discovered for its association with the interleukin-2 Receptor (IL2R) subunit 
IL2Rβ (Takeshita, Asao et al. 1990; Takeshita, Ohtani et al. 1992) which achieve 
cytoplasmic signalling on heterodimerisation (Nakamura, Russell et al. 1994). Together
with IL2Rα the high affinity receptor complex, IL2Rαβγ, binds IL-2 which in turn induces 
tyrosine phosphorylation of Jak1 and Jak3 (Miyazaki, Kawahara et al. 1994) located on
the cytoplasmic tails of IL2Rβ and γc respectively (Russell, Johnston et al. 1994). This 
recruits STAT proteins via their Src homology (SH2) domains, which are in turn
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phosphorylated giving rise to STAT dimerisation and subsequent translocation to the
nucleus where the dimer is recruited by an IFNγ activation sequence (GAS) motif and in 
the presence of other transcription factors, regulates transcription (Leonard and
O'Shea 1998; Leonard 2001) (Figure 1.1a). Jak3 is only activated by the presence of γc 
(Leonard and O'Shea 1998) and mutations in its gene also give rise to
immunodeficiencies with the same immune cell profile as SCID-X1 (Candotti, Oakes et
al. 1997). The immune cell profile of SCID-X1 patients could not be attributed to
disruptions in IL-2 signalling alone as normal absolute numbers and percentages of
circulating CD4+ and CD8+ T cells are observed in humans with IL-2 deficiency (Chatila,
Castigli et al. 1990). This observation was supported by the normal development of
thymocytes in IL-2 deficient mice (Schorle, Holtschke et al. 1991).
The IL2R receptor subunit γc was subsequently found be common to the receptor 
complexes for IL-4 (Kondo, Takeshita et al. 1993; Russell, Keegan et al. 1993), IL-7
(Noguchi, Adelstein et al. 1993; Kondo, Takeshita et al. 1994), IL-9 (Kimura, Takeshita
et al. 1995), IL-15 (Giri, Ahdieh et al. 1994) and IL-21 (Asao, Okuyama et al. 2001) each
contributing to immune cell function. IL-2 was originally identified as a T cell growth
factor (Morgan, Ruscetti et al. 1976), is involved in further regulation of T cell
populations (Liao, Lin et al. 2011) and is in-disposable for inducing T regulatory cells
(Malek and Bayer 2004). IL-4 was first identified as a B cell growth factor (Howard,
Farrar et al. 1982), is involved in B cell development including immunoglobulin class
switching to IgE in humans and is implied in thymic development (Paul 1991). IL-7 was
also identified for its B cell proliferation properties in mice (Namen, Lupton et al. 1988)
however patients with IL7Rα deficiency lack T cells but their B cell and NK cell 
populations remain intact (Puel, Ziegler et al. 1998). IL-9 was first observed in mice and
originally characterized as a T cell growth factor (Van Snick, Goethals et al. 1989) and
subsequently shown to prolong human T cell activation in vitro (Renauld, Goethals et
al. 1990). IL-15 was first observed to stimulate peripheral blood mononuclear cells in
humans (PBMC) (Grabstein, Eisenman et al. 1994) and studies in IL-15 knockout mice
have revealed its potential in NK cell and CD8+ T cell development (Lodolce, Boone et
al. 1998). IL-21 was investigated due to its structural similarities with IL-2, IL-4 and IL-
15 (Asao, Okuyama et al. 2001) and was found to induce proliferation in human B cells
lines (Habib, Senadheera et al. 2002) and IL12R was later found responsible for human
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B cell differentiation in vivo (Recher, Berglund et al. 2011). It is the wide application of
the γc in these cytokine receptors and the fact γc is constitutively expressed on all 
peripheral blood leukocytes (Takeshita, Asao et al. 1992) that the immune system is
severely compromised in SCID-X1 patients.
SCID-X1-causing mutations including point mutations, insertions and deletions have
been found throughout the 8 exons of IL2RG (Figure 1.1b). Mutations were identified
in 23 of 87 unrelated patients in the WSXWS containing exon 5. This exon is host to
mutational hotspots including a CpG dinucleotide mutated in 11 of the patients
studied. 5 were point mutation C690T causing amino acid code change R226C and 6
were G691A causing R226H (Puck, Pepper et al. 1997). The amino acid at position R226
is conserved between human, dog (Henthorn, Somberg et al. 1994) and mouse (Cao,
Kozak et al. 1993) IL2RG. Interestingly, a larger T cell population is observed as a result
of the R226C conversion than R226H (Pepper, Buckley et al. 1995; Kumaki, Ishii et al.
2000). The mutation G691A is the common SCID-X1 mutation considered for targeted
correction in this project.
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Figure 1.1 The common gamma chain (γc) at the cell surface and SCID-X1 associated
mutations.
(a) A schematic of the downstream signalling events on IL-2 binding at the receptor
resulting in the signalling pathway whereby Jak1 and Jak3 associate with and phosphorylate
STAT which dimerises, enters the nucleus and is recruited by a GAS motif in proximity to a
transcriptional start site. Figure adapted from Leonard, O’Shea 1998 (Leonard and O'Shea
1998; Maeder, Thibodeau-Beganny et al. 2008). (b) A map of mutations observed in SCID-X1
patients www.research.nhgri.nih.gov/scid/IL2RGbase with the location of the G691A
mutation (red arrow).
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1.3 Treatment of SCID-X1
The most successful current treatment for SCID-X1 is a bone marrow transplant (BMT)
from which donor haematopoietic stem cells (HSC) can provide a constant source of
immune cells and due to the absence of immune cells in the recipient, transplant
rejection is avoided. Whilst the patient waits for a transplant, prophylaxis is
administered including antimicrobial drugs and immunoglobulin therapy. However,
obtaining an identical HLA match is not always possible as there is not always a sibling
who is a fully matched donor. Haploidentical (half a tissue match) bone marrow from a
parent or an unrelated donor can be used and the incidence of graft versus host
disease (GVHD) reduced by depleting the donor cells of the T cell compartment before
transplantation (Reisner, Kapoor et al. 1983). In a report of European SCID (all severe
combined immunodeficiency) cases treated with haematopoietic stem cell therapy
(HSCT), identical donor matches were found to be significantly more successful at
restoring a SCID patient’s immune system than haploidentical, T cell depleted donors
(Antoine, Muller et al. 2003). In a later comparison, survival rates were seen to be
>90% for fully matched HSCT and 75% for haploidentical T cell depleted donor bone
marrow (Cavazzana-Calvo, Lagresle et al. 2005). In another study, transplants in the
surviving recipients were able to restore T cell numbers to normal levels and increase
NK cell populations however 62% of patients still required immunoglobulin
replacement therapy (Buckley, Schiff et al. 1999). Due to limited availability of
matched donors for HSCT and ineffective engraftment of donor derived B cells,
therapeutic strategies progressed to gene therapy by inserting a functional copy of
IL2RG into the genome of the SCID-X1 patient’s haematopoietic stem cells by retroviral
gene transfer.
1.3.1 HSCT
The multipotent quality of HSC has been demonstrated by the repopulation of all the
blood cell lineages in animal models. By using the HSC cell surface marker CD34, CD34+
cells isolated from bone marrow have returned bone marrow cellularity to normal in
lethally irradiated baboons (Berenson, Andrews et al. 1988) and human bone marrow
CD34+ cells achieved chimeric immune cell populations when transplanted into sheep
in utero (Srour, Zanjani et al. 1993). Humans receiving autologous (Civin, Trischmann et
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al. 1996) or haploidentical (Link, Arseniev et al. 1996) CD34+ cells also achieved
successful immune cell reconstitution.
CD34+ cells make up approximately 1% of human bone marrow and <10% of these are
lineage negative (lin-) precursor cells, capable of differentiation into various blood cell
types. Such cells from human sources were capable of restoring long term,
multilineage engraftment in sheep (Civin, Almeida-Porada et al. 1996) and NOD/SCID
mice (Bhatia, Wang et al. 1997). Although these are not the only cells capable of
haematopoietic repopulation, the small fraction of bone marrow capable of
maintaining the blood can be exploited in HSCT.
1.3.2 Retroviral vectors
Vectors designed to modify a patient’s stem cells by the incorporation of a therapeutic
gene are based on members of the retrovirus family due to their ability to integrate
their genetic payload into the host’s genome (Provirus). The main candidates for
retroviral vector design to deliver IL2RG have been gammaretroviruses and
lentiviruses. The single stranded RNA genomes of these two viruses are very similar
and the basic processes involved from cell entry to provirus integration in brief are
described in Figure 1.2a.
Retroviral vectors are designed to keep the essential proteins required for packaging
and delivery of the viral genome, but any non-essential accessory proteins including
those responsible for their disease profile are removed. Importantly, the vectors have
been made replication defective by splitting the genome into separate parts, which
can then be individually expressed by plasmid vectors or in specifically engineered
packaging cell lines. The gag polyprotein is responsible for the structural proteins for
the protein matrix, capsid and nucleocapsid. The Gag-Pol polyprotein contains reverse
transcriptase, necessary for viral ssRNA processing into dsDNA, integrase, for viral DNA
integration into the host genome and protease. The env protein is involved in viral-cell
membrane fusion. By isolating the gag, pol and env genes and permitting their
expression with accompanying promoters, the viral proteins generated can package
the separate, LTR flanked ssRNA carrying the therapeutic gene, but renders the
resulting particle unable to generate further virions (Figure 1.2b). Once the viral
genome has been reverse transcribed into dsDNA and has entered the nucleus of the
cell, this nucleic acid is integrated into the host genome aided by the viral enzyme,
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integrase. The therapeutic gene is now expressed due to the promoter/enhancer
elements of the viral LTR, additional modifications can remove this feature from the
LTR, resulting in a self-inactivating (SIN) vector where therapeutic gene expression is
mediated by a provided promoter. This multipart genome also avoids the risk of
recombining with other wild type retroviruses that may be present in the target cell.
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Figure 1.2 The life cycle of a retrovirus and the essential proteins for lentiviral production.
(a) The env protein makes contact with the host cell and the membrane fuses with the host
membrane delivering the capsid into the cell’s cytosol. The viral core is uncoated and reverse
transcription is initiated in order to convert the single stranded (ss)RNA genome into double
stranded (ds)DNA. This now enters the nucleus where it is integrated into a host
chromosome by the viral integrase. Now the LTR initiates transcription of the gag, pol and
env genes which are required for packaging and viral processes. The proteins assemble at the
host membrane and the ssRNA contains a packaging signal necessary for virion assembly. The
virion leaves the cell by budding off. (b) Viral vector plasmid constructs containing the LTR
flanked transgene with packaging signal or the gag and pol genes or the env gene.
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1.3.3 Retroviral gene therapy of SCID-X1
By introducing a transgene via retroviral vectors into the genome of multipotent stem
cells from a patient, it is possible to repopulate tissue with corrected cells without the
complications from mismatched tissue. SCID-X1 is an ideal candidate for such ex vivo
treatment as it is a monogenic disorder and there is no immune system to recognise
the newly incorporated protein as foreign thus avoiding challenge of the adaptive
immune system towards the corrected cells. Furthermore, the incorporated γc should 
provide a selective advantage, due to the growth signals mediated by IL-2 binding at
the cell surface, as demonstrated by the functional T cells seen in a patient who
experienced a spontaneous mutation reversion in a single T cell precursor (Stephan,
Wahn et al. 1996).
Three individual groups demonstrated that they were able to reconstitute the T, B and
NK cells lacking in γc deficient mice by transducing bone marrow with retroviral 
vectors to deliver human IL2RG (Lo, Bloom et al. 1999) or murine il2rg (Otsu, Anderson
et al. 2000; Soudais, Shiho et al. 2000). All 3 studies demonstrated long term
reconstitution with no toxic effects.
Gene therapy trials have been carried out on infants with no HLA-identical donor using
gammaretroviral vector mediated gene transfer of IL2RG to autologous CD34+ HSC for
subsequent re-infusion. 10 patients were recruited in Paris (Cavazzana-Calvo 2000;
Hacein-Bey-Abina, Le Deist et al. 2002; Cavazzana-Calvo, Lagresle et al. 2005), 10 in
London (Gaspar, Parsley et al. 2004) and 1 in Sydney who had a T-B+NK+ phenotype
(Ginn, Curtin et al. 2005). Of the total 21 SCID-X1 patients, 20 developed T and NK cells
plus functional B cells. Furthermore, 15 patients had polyclonal T cell populations
reaching normal levels (Gaspar, Parsley et al. 2004) from a limited number of
transduced progenitor cells (Schmidt, Hacein-Bey-Abina et al. 2005). The level of
reconstitution reflected the number of transduced CD34+ cells the patient received.
The French trial observed clearance of Varicella zoster virus, responses to vaccination,
immunoglobulin production and the development of a normal size thymus in their
patients. Their patient who did not develop immune cells as a consequence of gene
therapy had accumulated the transduced cells in their spleen and subsequently
underwent a BMT from an unmatched donor (Cavazzana-Calvo, Lagresle et al. 2005).
The British trial observed responses to vaccination and Candida and immunoglobulin
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production (Gaspar, Parsley et al. 2004). The Australian patient initially responded well
but after an upper respiratory tract infection and neurological complications was
subsequently treated by BMT from an unrelated donor (Ginn, Curtin et al. 2005).
The overall observations of the clinical trials for retroviral gene therapy of SCID-X1
holds much promise for permanent disease treatment with a better success rate than
haploidentical HSCT. Unfortunately, due to the uncontrolled integration of these viral
vectors, 5 patients went on to develop a lymphoproliferative disease 2-6 years after
gene therapy.
1.3.4 Severe adverse effects of the SCID-X1 clinical trials
The key events leading to T cell acute lymphoblastic leukaemia (T-ALL) in these
patients resulted from insertional mutagenesis due to the viral vector transformation
of the treated cells. 4 patients were reported from the French trial (Hacein-Bey-Abina,
von Kalle et al. 2003; Marshall 2003; Check 2005; Baum 2007) and 1 from the British
trial (Howe, Mansour et al. 2008). Longitudinal sample analysis revealed that the copy
number did not increase over time (Hacein-Bey-Abina, Garrigue et al. 2008) and
Southern blots confirmed there was no presence of env, reverse transcriptase or
transposons (Hacein-Bey-Abina, Von Kalle et al. 2003) negating the possibility that the
viral vector had become capable of replication.
In 4 of these patients, the clonal expansion correlated with vector integration sites
near to or within LMO2, a gene implicated in T-ALL (Boehm, Foroni et al. 1991),
resulting in its expression (Hacein-Bey-Abina, Garrigue et al. 2008; Howe, Mansour et
al. 2008). A second insertion site was also found in one patient located near the T-ALL
associated gene BMI1 resulting in up-regulated gene expression. The remaining patient
who developed cancer in the absence of LMO2 interference had a vector integration
site upstream of the transcription start site of the oncogene CCND2 and quantitative
mRNA analysis revealed high expression levels in the patient’s leukemic cells,
consistent with T-ALL patients.
As these oncogenes are not expressed in mature T cells, their expression was
attributed to the LTR viral promoter/enhancer which also appeared responsible for the
up-regulation of nearby genes (Howe, Mansour et al. 2008). This widespread enhancer
effect of the LTR was therefore considered a major determinant in the development of
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the cancer. In addition, the LTR of Moloney murine leukemia virus (MoMLV) on which
this therapy vector was based has been shown to activate genes at long distances in
rats (Lazo, Lee et al. 1990). Furthermore, MoMLV has a preference for actively
transcribed genes with an insertional profile near transcriptional start sites (Wu, Li et
al. 2003). Further study into the relationship of the LMO2 gene and T cell development
revealed that LMO2 is actively transcribed in CD34+ HSC and down regulated during T
cell development, this may have been overridden as a consequence of the proximal
LTR compounded by the pressure for T cell proliferation (Pike-Overzet, de Ridder et al.
2007).
Both groups observed that the leukemic clones had acquired oncogenic
rearrangements associated with T-ALL, indicative of a multistep pathway leading to
tumorigenisis and a reasonable explanation for cancer progression considering the late
onset of presentation. With the suggestion that these cancers were not due to a single
transformation event, it was speculated that IL2RG itself aided cancer progression as it
has been shown to be dysregulated alongside Lmo2 in a proportion of murine
leukaemias (Dave, Akagi et al. 2009) and thymic lymphomas develop in mice
overexpressing γc (Woods, Bottero et al. 2006). This theory was subsequently 
confounded with the observation that an excessive amount of retroviral vector was
used to achieve high expression, increasing the likelihood of insertional mutagenesis,
IL2RG had not been shown to be oncogenic in previous studies and Jak3 kinase was not
constitutively active in the patient leukaemias (Pike-Overzet, de Ridder et al. 2006).
It can be concluded from the SCID-X1 gene therapy clinical trials that although the
efficacy of the treatment to reconstitute the immune system was high, the long term
production of immune cells conferred by transduced multipotent HSC also included a
risk of leukaemia in approximately 1 in 4 patients as a direct result of viral vector
insertion. Consequently, all but one of these patients have responded to
chemotherapy and survived.
1.3.5 Improved retroviral vectors
Since the adverse events resulting from the retroviral vector treated cells, the LTR has
been identified as a likely candidate for pathogenicity due to its strong
enhancer/promoter properties. This has been improved with the incorporation of Self-
Inactivating (SIN) LTR which lose function after reverse transcription in the host cell
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(Figure 1.3a). By deleting the 3’ U3 sequence in the ssRNA viral genome, the
duplication event of the 3’ end in order to initiate 5’ cDNA synthesis means the dsDNA
integrated into the cell has inactive LTR ends (Yu, von Ruden et al. 1986) (Figure 1.3b).
In a comparative study SIN retroviral vectors were shown to be less likely to cause
bone marrow cell immortality in vitro than the original LTR retroviral vector (Modlich,
Bohne et al. 2006). In the absence of a viral promoter, the promoters of housekeeping
genes can be introduced such as PGK or EF1α which do not have far reaching enhancer 
activity (Zychlinski, Schambach et al. 2008) and can include regulatory elements that
confer tissue specific expression.
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Figure 1.3 Reverse transcription of HIV and the generation of the SIN lentiviral vector.
(a) Reverse transcription of the retroviral genome. Host tRNA primer anneals to the viral
genome’s (blue) primer binding site (PBS). Viral reverse transcriptase (RT) synthesises minus
strand cDNA (yellow) from the 5’ end of the genome and copies the U5 and repeat (R) sequence
of the viral genome. This minus strand disassociates and transfers to the 3’ R sequence. Minus
strand cDNA synthesis continues to copy the viral genome up to and including the PBS.
Meanwhile the RNase H activity of RT cleaves the RNA leaving the 3’ polypurine tract (PPT)
intact which then acts as a primer to synthesis the positive strand cDNA from the 3’ end of the
minus strand cDNA. The result is a dsDNA with the U3, R and U5 (LTR) sequences originating
from the 5’ end flanking the genome on either-side. (b) The self-inactivating (SIN) lentiviral
provirus. By deleting the U3 sequence in the 3’ LTR, the resulting provirus does not have
functional LTRs and allows for the incorporation of different promoters.
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Other modifications to viral vector design have been made to aid production and
transduction. In order to alter the vector’s tissue tropism, different envelope proteins
may be incorporated into the packaging vector, a process known as pseudotyping.
Where the clinical trials used the envelope of moMLV (Hacein-Bey-Abina, Le Deist et
al. 2002; Ginn, Curtin et al. 2005) or the gibbon ape leukemia virus (GALV) (Gaspar,
Parsley et al. 2004)a wider tissue tropism is asserted by the vesicular stomatitis virus
glycoprotein (VSV-G) (Naldini, Blomer et al. 1996) and is more commonly used.
Another addition was the woodchuck post-transcriptional regulatory element (WPRE)
which aids nuclear export and the accumulation of viral RNA in the cytoplasm (Donello,
Loeb et al. 1998; Popa, Harris et al. 2002) and was found to enhance viral vector titre
(Schambach, Bohne et al. 2006). All of these modifications can be applied to all
retroviruses.
HIV based lentiviral vectors are created with the same design as the Gammaretroviral
vectors but with the inclusion of their rev protein in the packaging constructs as Rev
binds the rev response element (RRE) and is thought to aid nuclear export of viral RNA
and viral encapsulation (Colleaux, D'Auriol et al. 1988) and therefore the RRE sequence
is included alongside the therapeutic gene.
Unlike Gammaretrovirues, Lentiviruses are able to transduce quiescent cells. This
makes them a more attractive candidate for gene therapy as they avoid the necessity
for cell cycle progression during ex vivo transduction which can cause the loss of stem
cell qualities and will cause cell cycle progression genes to be openly transcribed and
more accessible for vector integration. The central polypurine tract (cPPT) of HIV-1 aids
nuclear import of the viral genome (Zennou, Petit et al. 2000) and lentiviral
transduction was enhanced by the inclusion of the cPPT in the viral vector design
(Follenzi, Ailles et al. 2000). Another difference between these vectors is the
integration profile. Where MoMLV has a preference for actively transcribed genes with
an insertional profile near the transcriptional start site, HIV is more likely to insert
within the gene (Schroder, Shinn et al. 2002; Wu, Li et al. 2003). This pattern has also
been shown in MoMLV vectors and HIV based SIN lentiviral vectors (Montini, Cesana et
al. 2006). Although this integration pattern does not defy insertional mutagenesis, SIN-
Lentiviral vectors did not accelerate tumour progression in tumour prone mice
compared to the MoMLV vector. However, MoMLV is a murine leukaemia virus
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whereas HIV is not and the lack of viral promoter/enhancer in the SIN LTR is more
likely to confer the reduced incidence of cancer than it’s integration profile as HIV has
been implied in causing B-cell lymphoma by integrating upstream of the c-fes/fps
proto-oncogene (Shiramizu, Herndier et al. 1994) however this is achieved by WT virus.
Viral vector mediated gene addition strategies have proven to be beneficial due to the
long term gene expression as a result of gene insertion and although safer vector
constructs have been engineered, it cannot truly be pre-determined whether
treatment with SIN-Lentiviral vectors modified to control gene expression will prevent
pathogenic transforming events. Such events may include bystander enhancer effects
leading to proto-oncogene activation, intergenic insertion which could disrupt a
tumour suppressor gene or due to the splice donor and acceptor sites within the
integrated sequence, aberrant splicing can lead to mRNA species consisting of host
cellular mRNA fused to viral mRNA with unknown pathogenic potential as seen in a
recipient of an integrating therapeutic vector for β-thalassaemia (Cavazzana-Calvo, 
Payen et al. 2010). Due to the relatively unpredictable location of integration, gene
dysregulation may still be unavoidable with the viral vector gene insertion strategy.
Another complication arising from viral vector gene insertion is the host defence
mechanism of viral DNA silencing. DNA methylation is a normal process in gene
expression regulation and attained by the transfer of methyl group to CpG
dinucleotides by methyl transferases. Methylation of CpG islands in viral promoters
can occur and silence viral gene expression which has been observed with MoMLV
vectors in mHSC (Challita and Kohn 1994). Progress in vector design has incorporated
viral promoters without methylation sensitive CpG elements in order to maintain long-
term gene expression, for example the ubiquitously actin chromatin opening element
(Zhang, Thornhill et al. 2007).
1.3.6 Non integrating viral vectors
The gene delivery efficiency mediated by viral transduction can still be utilised without
active integration with the use of integrase deficient lentiviral vectors (IDLV) (Leavitt,
Robles et al. 1996). By mutating the integrase gene the lentiviral vector will not
actively integrate into the host genome and remain episomal either as linear dsDNA or
the LTR ends can be joined by end to end or can recombine resulting in circular DNA
(Wanisch and Yanez-Munoz 2009). IDLV can either transduce dividing cells and
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meditate transient expression as the episomal vector cDNA is lost with cell division or
transduce non-dividing cells for long term gene expression (Yanez-Munoz, Balaggan et
al. 2006). However background integration can still occur via integrase independent
recombination mechanisms between vector and chromosomal DNA due to regions of
microhomology and homologous recombination.
1.4 Targeted gene correction
Although retroviral gene therapy is an effective method of treating genetic disease,
due to random integration leading to insertional mutagenesis, the necessity to develop
a safer genome modification strategy is a priority for gene medicine. An alternative
strategy for gene therapy is to correct the genetic mutation in situ. Genomic
modifications can be executed without the need for insertion vectors by harnessing
the cell’s HR machinery. It has been estimated that HR events occur at a frequency of 1
in 106 mammalian cells (Vasquez, Marburger et al. 2001) however this rate of
recombination can be increased by introducing a double strand break (DSB) and
thereby activating cellular DNA repair mechanisms. This resolution will permit
endogenous gene expression and will avoid any viral vector “footprint” left in the
genome. A DSB can be introduced in a specific sequence of DNA by enzymatically
active molecules such as Zinc finger nucleases (ZFN), Transcription Activator-Like
Effector Nucleases (TALEN) and Meganucleases.
1.4.1 Homologous recombination (HR)
HR is an endogenous gene editing process which brings about the exchange of genetic
material between DNA sequences with high sequence similarity. During meiosis, HR is
employed by the cell to exchange genetic material between homologous regions of
parental chromosomes, creating new DNA combinations. HR is also essential for
genome maintenance and capable of repairing DNA lesions in the form of DSB which
can lead to deleterious mutations or cell death. Repair in somatic cells by HR is
possible due to the diploid karyotype as the undamaged chromosome can act as the
repair template. In addition, HR usually occurs after DNA replication, in the S/G2 phase
of the cell cycle, so the homogenous sister chromatid can act as the repair template.
Using the correct DNA sequence to repair a DSB is more beneficial to the cell than the
alternative mechanism, non-homologous end joining (NHEJ). NHEJ occurs throughout
the cell cycle and acts only to re-ligate the broken ends of the DNA, an error prone
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system which frequently involves deletions or insertions of nucleotides resulting in
sequence frame shift and/or mutation.
1.4.2 Models of HR.
As pathways of HR are varied and coupled to specific cell fate, this section will focus on
the DNA repair pathways that can be engaged as a result of targeted gene DSB with
and without provision of repair template.
When DNA replication is halted due to a DSB, a signal is generated to activate the
transcription of DNA repair genes, for example those used in HR. Models of HR and the
proteins which regulate the process of eukaryotic HR are reviewed by Sung and Klein
(Sung and Klein 2006) and are depicted in Figure 1.4. In short, the 5’ ends of the DSB
are resected leaving behind 3’ overhangs. This single stranded DNA is bound by the
repair protein Rad51. Rad51 is a DNA dependent ATPase able to support a DNA
synapse of both single stranded and double stranded DNA and catalyse directional
branch migration with ATP. In humans the presynaptic filament can also be formed by
Dmc1. The presynaptic filament can search for, invade and pair with undamaged
homologous DNA, forming a Holliday structure and, in so doing, is referred to as the
invading strand. As a result of this strand invasion, the unpaired strand on the recipient
DNA is displaced forming a D-loop. Having synthesised genetic material to accurately
repair the DSB, the synapse can be resolved in a number of ways. Firstly, the double
strand break repair (DSBR) model is possible whereby a subsequent strand exchange
results in a second Holliday junction. This junction can be resolved to generate
repaired DNA molecules with or without homologous DNA crossover (Szostak, Orr-
Weaver et al. 1983). Either the double Holiday junction is cut in the orientation it was
formed resulting in the exchange of the joining molecule only, this is known as non-
crossover. Alternatively, the junction is resolved as the isomer and the non-invading
strands are cut, resulting in crossover. The latter resolution is regarded as meiotic
crossing-over between the parental chromosomes. Alternatively, a process distinct
from DSBR and independent of a second Holliday junction is the synthesis dependent
strand annealing (SDSA) model of HR (Allers and Lichten 2001). In this case the newly
synthesised DNA is displaced from the D-loop and anneals with the other DSB end. This
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model always results in non-crossover DNA resolution and is more likely to be utilised
in mitotic cells.
Non-crossover resolution of homologous DNA is followed by a multistep repair
pathway resulting in the exchange of genetic material between homologous strands
whereby the information on the DNA with the DSB is replaced by the homologous
information of the repair template and vice versa. Homologous regions between
chromosomes are likely to be the same allele of a gene, however, if the alleles differ,
the recombination event may result in gene conversion. Gene conversion following a
DSB is exploited by certain organisms as discovered by the identification of
meganucleases in Saccharomyces cerevisiae.
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Figure 1.4 A schematic of the events that follow a double strand break (DSB) and resolved
by homologous recombination (HR) in S. cerevisiae.
Limited degradation occurs at the 5’ ends by a nuclease complex containing MRX, Exo1,
Dna2 and Sae plus the helicase Sgs1 in. After 5’ end resection a 3’ single stranded DNA
(ssDNA) overhang remains. Rad51 polymerises on the single strand to form the presynaptic
filament, overcoming competition for ssDNA with replication protein A (RPA) by other
proteins from the Rad52 gene group such as Rad52 and the Rad55-Rad57 complex. The
presynaptic filament (a) invades and displaces homologous DNA resulting in a D-loop (b) and
forming a Holliday junction (c). DNA is synthesised from the 3’ end of the invading strand
(d). Resolution of the D-loop. (i) Double strand break repair (DSBR) resolution results in Non-
crossover (White arrows) or crossover (Black arrows). (ii) Synthesis dependent strand
annealing (SDSA) non- crossover resolution of a single Holliday junction.
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In addition to the DSBR and SDSA models of HR there are further, non-conservative
types of DNA repair. In the event that a DSB occurs in the middle of 2 repeat
sequences, the 5’ degradation at the cut ends can lead to the exposure of single
stranded complementary homologous DNA which anneal allowing DNA synthesis to
repair the DSB. This form of recombination is known as single-strand annealing (SSA)
and results in the loss of DNA (Figure 1.5a). Another non-conservative DNA repair
model is NHEJ which does not depend on the availability of homologous DNA and acts
to re-ligate the broken DNA ends. This process frequently incorporates or deletes
nucleotides but can sometimes faithfully restore DNA to its WT sequence (Figure 1.5b).
Figure 1.5 DSB stimulate non-conservative repair pathways.
(a) SSA, repetitive DNA (Red) either side of a DSB undergo 5’ end degradation and the
single strands anneal followed by DNA synthesis. (b) NHEJ in mammals, the broken end of
the DSB protected by Ku proteins (Ku70 & Ku80) in association with DNA-PK
cs
which
activates XRCC4 which interacts with DNA ligase IV (LIG4) resulting in DNA with or without
mutations.
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1.4.3 Introducing novel DNA into eukaryotic genomes by HR
In order to modify the endogenous genome by HR, a molecule of extragenous DNA can
be introduced into a known locus as part of a donor DNA repair matrix. It is possible to
integrate genes carried on a bacterial plasmid into the yeast genome via
transformation. Hinnen et al. transformed leu2- mutant yeast with donor DNA
comprising of a segment of the yeast chromosome III with the LEU2+ gene carried by
the E.coli plasmid ColE1 (Hinnen, Hicks et al. 1978). Transformants able to grow in
leucine negative media occurred at a rate of 10-7 where gene targeting frequency =
targeting events/total cells transfected. 71% of cells had transformation events in
chromosome III that showed close linkage to the original leu2- gene. 12% had an
unchanged chromosome III and linkage analysis of the LEU2+ and leu2- gene confirmed
that the transformation event had occurred on a different chromosome. No evidence
of donor DNA was detected in the remaining transformants as in the untreated
control. As revertants had not been seen in this model before, it was suggested that
LEU2+ was incorporated by conversion or double crossover. This study explored the
opportunity of harnessing HR to modify endogenous eukaryotic genome with
prokaryotic plasmid DNA. It also revealed the possibility that recombination can occur
off site.
Engineering of mouse strains to investigate genetic disease has relied on HR events to
incorporate or excise genetic material. Capecchi et al. found the rate of recombination
in mES when microinjecting donor DNA to be, on average 10-3 per treated cell
(Thomas, Folger et al. 1986). Due to the labour intensive process of microinjection, the
system was developed to include double selection to engineer knockout (KO) strains
where extragenous donor DNA containing the gene of interest (GOI), disrupted by a
neomycin gene (neo) and with a tyrosine kinase gene (tk) outside the region of
homology. Murine embryonic stem (mES) cells were electoporated and the cells that
had incorporated the donor DNA by random integration were negatively selected by
gancyclovir treatment, and HR events were positively selected by G418 treatment
(Mansour, Thomas et al. 1988). Out of the cells that had survived electroporation, up
to 5.4 x 10-6 survived positive and negative selection.
1.4.4 DSB increase the rate of HR
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Early studies in HR revealed that cleaving the DNA increases the frequency of
recombination. Orr-Weaver et al. 1961 showed that transforming yeast with linearised
plasmid vector cut in the region of homology increased plasmid integration up to 1000
fold compared to circular vector (Orr-Weaver, Szostak et al. 1981). The ability of
transformed yeast to integrate linear plasmid DNA was greatly reduced in Rad52
mutant strains however this was not observed for circular plasmids indicating different
processes for these events. It was also shown that introducing the cut site outside of
the homologous region reduced the efficiency of recombination. To add weight to the
advantage of introducing a DSB into the vector, plasmids containing multiple
homologous regions to distinct chromosomal sites only integrated at the chromosomal
site corresponding to the cut homologous region. Furthermore plasmids made linear
with a 300-1200bp gap were repaired by homologous chromosomal DNA.
It was later identified that 3 genetic modifications could occur on transforming yeast
with a plasmid made linear by removing 60bp from its region of yeast homology (Orr-
Weaver and Szostak 1983). (i) The gapped plasmid was repaired with yeast
chromosomal DNA, the rational for this event was non-crossover HR (ii) the plasmid
was integrated into the yeast chromosome in the region of homology. In this instance,
it was reasoned that the D-loop created by the plasmid’s 3’ invading strand migrated
by DNA synthesis until the plasmids 5’ break was met and the free end ligated to the
yeast chromosomal DNA and therefore the plasmid had integrated (iii) the broken
ends of the plasmid were re-ligated by NHEJ.
Lin, Sperle and Sternberg continued the assessment of DSB stimulated HR in
mammalian cells (Lin, Sperle et al. 1984). Phage constructs containing defective
tyrosine kinase (tk) genes were delivered to mouse L cells (mouse fibroblast cells,
strain L (Miyamoto, Zeuthen et al. 1973)), where recombination between 2 defective
copies would result in a functional tk gene (tk+ transformants). Firstly, a construct
containing 2 defective tk genes in the same orientation and sharing 984bp of
homology, were separated by 3kb of non tk DNA. Cleavage by a restriction enzyme in
the 3kb separating region resulted in intramolecular recombination leading to tk+
transformants at a rate 30 fold higher than un-cut control. Intermolecular
recombination between the defective tk genes on separate plasmids was as efficient as
the intramolecular recombination however no significant increase in tk+ transformants
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was observed when cleaving only one plasmid compared to uncut. Therefore the type
of HR observed here was SSA due to the obligation of 2 exposed homologous genes to
anneal. It was also noted that a region of 320bp homology shared between the 2
plasmids resulted in a transformation efficiency of 7.2%. When the homologous region
was reduced to 46bp the transformation efficiency dropped to 0.2%. These findings
show that the rate of recombination declines as the region of homology is reduced.
Further studies of intermolecular recombination between plasmids in mammalian cells
verified the relationship between the length of homology and rate of recombination.
Gradually decreasing the homologous region from 500bp to 25bp caused a drop in
recombination in both in monkey COS cells and EJ human bladder carcinoma cells
(Ayares, Chekuri et al. 1986). Although a homologous region of 25bp is sufficient for
recombination between plasmids, a greater length of 295bp is necessary to achieve HR
between chromosomes (Liskay, Letsou et al. 1987). An explanation for the greater
extent of homology required between chromosomes is to avoid any fortuitous
recombination between repeat sequences.
These observations provided evidence that the rate of HR is increased when DNA
damage in the form of a DSB is experienced in mammalian cells and that the type of
DNA repair varies. Furthermore, HR depends on the extent of homology provided by
the donor DNA.
1.4.5 Meganucleases
Considering a DSB stimulates HR, it is an attractive prospect to control the site of DNA
repair with reagents that can increase the rate of gene targeting at a pre-determined
location in the genome and thus avoiding the unpredictable integration profile of
retroviral vectors that may lead to insertional mutagenesis.
Meganucleases are sequence specific endonucleases which can recognise target DNA
of ≥12bp (Thierry and Dujon 1992), greater than the 6-8bp recognition site necessary 
for the rare cutter type II restriction endonucleases. The meganuclease I-SceI
recognises an 18bp sequence (Colleaux, D'Auriol et al. 1988) and was shown to
stimulate SSA in extrachromosomal DNA in mouse cells (Rouet, Smih et al. 1994).
Furthermore, there is no naturally occurring I-SceI recognition site in the mouse
genome and the highly specific endonuclease activity was confirmed by the lack of
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genotoxicity in the cells. Early gene targeting studies in mammalian cells using the
meganuclease I-SceI, are listed in the overview by (Paques and Duchateau 2007) and
although gene targeting does not represent targeted HR it is of note that gene
targeting frequencies of 10-1 can be achieved in human 293T cells (Alwin, Gere et al.
2005). However, these experimental models require the pre-requisite of introducing
the naturally occurring I-SceI target site into cell types which do not normally harbour
this sequence. When the LAGLIDADG protein motif was identified in the so called
family of meganucleases, shuffling of these residues revealed that the recognition
sequence could be modified. Further identifying 2 subdomains and engineering 4
mutants gave rise to a practical approach to modify the DNA binding domain of this
protein as shown by a meganuclease engineered to cleave the human Rag1 gene
(Smith, Grizot et al. 2006).
Given the development of engineered proteins to cut predetermined sequences within
the genome, it is possible to introduce novel DNA at these sites via HR. For this
technology to progress certain factors must be considered in order to permit HR with
extragenous DNA. The length of the homologous tract on exogenous donor DNA for
endogenous gene targeting is vital to the efficiency of HR mediated repair. However,
an ensuing question is the necessary extent of homology in this homologous tract. In
order for a mutant gene to be corrected, some change in sequence must occur and
therefore some disparity in gene sequence will be expected between the chromosomal
and donor DNA.
Important factors concerning the disparity of donor DNA repair template were
investigated by Elliot et al. (Elliott, Richardson et al. 1998). Analysis of gene conversion
between plasmid and chromosomal DNA was studied in mES cells modified to contain
the I-SceI target site in their genome. Using I-SceI to induce a DSB in the chromosome,
plasmid donor DNA was provided containing increasing numbers of silent mutations. It
was observed that as the sequence disparity increased by 5, 7 and 8bp the rate of
targeted HR decreased by 2.5, 4 and 6 fold respectively. Furthermore, silent mutations
close to the DSB were more likely to be incorporated than the silent mutations further
upstream. This indicated that the extent of gene tract conversion is finite. 68% of the
analysed clones had gene conversion tracts of 58bp and the longest was 511bp seen in
just 2.5%. The combined results gave an estimated average of a 200bp conversion
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tract. Another interesting observation made from these recombinants was the
direction of repair from the DSB. The transformants that displayed a short tract of
gene conversion also displayed unidirectional conversion. Conversely, the
transformants that had longer gene conversion tracts showed bidirectional conversion.
This could be interpreted as evidence that 2 different HR pathways can be employed to
repair the DSB in this model. For example, SDSA could account for the unidirectional
gene conversion due to the nature of the single strand synthesis. Alternatively non-
crossover resolution of DSBR could account for the bidirectional repair observed with
more extensive gene conversion due to the gene synthesis that occurs off of both
strands of the donor DNA. Similar observations were made where the length of
homologous region dictates the nature of HR and longer homologous regions in the
donor DNA can retain homology after 5’ end resection allowing for a second Holliday
junction to form and be resolved by DSBR. In contrast, short homology regions, 25-
35bp can lose homology by 5’end resection and are more likely to recombine via SDSA
(Ayares, Chekuri et al. 1986).
So far it has been established that the cell’s endogenous repair mechanism, HR, can be
adopted to integrate novel DNA from plasmid DNA into a mammalian genome as long
as the prerequisites for HR are available. It is also possible to greatly increase the rate
of HR by the introduction of a DSB which can be administered to a target site by
nucleases thus resulting in gene targeting.
1.5 Zinc Finger Nucleases
Like meganucleases, ZFN can be manufactured to confer specificity for and cleave a
target site in the genome increasing the rate of HR (Porteus and Baltimore 2003). ZFN
are chimeric proteins consisting of a DNA binding domain made up of an array of zinc
fingers (ZF) joined to a FokI nuclease domain. The FokI nuclease domain is active as a
dimer so 2 ZFN monomers pair at the DNA target site in order to achieve cleavage, the
structure and DNA recognition of a ZFN pair is shown in figure 1.6a. Due to the
modular nature of ZF, there are fewer constraints than meganucleases for modifying
the DNA binding domain.
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Once the chromosomal target site has been activated by a DSB, subsequent
modification of the gene via the HR pathway can include correction in situ by the
exchange of base pairs, targeted gene addition by the introduction of a new DNA
sequence and gene excision or gene disruption by NHEJ (Figure 1.7). ZFN mediated
gene targeting is an attractive alternative to retroviral gene therapy as it avoids the
introduction of viral elements into the host genome and the target site is pre-
determined.
Figure 1.6 Binding of the ZFN heterodimer.
(a) A diagram of the Zinc finger nuclease (ZFN) chimera as shown as a dimer. Multiple zinc
fingers are joined to heterodimeric FokI nuclease subunits via a linker domain and the ZF
binding domains are separated by a spacer region. (b) Homodimers are avoided by the
repelling forces of the Fok1 domains and the lack of DNA recognition by the ZF.
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Figure 1.7 The preferential outcomes of a DSB
Gene correction of a mutation (yellow star) proximal to the DSB can be mediated on the
provision of homologous DNA containing restorative sequence. Gene insertion can be
targeted to a DSB on provision of the GOI flanked by sequence homologous to the target
locus. Gene disruption results when no homologous DNA is used to correct the DSB
frequently resulting in mutation. Gene excision is mediated by two ZFN pairs which are
directed to 2 loci resulting in the removal of a stretch of DNA.
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1.5.1 The Zinc Finger
Zinc fingers (ZF) were first discovered as part of the eukaryotic transcription factor
TFIIIA (Miller, McLachlan et al. 1985). The common Cys2-His2 zinc finger comprises of a
ββα-fold made up of ~30 amino acids that co-ordinate a Zn+ atom. The helix of one ZF 
binds the major groove of DNA and typically confers affinity to a triplicate of DNA
nucleotides. It is with this DNA specificity of the α-helix protein motif that transcription 
factors are able to assemble at the promoter sites of specific genes or groups of genes
and control their expression. Multiple variants of ZF can be linked to form polydactyl
zinc finger proteins (ZFP) (Liu, Segal et al. 1997) designed to recognise DNA targets in
multiples of 3bp. Polydactyl ZF are capable of re-directing DNA effector molecules
(Blancafort, Segal et al. 2004) and ZF can also be used to bind an unwanted gene and
serve to inhibit transcription, such blocking ZF were generated against the BCR-ABL
carcinogenic translocation (Choo, Sanchez-Garcia et al. 1994).
1.5.2 Modification of ZF DNA recognition
A complete set of ZF capable of recognising all the possible DNA triplicates would
amount to 64 molecules (Beerli and Barbas 2002). The length of DNA sequence to
confer exclusivity in the human genome is calculated to be at least 16bp. The
meganuclease, I-SceI has an 18bp recognition site which is emulated by fusing 6 ZF
domains (Moore, Klug et al. 2001).
Based on 6 residues in the conserved α-helix, ZF with different DNA binding 
specificities can be rationally designed and selected according to their dissociation
constant by using phage display (Segal, Dreier et al. 1999; Dreier, Segal et al. 2000;
Pabo, Peisach et al. 2001; Dreier, Fuller et al. 2005). Identifying families of ZF formed
libraries from which modular assembly of polydactyl ZF can be constructed. These ZF
combinations can also be selected in accordance with the effect of target site overlap
seen when neighbouring ZF bind 4bp instead of 3bp. This modular method of designing
ZFP has provided effective reagents for gene targeting studies (Bibikova, Golic et al.
2002) however at an estimated success rate of 24% for the assembly of a 3 finger
domain (Cathomen and Joung 2008) which is further reduced for a 6 finger domain,
has limited the use of this method.
An alternative approach to engineering ZF domains is by bacterial cell based two-
hybrid system (B2H). In this method candidate ZF are individually selected for low
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stringency for the target site and supported by known ZF. These potential ZF are
randomly recombined and selected for high stringency for the target site. This second
round accounts for both target site specificity and neighbouring ZF interference (Joung,
Ramm et al. 2000; Hurt, Thibodeau et al. 2003). The reagents and method for this
strategy were made available to the public as “Oligomerized Pool Engineering” or
OPEN (Maeder, Thibodeau-Beganny et al. 2008) and custom ZFN for zebrafish were
promptly developed (Foley, Maeder et al. 2009; Foley, Yeh et al. 2009).
An archive of 2-finger modules that are randomly combined and selected by target
sequence specificity by a B1H-based selection is also utilised (Gupta, Christensen et al.
2012) and is thought to be a similar strategy to the system employed by Sangamo
Biosciences.
Modification of the ZF binding domain has provided novel DNA binding proteins with a
variety of applications for gene targeting, one of which is the ZFN which mediates
targeted DSB.
1.5.3 The ZF-FokI chimera
Work by the Chandrasegaran laboratory established that the type II restriction
endonuclease, FokI, had a non-specific DNA cleavage domain which could be
separated from its DNA recognition domain and fused to the Ultrabithorax (Ubx)
homeobox domain of Drosophila with a (glycine3Serine)2 linker and demonstrated that
this chimera could cleave the Ubx target site on a pUC13 plasmid (Kim and
Chandrasegaran 1994). Subsequently, they combined ZF molecules with the FokI
cleavage domain to produce the chimeric ZFN protein (Kim, Cha et al. 1996). Having
two (ZF)3 constructs at their disposal, they fused both with FokI to produce 2 individual
hybrids. In their analysis of λ DNA digestion by these hybrids, they showed preferential 
cleavage by one construct and specific, yet unpredicted cleavage by the other. Their
findings emphasised the importance of rigorous ZF screening and also highlighted the
possible interference by FokI itself and the necessary optimisation of the linker domain
between the FokI and ZF.
1.5.4 The ZFN pair
Subsequent to the ZF-FokI hybrid now given the more general term ZFN, FokI was
discovered to be active as a dimer (Bitinaite, Wah et al. 1998). Importantly it was
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shown that, so long as DNA recognition is provided by one WT FokI monomer, a
catalytic dimer can be formed with a second FokI molecule with a disrupted DNA
binding domain. Due to this character of the FokI dimer, DNA binding at off target sites
would result in cleavage at unwanted sites. This was proven by an early study in the
pairing of ZFN monomers by the Carroll-Chandrasagaran collaboration (Smith, Bibikova
et al. 2000). Here they used ZFN monomers and target DNA with either a single ZFN
target site or inverted repeats of the target site. It was shown in vitro that the target
DNA with a single ZFN recognition site which would bind one ZFN monomer could be
cleaved at high concentrations of the ZFN. Further observations made with the target
DNA with inverted repeats revealed that the FokI dimer cleaved in the middle of the 2
ZF binding domains, now known as the spacer region. These findings had implications
for the imminent ZFN pair design where the total number of ZF selected for specific
DNA binding are distributed equally between 2 FokI monomers. With this design, the
ZFN will recognise 2 adjacent DNA binding half sites and the FokI will dimerise and
cleave the at spacer region.
Using a similar experimental model but this time targeting extrachomosomal DNA in
Xenopus oocyte nuclei, the group identified the relationship between linker length and
spacer domain. It was seen that longer linkers (up to 18 amino acids) could target a
broad range of spacer regions from 6-35bp, conversely, short linkers (0 amino acids to
diminishing the FokI domain) were more restricted in the range of spacer length they
could target and able to cut short spacers of 4-6bp. This study also attempted the first
ZFN pair using ZFN that recognised different sequence which yielded 19%
recombination in a plasmid designed to correspond to the respective ZFN (Bibikova,
Carroll et al. 2001). The linker to spacer relationship was also reported by Porteus et al.
(Porteus and Baltimore 2003) and was confirmed by Hӓndel et al., who also noted that
longer linker domains which conveyed broader activity were also more toxic (Handel,
Alwin et al. 2009).
The Carroll group moved their ZFN analysis in vivo by constructing two 3-finger ZFN
monomers by modular assembly that, when paired, would bind 2 adjacent 9bp “half
sites” separated by a 6bp spacer in the yellow gene of Drosophila. Targeted DSB was
measured by the rate of mutation in yellow resulting from the NHEJ pathway of repair.
The rate of germline mutation was calculated to be 1/250 confirming in vivo targeted
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DSB (Bibikova, Golic et al. 2002). A subsequent study observed HR events in this
model. Circular or linear donor DNA, homologous to yellow, were provided alongside
the ZFN. The best rate of HR was found using linear donor and occurred in mutant
male and female germlines at 63% and 73% respectively (Bibikova, Beumer et al.
2003). Lethality was associated with one of the ZFN used in these studies and
explained by its potential to recognise “half sites” throughout the genome. As seen
previously, the DNA binding event of one ZFN allowed a second FokI catalytic domain
to dimerise and introduce a DSB off target. To circumvent this, a mutation was
introduced to inactivate the FokI domain and no lethality was observed in flies as a
result (Beumer, Bhattacharyya et al. 2006). Studies carried out by the Carroll group
made important observations regarding the DNA repair pathways NHEJ and HR
stimulated by ZFN and the toxic effects of off target DSB.
1.5.5 ZFN associated toxicity
In order to make ZFN a viable therapeutic reagent, the degree of damage they exert on
the cell must be understood and minimised. DSB are genotoxic and if a second cut is
administered, chromosomal translocations can occur >2000 fold more than in the
presence of a single cut due to the non-conservative DNA repair pathways NHEJ and
SSA (Richardson and Jasin 2000). Toxcitiy can be measured by cell viability and
quantification of DNA repair foci components, phosphorylated histone H2AX (ϒ-H2AX) 
and 53BP1.
By attributing the majority of toxic incidence caused by ZFN to the frequency of DSB
they exert, it can be conceived that by constructing ZFN that are only capable of
cleaving a single site in the genome cell injury will be reduced. The potential areas for
improving the ZFN architecture are: resolving the promiscuity of FokI dimerization,
improving the sequence specificity of the DNA binding domain and using a linker with a
narrow range of spacer region affiliation.
A solution to the problem of off target DSB due to nonspecific FokI dimerization was
developed whereby charged residues introduced at the dimer interface resulted in
polar FokI domains which maintained the ability to cleave DNA. This absolved the WT
homodimer and forced the FokI monomers to heterodimerize (Figure 1.7b). Obligate
heterodimers permit cleavage of the target site by the ZFN pair and greatly reduced
the toxicity associated with off target DSB. Miller et al. exchanged 2 residues in the
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dimer interface of WT FokI which reduced the number of γ-H2AX positive cells from 
18.9% to 1.7% with no loss of target site cleavage (Miller, Holmes et al. 2007).
Similarly, Szczepek et al., demonstrated that 4 ZFN pairs with different catalytically
active FokI heterodimers each resulted in a significant reduction of γ–H2AX+ cells 
compared to WT (Szczepek, Brondani et al. 2007). Further reduction in DNA damage as
measured by 53BP1 was reported when testing a FokI heterodimer that combined 3 of
the polar residues used in the Miller et al. and Szczepek et al. studies (Ramalingam,
Kandavelou et al. 2011).
Another approach to control the cleavage domain of ZFN is to fuse the ZF to a
sequence specific nuclease rather than the catalytic FokI domain. This was done with
the type II endonuclease PvuII and no off target cleavage activity was observed
(Schierling, Dannemann et al. 2011). This design of ZFN is constrained to cleaving
sequence that includes both the PvuII and ZF recognition sites and will limit their
application for endogenous genes, however, progress in protein engineering may
provide a library of site specific cleavage domains which could be applied to targeted
gene therapy.
An inverse correlation exists between ZF specificity and toxicity. Using the B2H system
of ZF selection, Cornu et al. assembled 3 ZFN for 3 different targets and compared
their binding activity and toxicity. They noted that in the majority of cases the ZFN that
activated the greatest frequency of targeted HR incurred the lowest incidence of γ-
H2AX+ cells (Cornu and Cathomen 2007). A direct comparison of modular and B2H
based assembly of ZFN revealed that not only does the B2H method result in ZFN with
greater gene targeting efficiency but also achieved 100% cell survival in HEK293 cells
whereas ZFN created through modular assembly resulted in a 50% cell survival rate
(Pruett-Miller, Connelly et al. 2008). It was speculated that increasing the number of ZF
in a ZFN could increase specificity thereby decreasing off target DSB. However,
changing the number of ZF from 3 to 6 per ZFN considerably decreased the target
activity and showed the optimal finger number to be 3 or 4 per ZFN monomer
(Shimizu, Sollu et al. 2011).
In addition to optimising the structure of the ZFN, further adjustments can be made in
administering ZFN to reduce genotoxicity. The off target events of ZFN appear to have
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a positive correlation with dosage (Pruett-Miller, Connelly et al. 2008) as observed
with heterodimeric ZFN designed for zebrafish using the B2H system (Meng, Noyes et
al. 2008). Analysis of these off target events incurred at high ZFN doses revealed that
sites with 5bp mismatch from the intended target were cleaved at a statistically
significant frequency whereas sites with 1 or 2bp differences remained uncut (Gupta,
Meng et al. 2011). The unexpected observation that the relationship between target
homology and ZFN binding was not necessarily linear prompted more investigation.
In order to minimise and monitor off target ZFN activity, software such ZFN-Site
(Cradick, Ambrosini et al. 2011) and Systemic Evolution of Ligands by Exponential
Enrichment (SELEX) are available to predict potential ZFN binding sites based on target
site homology which account for spacer length. Potential off target sites of the ZFN
designed to target the CCR5 gene (CCR5 ZFN) were predicted in silico by SELEX and of
the top 15 matches only the closest match, in CCR2, had been disrupted in vitro at a
tenfold lesser extent than CCR5 (Perez, Wang et al. 2008). Because DSB can capture
fragments of linear DNA by NHEJ, the accuracy of in silico predictions, based on target
site homology was evaluated by mapping the sites of linear IDLV capture at DSB sites
incurred by the CCR5 ZFN (Gabriel, Lombardo et al. 2011). Clustered integration site
(CLIS) analysis of the captured IDLV revealed that unintended target sites could differ
by as many as 7-8bp from the target site and only represented a portion of the in silico
predicted sites. This capture assay is thought to give a more accurate representation of
off target activity by ZFN. Studying in silico predicted sites for CCR5 ZFN also revealed
that increasing the concentration of ZFN leads to more cleavage sites in vitro and
mutations can be tolerated in a DNA binding “half site” if a ZFN monomer has bound a
corresponding non-mutated half site. The threshold of base pair dissimilarity was
calculated to be up to 3bp hence ZFN should be designed to recognise a target site
with at least 3bp difference than the next closest possible target (Pattanayak, Ramirez
et al. 2011). These observations reveal that ZFN targets can be unpredictable and
probably not entirely conducted by target site homology. One possible explanation is
that targets can be made inaccessible to endonucleases by CpG methylation (Valton,
Daboussi et al. 2012).
The positive correlation between ZFN dose and toxicity indicates the necessity to
ensure transient ZFN expression in the cell. Transient expression can be deployed in a
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number of ways including using an expression vector that does not integrate into the
genome, incorporating the ZFN target site in the ZFN expression vector, as
demonstrated with I-SceI (Takashima, Sakuraba et al. 2009), adding a ubiquitin tag to
the ZFN and therefore marking it for proteasome degradation (Pruett-Miller, Reading
et al. 2009) and treating the cell with ZFN protein rather than expression vectors has
shown gene targeted frequencies of up to 27% (Gaj, Guo et al. 2012).
As optimisation of the ZFN architecture develops and the associated toxicity is
monitored, ZFN gene targeting strategies can be assessed for safer therapeutic
intervention.
1.5.6 NHEJ vs HR
Different DNA repair pathways result in different DSB repair outcomes so depending
on the gene targeting strategy it is of interest to monitor the type of DNA repair
employed by cells treated with ZFN and to determine a strategy that will utilise the
desired pathway.
DNA repair pathways are dependent on the type of DNA damaging agent and the
phase of the cell cycle. HR is more likely to occur during the S and G2 phases of the cell
cycle as indicated by the assembly of Rad51 at the site of DNA damage in these phases
(Gasior, Olivares et al. 2001). NHEJ is the main repair mechanism in G1 as shown by
increased γ–H2AX foci in this phase when part of the NHEJ repair complex, DNA-PKcs is 
inhibited (Rothkamm, Kruger et al. 2003). However NHEJ and HR repair pathways are
not always mutually exclusive as seen in intrachromosomal gene exchange stimulated
by I-SceI where DNA synthesis initiated by HR goes beyond the region of homology and
ends with NHEJ resulting in a junction containing random nucleotide deletions
(Richardson and Jasin 2000).
The studies in Drosophila demonstrated that NHEJ and HR are both stimulated by ZFN
induced DSB when a donor DNA is provided. Of the total gene targeted events
mediated by rosy specific ZFN in female and male parents, HR was observed at
frequencies of 59% and 41% respectively and the remaining modifications were a
result of NHEJ (Beumer, Bhattacharyya et al. 2006). Inhibition of the Drosophila Rad51
homologue significantly reduces HR and disallowing SSA to occur by using circular
plasmid inhibits HR completely. Furthermore, inhibition of the Drosophila Ligase IV,
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part of the NHEJ repair complex, results in a higher frequency of HR events than in
Ligase IV+ controls (Bozas, Beumer et al. 2009).
The choice of DNA repair pathway can be moderated by manipulating levels of repair
pathway proteins. For example targeted HR will increase 2.1 fold in HT1080 cells
overexpressing Rad51 without any increase in random integration and in the absence
of targeting endonucleases (Yanez and Porter 1999). However, when considering other
members of the RAD52 epistasis group of genes, chromosomal targeted HR is inhibited
by Rad52 overexpression and this environment significantly increases cell morbidity
(Yanez and Porter 2002).
The availability of sister chromatids, hence a homologous copy of DNA, is the preferred
template for DNA correction (Kadyk and Hartwell 1992) and their availability after
replication in S phase reflects the increased incidence of HR at the S/G2 phase.
However the possibility that donor DNA template could compete with NHEJ to initiate
repair by HR at G1 is unlikely due to blocking of end resection and therefore the
presynaptic filament in this phase (Shrivastav, De Haro et al. 2008).
It can be inferred from these observations that the incidence of NHEJ is unavoidable
when incurring a DSB and that inhibition or support of a particular DNA repair pathway
may be an opportunity to promote the desired repair however this may result in cell
damage.
1.5.7 ZFN as therapeutic reagents
Up to this point general considerations of ZFN mediated gene targeting have been
discussed. Some of the remaining factors such as delivery of ZFN, design of donor DNA
repair matrix and the rate of gene targeting may depend on cellular factors and the
manner of genome editing. This section will discuss these considerations in the context
of targeting disease genes with ZFN in the interest of gene therapy.
The outcomes of the targeting of various human disease associated genes are
summarised in Table 1.1. (Urnov, Miller et al. 2005; Lombardo, Genovese et al. 2007;
Moehle, Rock et al. 2007; Maeder, Thibodeau-Beganny et al. 2008; Perez, Wang et al. 2008;
Benabdallah, Allard et al. 2010; Cradick, Keck et al. 2010; DeKelver, Choi et al. 2010;
Greenwald, Cashman et al. 2010; Holt, Wang et al. 2010; Chen, Pruett-Miller et al. 2011;
Herrmann, Garriga-Canut et al. 2011; Li, Haurigot et al. 2011; Lombardo, Cesana et al. 2011;
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Sebastiano, Maeder et al. 2011; Soldner, Laganiere et al. 2011; Yusa, Rashid et al. 2011; Zou,
Sweeney et al. 2011; Gaj, Guo et al. 2012; Overlack, Goldmann et al. 2012; Provasi, Genovese
et al. 2012; Sakkhachornphop, Barbas et al. 2012; Yuan, Wang et al. 2012)
From the observations made in these studies it can be seen that, regardless of
strategy, a greater rate of gene targeting is seen in cell lines compared to primary cells.
This could be due to altered DNA repair in transformed cells or differences in
chromatic structure for example, less efficient gene targeting in iPS cells is probably
due to inactive chromatin blockage of the ZFN target site (van Rensburg, Beyer et al.
2013). Various methods of gene delivery have been utilised to introduce ZFN
expression vectors and/or donor DNA to target cells. In the majority of studies,
integrating deficient vectors were used with the exception of the Adeno-Associated
viral vector (AAV) which has a low propensity for integration into the host genome
(Nathwani, Davidoff et al. 2005). The different methods of gene targeting
quantification prohibit comparison of ZFN and donor delivery however it is of note that
nucleofection or other methods of plasmid transfection strategies are the most
popular, probably chosen to avoid any background integration of viral sequence, and
that direct treatment with ZFN protein is promising. The most frequently used donor
DNA construct was circular plasmid however, a high rate of HR was achieved with a
2.9Kb linear plasmid (Greenwald, Cashman et al. 2010) but as these results were
extrapolated from qPCR values, the method of quantification is not comparable with
the more common Southern and RFLP methods. Interestingly, when quantification was
done by flow cytometry and PCR or flow cytometry and the Cel-1 surveyor assay the
methods consistently gave similar values demonstrating the robustness of these
procedures. The frequency of NHEJ concurring with HR is extremely variable and not
routinely assessed. Also, due to the infrequent analysis of off target DSB, no insight
into the delivery strategies or ZFN design was made.
.
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Rate of HR Rate of NHEJ
Author et al(year) Target gene Cell or animal model ZFN Donor (method) (method)
Urnov (2005) IL2RG k-562 T T 13.4% (RFLP) n.q.
Urnov (2005) IL2RG Primary CD4+ T cells T T 5.3% (RFLP) n.q.
Lombardo (2007)# IL2RG k-562 IDLV IDLV 16 ± 9% (RFLP) 10% (RFLP)
Lombardo (2007)# IL2RG Lymphoblastoid IDLV IDLV 5 ± 1.5% (RFLP) 5% (RFLP)
Maeder (2008) IL2RG k-562 T T 4.1% (RFLP) 1.8% (S)
Maeder (2008) VEGF-A k-562 T T 7.7% (RFLP) 9% (S)
Greenwald (2010) rhodopsin Her cells L L 17% (qPCR) n.q
Herrmann (2011) p53 Human BT549 T T 0.1% (S) n.q
Soldner (2011) α-Synuclein Patient iPS T T 0.004% (S) 2% (SB)
Overlack (2012) mUsh1c Murine Ush1c-mut L L PCR+ Protein+ (n.q.) n.q
Chen (2011) RPS6KA3 k-562 N N :ssODN 22-32% (RFLP) n.qGe
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Moehle (2007)# IL2RG K-562 T T: 12bp 15% (RFLP) n.q.
Moehle (2007)# IL2RG K-562 T T 1.5Kb 6% (FACS+PCR) n.q.
Moehle (2007)# IL2RG K-562 T T 7.6Kb 5-8% (SB) n.q.
Lombardo (2007)# IL2RG K-562 IDLV IDLV 3.4 ± 1% (FACS) n.q.
Lombardo (2007)# IL2RG Lymphoblastoid IDLV IDLV 1.8 ± 0.7% (FACS) n.q.
Zou (2011) PIG-A human ESC N N 83%* (FACS) n.q.
Zou (2011) PIG-A human iPS N N 45 ± 20%* (FACS) n.q.
Yusa (2011) A1AT human iPS E E 58%* (PCR) n.q.
Sebastiano (2011) β-Globulin patient iPS N N 9.8%* (PCR) 0% (S)
Li (2011)# F9 Mouse (hF9 ) AAV I.P. AAVI.P. 2.2% (PCR) 13.8 (Cel-1)
DeKelver (2010)# (GFP) K562 N N 10% (FACS) n.q.
DeKelver (2010)# (GFP) HEK293/Hep3B N N 3% (FACS) n.q.
DeKelver (2010)# (GFP) hTERT Fibroblasts IDLV IDLV 3% (FACS) n.q.
Lombardo (2011)# (GFP) Primary h T cells Ad5/35 IDLV 5% (FACS) n.q.
Lombardo (2011)# (GFP) NSC IDLV IDLV 6% (FACS) n.q.
Lombardo (2011)# (GFP) iPS IDLV IDLV 1% (FACS_ n.q.
Zou (2011) (CYBB ) human iPS N:mRNA N 75%* (PCR) 50%~ (S)
Lombardo (2007)# (GFP) CD34+ Progenitor cells IDLV IDLV 0.06 ± 0.02% (FACS) n.q.
Lombardo (2007)# (GFP) hES IDLV IDLV 3.5 ± 1.1% (FACS) 12.7 ± 6.4%~ (Cel1)
Benabdallah (2010)# (mEpo) hMSC Ad5/35 IDLV PCR+ (n.q.) n.q.
Lombardo (2011)# (GFP) Primary h T cells Ad5/35 IDLV 5% (FACS) n.q.Ge
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Perez (2008)# CCR5 Primary CD4+ T cells Ad5/35 n.a. n.a. 2.4% (Cel-1)
Holt (2010)# CCR5 CD34+ Progenitor cells N n.a. n.a. 17 ± 10% (Cel-1)
Cradick (2010) HBVgenome Huh7 Hepatoma cells T n.a. n.a. 36% (RFLP)
Sakkhachornphop (2012) HIV 2-LTR 293T cells N n.a. n.a. 26-49% (FACS)
Li (2011)# F9 Mouse (hF9 ) AAV8 I.V. n.a. n.a. 41% (Cel-1)
Yuan (2012)# CXCR4 SupT1 T cells Ad5/35 n.a. n.a. 20-35% (Cel-1)
Provasi (2012)# TRBC Primary T cells IDLV n.a. n.a. 6-7% (FACS, Cel-1)
Provasi (2012)# TRBC Jurkat IDLV n.a. n.a. 20% (FACS) 26% (Cel-1)
Gaj (2012) CCR5 HEK293 S P n.a. n.a. 27% (Cel-1)
Gaj (2012) CCR5 THP1 S P n.a. n.a. 14% (Cel-1)
Gaj (2012) CCR5 HDF S P n.a. n.a. 23% (Cel-1)
Gaj (2012) CCR5 Primary CD4+ T cells S P n.a. n.a. 8% (Cel-1)
Gaj (2012) DHFR CHO S P n.a. n.a. 12% (Cel-1)
AAVS1 (Safe Harbour)
CCR5 (Safe Harbour)
Ge
ne
Di
sr
up
tio
n
Ge
ne
in
se
rti
on
Delivery
Ge
ne
Co
rre
ct
io
n
Table 1.1 Publications assessing ZFN targeting of genes with therapeutic potential.
Transfection (T), nucleofection (N), lipofection (L) and electroporation (E) were carried out
with plasmid unless otherwise noted. Abbreviations: Sharkey protein (SP), intraperitoneal
injection (IP), intravenous injection (IV), Integrase deficient lentivirus (IDLV),
Adenoassociated virus (AAV), Adenovirus (Ad), Restriction Fragment Length Polymorphism
(RFLP), Sequencing (S), Southern blot (SB), not quantified (n.q.), Not applicable (n.a.). Key to
symbols: (#) in collaboration with or directly from Sangamo Biosciences, (*) Selection of
resistance marker in the transgene, (~) quantification carried out on a sub-population.
(Method) = (Method of quantification). Rates of targeting are given as the range (-), mean
or mean ± standard deviation when provided. Values for NHEJ are observed when in
conjunction with HR unless excluding gene disruption. Nucleofection is with plasmid unless
otherwise stated.
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Although these examples of ZFN mediated gene therapy are predominated by genetic
disease, ZFN strategies are also being developed to combat globally significant
infectious diseases. This challenge can be approached in two ways, the disruption of
the infectious agent’s genome or the modification of host factors that confer
resistance. In the instance of malaria, ZFN are being developed to target the
Plasmodium genome itself (Nain, Sahi et al. 2010) or disrupt the DARC and
glycophorin-α genes in erythrocytes, seen to confer resistance to Plasmodia vivax and
falciparum infection respectively (Kajumbula, Byarugaba et al. 2012). HIV is a major
candidate for ZFN mediated gene therapy. ZFN have been designed to target the LTR
(Sakkhachornphop, Barbas et al. 2012) and Pol (Wayengera 2011) regions of the HIV
genome however, the most promising development is by ZFN mediated disruption of
the host’s HIV entry molecule, CCR5, which in turn provides disease resistance (Perez,
Wang et al. 2008) and is the first ZFN mediated gene therapy to start phase I clinical
trials.
There is much impetus on correcting patient stem cells as their regeneration
properties can repopulate autologous tissue with as little as a single cell thereby
avoiding heterologous BMT. Due to the limited availability of stem cells, a current area
of research is the generation of induced pluripotent stem (iPS) cells which are re-
programmed differentiated cells that have the pluripotent quality of stem cells
(Takahashi, Okita et al. 2007). These cells can be corrected by ZFN, as ZFN treatment
does not disrupt stem cell properties (Soldner, Laganiere et al. 2011; Hoher, Wallace et
al. 2012), and reintroduced into the original patient. With this in mind CCR5 disrupted
by ZFN in hES and iPS cells are capable of multi-lineage differentiation in vitro and in
vivo thus suggesting that pluripotency is maintained regardless of CCR5 expression
(Holt, Wang et al. 2010; Yao, Nashun et al. 2012). As a result, the CCR5 locus is
considered a suitable target site for transgene insertion. Another target locus deemed
a “safe harbour” is the AAV integration site 1, AAVS1, within the PPP1R12C gene.
Insertions at this site have no known pathophysiological side effects thus avoiding
insertional mutagenesis and the PPP1R12C promoter can be used for expression of a
transgene. Furthermore, integration at this site is stable (DeKelver, Choi et al. 2010)
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and does not affect the pluripotency of ES or iPS cells (Hockemeyer, Soldner et al.
2009).
The CCR5 and AAVS1 loci were compared by inserting GFP at the respective locus and
subsequent expression was analysed. (Lombardo, Cesana et al. 2011). Separate
integration of 3 GFP constructs with SFFV, PGK or EF1α promoters showed equal target 
recombination efficiency at the 2 loci, however, the expression of GFP at the AAVS1
locus was consistently greater than at the CCR5 locus. Importantly, introducing a
promoter at the CCR5 locus up-regulated CCR5 and the proximal genes CCR3 and CCR1.
Such an effect was not observed in AAVS1 likely due, in part, to the chromatin
insulator in the PPP1R12C promoter. Epigenetic markers RNA polymerase II and
histone H3 revealed AAVS1 to be a more open and transcribed region than CCR5 (van
Rensburg, Beyer et al. 2013) yet transgene insertion at both loci enhanced active
transcription.
Due to the low rate of HR induced by ZFN it is beneficial to have a selection advantage
within the treatment strategy. This can be achieved by including a resistance marker in
the donor DNA and therefore selecting recombinants or the selective advantage may
be conferred by the genomic modification itself, as seen when CXCR4- or CCR5- cells
proliferate in favour of CXCR4+ or CCR5+ cells respectively during HIV-1 infection
(Perez, Wang et al. 2008; Yuan, Wang et al. 2012).
Gene deletion is another genome editing outcome made possible by sequence specific
endonucleases. Up to 15,000kb can be specifically deleted from a chromosome (Lee,
Kim et al. 2010). Such a strategy was employed to mimic the F8 inversion associated
with Haemophilia A in HEK293 cells with the hypothesis that such a manipulation could
be carried out to correct the disease’s genetic abnormality (Lee, Kweon et al. 2012). It
is also possible that 2 pairs of ZFN can be administered with 2 different FokI obligate
heterodimers that do not cross react (Sollu, Pars et al. 2010) thus minimising the
possibility of off target DSB when 4 ZFN monomers are administered.
In addition to gene therapy strategies mentioned in Table 1.1, ZFN can also be used to
add fluorescent markers to endogenous genes of interest in order to visualise
intracellular protein distribution including endocytosis (Doyon, Zeitler et al. 2011) and
iPS cell reprogramming (Hockemeyer, Soldner et al. 2009) and differentiation (Wang,
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Zhang et al. 2012). ZFN mediated gene targeting in the well-defined insertion sites,
AAVS1 and CCR5 can also be used to harbour the reprogramming factors necessary to
generate iPS cells (Ramalingam, London et al. 2013).
1.5.8 ZFN targeting of IL2RG
SCID-X1 is an ideal candidate for gene targeted correction. Firstly, the low rate of
targeted correction would be superseded by the selective advantage of corrected stem
cells. Secondly, due to the lack of T cells, introduction of the γc protein will not 
provoke an autoimmune response and thirdly, as SCID-X1 is an X linked recessive
genetic disorder, correction of only one allele is necessary to restore protein
expression.
A ZFN pair was designed by Urnov et al. (Urnov, Miller et al. 2005) at Sangamo
Biosciences to recognise exon 5 of IL2RG (IL2RG ZFN) at the mutation hotspot G691A.
The pair consists of 2 chimeric proteins that each have 4 zinc finger (ZF) domains and a
FokI domain. Considering each zinc finger recognises 3bp of DNA, the ZFN pair will
recognise 24bp of DNA which is a suitable length to target a single site in the genome.
The gene targeting capability of these ZFNs was examined in the same study in K-562
cells (an immortalised chronic myelogenous leukemia cell line) (Lozzio and Lozzio 1975)
by using a donor DNA to introduce the novel restriction enzyme recognition site BsrBI
with a single base pair exchange at the WT IL2RG locus. RFLP analysis of the novel
restriction enzyme site was carried out on PCR product 96 hours after transfection
with both ZFN and donor plasmids. Up to 13.4% of target loci had undergone
recombination and in cells arrested at the G2/M phase of the cell cycle HR had
increased to 18.3%. No background integration was observed in cells transfected with
donor alone and the recombination events were stable over time as shown by a
Southern blot 1 month later. Clonal cell lines of the K-562 cells transfected with both
ZFN and donor plasmid were analysed for biallelic modification and it was observed
that 13.2% of arrested cells had the BsrBI site in one allele and 6.6% in both alleles. In
asynchronous cells, 12.2% were mono-allelic and 2.4% were bi-allelic. The IL2RG ZFN
were also used to introduce a 1bp frameshift from a suitably designed donor DNA
which resulted in decreased mRNA expression, this frameshift was subsequently
corrected by using the BsrBI containing donor which restored mRNA expression. The
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ZFN and BsrBI donor also achieved HR in primary CD4+ T cells at a frequency of 5.3%
where the transfection efficiency was 30%.
Further non-selection based assays with this ZFN pair examined the rate of targeted
integration at the IL2RG locus (Moehle, Rock et al. 2007). A donor DNA was
constructed to contain two 750bp homology arms flanking a 12bp sequence encoding
a 4 amino acid tag and a novel Stu1 restriction enzyme site. K-562 cells transfected
with IL2RG ZFN and this donor DNA yielded Stu1 sites in 15% of IL2RG sites and a
precise copy of the 12bp tag sequence. Next, a 1.5kb GFP expression cassette provided
by a donor DNA was integrated into 6% of K-562 cells when co-transfected with the
ZFN pair, 8.5 fold above random integration. Random integration was not increased by
this ZFN pair as compared with etoposide, a reagent capable of random DSB, providing
evidence that this pair has low toxicity. Finally a donor consisting of a 7.6Kb gene
destined for insertion was flanked by 750bp homology arms was recombined with 5-
8% of the target loci. Subsequent analyses showed that this was homologous
integration and did not involve NHEJ events.
Lombardo et al., then assessed the efficiency of IL2RG ZFN mediated repair by
delivering the constructs using IDLV (Lombardo, Genovese et al. 2007). 2 constructs
were made to combine the donor region containing the novel BsrBI site and either ZFN
monomer with an SFFV promoter in the opposite orientation to the IL2RG homology
region, hence on delivery of both ZFN monomers, 2 donor homology regions were
delivered in unison. K-562 cells transduced with increasing ug/mL of these constructs
achieved up to 39% gene targeting events at the IL2RG locus, 74% of which were BsrBI
sensitive indicating HR and the remaining were a result of NHEJ. A lymphoblastoid cell
line (LCL) was created by transforming male B-lymphocytes with Epstein Barr Virus and
on transduction with the IDLV constructs yielded 13% gene targeting, 61% of which
was repaired by HR.
Subsequently, a donor DNA with a GFP gene flanked by IL2RG homology arms was
constructed which would disrupt exon 5 of IL2RG on recombination resulting in γc 
knockdown. LCLs were transfected with ZFN and GFP expression vectors and
interestingly, insertion of the GFP gene was achieved with lower doses of ZFN. The
GFP+ and - cells were sorted by flow cytometry and γc expression knockdown was 
56
observed from 73% in GFP- cells to 4% in GFP+ cells. A further donor DNA consisting of
promoter-less partial IL2RG cDNA flanked by IL2RG homology arms was delivered by
IDLV and integrated in 6% of LCLs (note the single IL2RG allele in male cells) when the
Donor:ZFN ratio was 3:1 and 3:2 and the donor was 0.75ug/mL. RT-PCR showed
evidence of the integrated IL2RG cDNA by mRNA expression however protein
expression wasn’t scrutinised.
As gene targeting was performed in K-562 cells using the IL2RG ZFN with WT FokI by
both Urnov et al.,(Urnov, Miller et al. 2005) and Lombardo et al. (Lombardo, Genovese
et al. 2007) the greater rate of HR achieved using IDLV may lead to the conclusion that
such a delivery is more efficient. However, neither the promoter used to achieve ZFN
expression nor the ratio of donor to ZFN was disclosed by Urnov et al.(Urnov, Miller et
al. 2005). Furthermore the combined IDLV design of donor and ZFN restricts the ratio
to 2:1 thereby limiting this potential area for optimisation and lastly, the transduction
and transfection efficiencies are not provided in either study.
The development of obligate FokI heterodimers led to a succeeding IL2RG ZFN pair
which, when using the Sangamo-designed BsrBI donor plasmid, achieved HR at
frequencies up to 12.5% compared to 10.6% observed for the WT FokI. Analysis of DSB
events in K-562 cells transfected with IL2RG ZFN alone revealed an 11 fold drop in γ-
H2AX when using the heterodimer pair as compared to the WT FokI with no loss of
IL2RG targeting (Miller, Holmes et al. 2007). This genome wide analysis of DNA damage
revealed that these ZFN were obligate heterodimers and therefore capable of targeted
gene modification. It is of interest that the same protocol and cell line was used by
Maeder et al., (Maeder, Thibodeau-Beganny et al. 2008) however in their hands the
frequency of HR was 4.1% with concurrent NHEJ at 9%. Pruett-Miller et al. determined
the maximal targeting efficiency of episomal DNA in HEK 293 cells by each ZFN to be
10-20ng per 106 cells (Pruett-Miller, Connelly et al. 2008).
The IL2RG ZFN pair bind 5bp apart, leave 5’ 5bp overhangs at the site of the DSB. Such
overhangs are capable of capturing short DNA fragments by NHEJ (Orlando, Santiago
et al. 2010). DNA capture analysis by CLIS was carried out using 2 IL2RG ZFN pairs
which differed in DNA binding domain (Gabriel, Lombardo et al. 2011). 14 and 15
genomic loci were identified as targets for these ZFN pairs, 3 of which, FAM133B,
57
SLC31A1 and SEC16A, were common for both pairs and the KIAA0528 locus was also
predicted in silico which has 88% homology with the IL2RG target. One IL2RG ZFN pair
was noted to have more on target and less off target activity however whether this
was the ZFN pair used in previous Sangamo studies was undisclosed.
Assessment of the potential application of the IL2RG ZFN is promising. The rates of
gene targeting would be suitable to restore immune cells in SCID-X1 patients and the
low toxicity associated with this particular ZFN pair may pass for clinical use like CCR5.
However in order to make this progression these ZFN must be analysed in a suitable
model of SCID-X1 containing human IL2RG that on correction will restore the model’s
immune system and reveal any toxicity that may have been overlooked in in vitro
studies.
1.5.9 TALENs
ZFN utilise the dimerization of the endonuclease domain of FokI to unite 2 ZF regions
and complete the DNA binding region. A more recent advance in this type of gene
targeting strategy has been found in Transcription Activator-Like Effector Nucleases or
TALENs which unite DNA recognition molecules from pathogenic plant bacteria and
the FokI nuclease dimer. Unlike ZF, the TALE DNA recognition molecule is defined by its
two adjacent amino acids also known as the repeat variable di-residue (RVD) each
recognising 1 base pair (Boch, Scholze et al. 2009) which appear to be context
independent (Moscou and Bogdanove 2009), granting simple assembly of the
complete recognition domain. Another difference is where ZFN have been optimised
to bind DNA half sites with a 5-6bp spacer, TALENs require a 12-15bp spacer. The
structure of meganucleases, ZFN and TALENs are compared in figure 1.9.
A TALEN pair has been designed to target the same region of IL2RG as the
aforementioned ZFN (Mussolino, Morbitzer et al. 2011). Each TALEN monomer
recognises an 18bp sequence separated by a 15bp spacer. The TALEN pair actively
cleave exogenous DNA at the same rate as the IL2RG ZFN obligate heterodimer
however ZFN gene targeting in HEK293 cells is twice as efficient as the TALENs as
measured by NHEJ. However, these TALENs appear to be less toxic than the ZFN as
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seen in the statistically significant drop in cell survival from nearly 100% in TALENs to
50% in ZFN treated cells.
Due to the low toxicity shown by TALENs they may supersede ZFN for gene therapy,
but yet again, suitable animal models are a necessary step to clinical trials.
Figure 1.8 Comparison of a meganuclease, ZFN and TALEN.
A schematic representation, adapted from Curtin et al. (Curtin, Voytas et al. 2012) comparing
the binding of engineered genome modifying enzymes to DNA. DNA is represented by
individual nucleotides (n). Top, a monomeric meganuclease, for example I-SceI bound to
DNA with the catalytic site in dark green. The DNA binding LAGLIDADG motif is not shown.
Middle, a zinc finger nuclease (ZFN) binding DNA via the zinc fingers (ZF) in green. Bottom, a
transcription activator like effector nuclease (TALEN) binding DNA via the transcription
activator like effectors (TALE) in green. In both cases, the ZF and TALE are fused to the
catalytic domain of the FokI heterodimer which cuts the spacer region between the DNA
binding domains.
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1.6 Models of SCID-X1 for gene targeting
Animal models of SCID-X1 assessed for the efficacy of gene transfer from viral vectors
were murine il2rg knockouts and although these animals do have an immunodeficient
phenotype suitable for such gene transfer analysis, these knockouts are unsuitable for
IL2RG targeted correction strategies due to the lack of human IL2RG target. In order to
assess the efficacy of targeted gene correction of SCID-X1 it is important to establish
mammalian in vivo models with a genome suitable for the analysis of targeting
nucleases intended for human genes.
The progress made in gene targeting has been applied to animal model engineering. A
rat γc knockout was achieved by targeting exon 2 of the rat il2rg with ZFN (Mashimo,
Takizawa et al. 2010). The homozygous founder animals showed an immunodeficient
phenotype similar to that of the γc-/- mouse, with depleted CD8+ T cells, NK cells, B
cells and reduced IgG and diminished IgA and with a hypoplastic thymus. Although this
model of SCID-X1 has a suitable phenotype, it does not contain the target for human
IL2RG and cannot be used to ascertain the effects of ZFN designed for human SCID-X1.
Murine models are a very useful resource for human disease as they are mammalian,
their genome has been sequenced and they have already been extensively studied in
regards SCID-X1. Furthermore there is evidence of successful ZFN mediated gene
targeting in in vitro and in vivo murine studies.
By micro-injection of murine eggs with ZFN mRNA the surviving foetuses showed NHEJ
in 24-75% (Carbery, Ji et al. 2010) and HR in up to 25% on provision of plasmid donor
DNA (Cui, Ji et al. 2011). In the interest of therapeutic strategies, gene targeting of
pluripotent cells from mice is relevant to the treatment of human disease. mES cells
with a GFP transgene treated with GFP ZFN delivered by lipofection achieved
knockdown in 8% of cells (Osiak, Radecke et al. 2011) and HR in 0.21% (Connelly,
Barker et al. 2010). These ZFN treated mES cells were capable of forming teratomas (a
tumour with various tissue types) in vivo thus providing evidence that ZFN treatment
does not abrogate the pluripotent quality of ES cells. However, chromosomal
abnormalities were observed in a clonal cell line from the ZFN treated mES cells which
may have been due to chromosome activation by DSB or long term cell culture.
Although it has been observed that high doses of ZFN can increase cytotoxicity in
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murine stem cells, this does not appear to effect the expression of stem cell markers or
differentiation in vitro (Hoher, Wallace et al. 2012).
Gene targeting in primary cells has also been observed using nucleofection. Targeted
NHEJ of the murine “safe harbour” locus, ROSA26, occurred at a frequency of 11% in
primary skeletal myoblasts (Perez-Pinera, Ousterout et al. 2012) and targeted
correction of a GFP transgene in 1.8% of fibroblasts and 0.17% of astrocytes,
furthermore, ZFN treated fibroblasts were successfully transplanted into an
immunocompetent recipient (Connelly, Barker et al. 2010).
A very promising development in the in vivo ZFN treatment of a humanised murine
model of Haemophilia B was carried out by Li et al., (Li, Haurigot et al. 2011). This
mouse model has a mutated human gene for factor IX (hF9) knocked into the ROSA26
locus and integration of a cDNA containing exons 2-8 at the ZFN binding site in intron 1
will restore Factor IX expression. Delivery of ZFN and donor DNA by intraperotineal
injection of hepatotophic AAV vector (AAV8) resulted in targeted HR ranging from 1-
3% in liver tissue analysed after 10 weeks. NHEJ also occurred at a frequency ranging
from 11-17% and no integration of donor alone was detected by PCR. The corrected
loci resulted in circulating hFactor.IX at 3-7% of the normal levels and reduced clotting
time to almost normal levels. Analysis of 20 off target sites predicted by SELEX showed
one site that had been targeted at a tenth of the rate of hF9 site.
It can be seen that ZFN gene editing is applicable in mice. The gene targeting
frequencies in murine primary cells are similar to the rates seen in human (Table 1.1)
and a range of DNA delivery can be utilised and optimised. The benefit of using
humanised mouse models is the analysis of designed for humans in an environment
that contains physiological epigenetic features and a mammalian DNA repair response.
1.7 Summary and Project Aims
Due to the efficacy of IL2RG modified HSCT for the treatment of SCID-X1 and the
potential to correct this gene in situ, the purpose of this project is to continue the
assessment of the suitability of IL2RG ZFN induced HR for the treatment of SCID-X1.
Using a novel cell line model of SCID-X1 it is hypothesised that ZFN plus a correction
donor plasmid will restore γc signalling in vitro. This project also investigates a new
humanised model of SCID-X1 to confirm a loss of γc function that can subsequently be 
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restored by gene targeted strategies and it is postulated that optimised ZFN mediated
correction of HSC could restore a complete and functional immune system in vivo.
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Materials and methods
2.1 Reagents and abbreviations
Reagent Supplier
Dimethyl sulfoxide (DMSO) Sigma
Restriction endonucleases and buffer
Promega or New
England Biolabs (NEB)
Agarose Life Technologies
1kb Plus DNA Ladder Life Technologies
SeeBlue Plus2 Life Technologies
Agar MERCK
Ampicillin Stratagene
Dulbecco’s modified eagle medium (DMEM) Life Technologies
Roswell Park Memorial Institute (RPMI) medium Life Technologies
Fetal Calf serum (FCS) Life Technologies
Antibiotic-Antimitotic (Anti-Anti) Life Technologies
OPTI-MEM Life Technologies
Trypan Blue Sigma
Phosphate Buffered Saline (PBS) Sigma
SOC medium Life Technologies
Stem Span StemCellTechnologies
ESGRO Millipore
Accutase Millipore
0.1% Gelatine Millipore
Alkaline phosphatase detection kit Millipore
10x Red Blood Cell Lysis buffer Biolegend
High Fidelity (HF) Taq New England Biolabs
Go Taq Green 2x mastermix Promega
Platinum Quantitative PCR supermix–UDG with ROX Life Technologies
Cells Direct One-step qRT-PCR kit Life Technologies
T4 ligase Promega
DNeasy Qiagen
Sodium Carbonate (Na2CO3) Sigma – Aldrich
Sodium Hydrogen Carbonate (NaHCO3) AnalaR
Bovine Serum Albumin (BSA) Sigma
Sucrose AnalaR
Tween 20 Sigma – Aldrich
Sulphuric Acid Aldrich
Sodium Dodecyl Sulfate (SDS) Sigma – Aldrich
Sodium hydroxide (NaOH) Sigma – Aldrich
Sodium Chloride (NaCl) Fluka
Tri-Sodium Citrate AnalaR
Tris base Fluka
Ethylenediaminetetraacetic acid (EDTA) AlfaAesar
Sodium phosphate dibasic (Na2HPO4) Sigma
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Sodium dihydrogen phosphate (NaH2PO4) Sigma
Potassium Chloride Sigma
KaryoMAX (Colcemid) Life Technologies
Methanol Sigma
Acetic Acid, 100% (analytical grade) Sigma
Tetramethylbenzidine (TMB) Solution BD biosciences
Streptavidin Horse Radish Peroxidase (Strep – HRP) BD Pharmingen
Streptavidin-Cy5 conjugate Life Technologies
AccuCheck Counting Beads Life Technologies
Kits
TnT quick coupled transcription/translation system Promega
QuikChange Site Directed mutagenesis kit Stratagene
Endofree maxi prep kit Qiagen
Gel extraction kit Qiagen
Mini/maxi prep kit Qiagen
PCR purification kit Qiagen
RNA extraction kit Qiagen
DNA labelling system GE Healthcare
Murine lineage negative Magnetic activated cell selection Miltenyi biotech
Amaxa Cell line nucleofector kit V Lonza
Amaxa mES cell kit Lonza
Amaxa human CD34+ cell nucleofector kit Lonza
Amaxa mouse macrophage nucleofector kit Lonza
Cytokines
Stem Cell Factor (SCF) Peprotech
Murine Flt3 Peprotech
Human Thrombopoietin (hTPO) Peprotech
Human Interleukin 2 (hIL-2) Peprotech
Human Interleukin 7 (hIL-7) Peprotech
Concanavalin A (ConA) MP Biomedicals
Table 2.1 Reagents and abbreviations
2.2 Antibodies
Antibody Clone Supplier
Western
Anti-HA (rabbit) Polyclonal Rabbit anti HA Novus Biologicals
Anti-HA-HRP (Goat) A190-107P Bethyl Laboratories
Anti-GFP (Mouse) MAB3580 Chemicon International
Anti-Rabbit - 680LT LI-COR
Anti-mouse - 680LT LI-COR
Flow Cytometry
Anti CD3 – PE Hamster anti mouse 145-2C11 BD Pharmingen
Anti CD4 – PE Rat anti Mouse GK1.5 eBiosciences
Anti CD4 – FITC Rat anti mouse GK1.5 BD Pharmingen
Anti CD8 – APC Rat anti mouse 53 – 6.7 BD Pharmingen
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Anti B220 – APC Rat anti mouse RA3 – 6B2 BD Pharmingen
Anti IgM – PE Rat anti mouse R6-60.2 BD Pharmingen
Anti IgM – FITC Rat anti mouse R6-60.2 BD Pharmingen
Anti NK1.1 – APC Mouse anti mouse PK136 BD Pharmingen
Anti γc – PE  AG184 BD Pharmingen 
Anti γc – APC  TUG-H4 BioLegend 
Anti pSTAT-5 – PE Mouse anti pSTAT5 pY694 BD Pharmingen
ELISA
Capture antibody
IgA C10-3 BD Pharmingen
IgE R35-72 BD Pharmingen
IgM II/41 BD Pharmingen
IgG Polyclonal rabbit anti mouse IgG AdD Serotec
IgG1 A85-3 BD Pharmingen
IgG2a R11-89 BD Pharmingen
IgG2b R9-91 BD Pharmingen
IgG3 R9-91 BD Pharmingen
Detection Antibody
IgA - Biotin C10-1 BD Pharmingen
IgE - Biotin R35-118 BD Pharmingen
IgM - Biotin II/41 eBioscience
IgG - Biotin Polyclonal rabbit anti mouse IgG Dako
IgG1 - Biotin X56 BD Pharmingen
IgG2a - HRP R19-15 BD Pharmingen
IgG2b - HRP R12-3 BD Pharmingen
IgG3 - Biotin R40-82 BD Pharmingen
Table 2.2 Antibodies
2.3 Cell lines
Escherichia coli (E. coli) XL10-Gold Chemically competent Stratagene
Escherichia coli (E. coli) DH5α Chemically Competent Cells Invitrogen 
ED-7R Human T cell line Gift: I. Alexander
ED-γc-7R Human T cell line Gift: I. Alexander 
293T
Human embryonic kidney cell line
(HEK293T) ATCC: CRL-11268
hγcmut mES 
Murine embryonic Stem cells
(mESC) InGenious
Table 2.3 Cell lines
2.4 Animal maintenance
All mice (wild type and genetically modified) came from the C57BL/6 genetic
background and were maintained adhering strictly to the Home Office licencing laws.
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All experimental practises were performed under both a personal licence (Celeste
Pallant unless otherwise indicated) and a project licence.
2.4.1 Engineering the humanised mouse model
The outline of the generation of the humanised mouse model was carried out by
InGenious as follows. A 5518bp region of the human γc gene was subcloned from a 
human BAC clone into a shuttle vector (pSP72, Promega). MluI sites were engineered
at the 5’ and 3’ ends by Red/ET recombineering. The G691A mutation was
incorporated into exon 5 of the human γc gene by overlap extension PCR before 
transfer into the mouse sequence. A 14.4kb region of the mouse γc gene was 
subcloned from a C57BL/6 BAC (RP23: 263O9) clone; this contained the murine
homology arms and the target region to be replaced by the human gene, flanked by
MluI. The 5’ murine homology arm was 7.1kb and the 3’ homology arm was 2.3kb. The
murine sequence replaced was 5106bps long and included the entire coding sequence
of the γc mouse gene. The resulting vector also included a neomycin resistance gene. 
The target vector was delivered to murine embryonic cells by electroporation.
Successfully recombined cells were selected for by neomycin treatment. The neomycin
cassette was flanked with LoxP-FRT allowing the neomycin resistance gene to be
excised from the genome via Cre-Lox recombination. Successful generations resulting
from the injection of these embryonic stem cells into pseudo-pregnant mice were
sequenced to confirm the presence of the mutant human γc allele and deletion of the 
neomycin resistance cassette.
2.4.2 Isolation of primary murine cells
Primary cells were harvested from the following tissues: Spleen, lymph nodes, thymus,
bone marrow (muscle were removed and thebone marrow was flushed from the
femurs and tibias using a 23G needle) and peripheral blood. Peripheral blood was
harvested either at sacrifice by cardiac puncture with a 23G needle or was harvested
from the living mouse by warming the animal with an infrared lamp to locate the tail
vein for blood extraction with a 23G needle. All tissues except peripheral blood were
macerated through 7um pore gauze to achieve a single cell suspension. The single cell
suspension was then centrifuged at 400g for 5 minutes, re-suspended in 10mL of red
blood cell lysis buffer and incubated at room temperature for 10 minutes. The cell
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suspension was then centrifuged at 400g for 5 minutes and re-suspended in the
medium suitable for the subsequent step.
2.4.3 Isolation and culture of Murine Lin- cells
Bone marrow isolate passed through 7um pore gauze was negatively selected for Lin-
cells as per the MACS Lin- selection kit instructions. 108 cells were prepared per LS
sized MACS column and values follow per 108 cells. Cells were centrifuged at 300g for
10 minutes and re-suspended in 400μl of MACS buffer (0.5% BSA, 2mM EDTA), 100μl 
Biotin-antibody cytokine cocktail was added and the cells incubated at 4ºC for 20
minutes. Cells were washed in 5ml of MACS buffer and centrifuged at 300g for 10
minutes. The cells were re-suspended in 800μl of MACS buffer and 200μl of Anti-Biotin 
microbeads added. Cells were incubated at 4ºC for 30 minutes. The cells were washed
in 5ml of MACS buffer and centrifuged at 300g for 10 minutes. Cells were re-
suspended in 500μl of MACS buffer and the cells were applied to the LS columns, pre-
prepared by rinsing with 3ml of MACS buffer. Cell effluent was allowed to drip through
by gravity. For the reconstitution experiment the effluent was applied to a second LS
column pre-prepared by rinsing with 3ml of MACS buffer. The effluent from the MACS
columns was centrifuged at 300g for 10 minutes and re-suspended at 106 cells/mL in
complete StemSpan 1% penicillin/streptomycin plus cytokines at the following
concentrations: SCF (100ng/mL), mFlt3 (100µg/mL) and hTPO (25ng/µL). A 24 well
plate was then seeded at 105 cells per well. The cells were left to recover at 37°C for 4
hours.
2.4.4 Transduction of Murine Lin- cells
To prepare the murine Lin- cells for tail vein injection into mice, the recovered Lin- cells
were transduced mL in complete StemSpan, 1% penicillin/streptomycin plus cytokines
at the following concentrations: SCF (100ng/mL), mFlt3 (100µg/mL) and hTPO
(25ng/µL), with integration proficient lentiviral vector at various multiplicity of
infection (MOI) overnight. The cells were then centrifuged at 300g for 10 minutes and
re-suspended in 200µl of RPMI.
2.4.5 Irradiation and tail vein injection of mice
Mice were irradiated with total of 10 Gray by a split dose of 6 Gray followed by 4 Gray
24 hours later. 2x105 transduced murine lin- cells were administered via tail vein. Both
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the irradiation and tail vein injection were performed by Michael Blundell, holder of a
personal licence and relevant project licence.
2.4.6 Splenocyte proliferation assay
Total splenocytes suspended in splenocyte medium (DMEM, 10%FCS, 0.05 Beta-2-
mercaptoethanol, 1x antibiotic-antimitotic) were plated at 2x105 cells per well in a
round bottom 96 well plate, in triplicate. The cells were incubated with and without
Concanavalin A (Con A) (1µg/ml). Cells from either splenocyte medium alone or with
Con A were also stimulated with either IL-2 (20ng/ml) or IL-7 (20ng/ml) or without.
Following incubation at 37°C, 5% CO2 for 48 hours, the cells were then pulsed with 1µl
of methyl-3H-thymidine (0.037 MBq) for 12 hours. Uptake of methyl-3H-thymidine was
determined by counts per minute detected by a beta-counter (MicroBeta TAILUX,
Wallac).
2.5 Tissue Culture
2.5.1 ED7R
The ED7R cell line is a non-adherent cell line (Table 2.1) (Maeda, Shimizu et al. 1985).
The cells were grown in ED7R growth medium (RPMI1640 with Glutamax, 20% FCS and
1% Antibiotic-Antimitotic) and incubated in 175cm2 tissue flasks (NUNC) at 37°C with
5% CO2. Following medium colour change, the cells were passaged to achieve a 1x105
cells/ml concentration.
2.5.2 293T
The 293T cell line is an adherent, packaging cell line. The cells were grown in 293T
growth medium (DMEM with Glutamax, 10% FCS and 1% Antibiotic-Antimitotic) and
incubated in 175cm2 tissue culture flasks (NUNC) at 37°C with 5% CO2. When the cells
reached 80-90% confluence, the monolayer was washed in PBS and detached from the
flask with trypsin/EDTA then incubated at room temperature for 5 minutes. The cells
were then passaged at a 1:10 dilution with growth medium.
2.5.3 murine ES cells (mES)
An adherent murine embryonic stem (mES) cell line from the hγcmut mouse were 
cultured in a feeder free system whereby 3ml of 0.1% gelatine is incubated in a 25 cm2
flask for 30 minutes and the excess removed. mES cells are then thawed, washed in
PBS and seeded in ESGRO. Once the cells formed embryoid bodies but before they
became completely differentiated, accutase (1x) was used to manufacturers
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instruction to detach the cells from the flask and from each other. The cells were then
split 1:3.
2.5.4 Long term storage
The cells were stored long term by centrifuging the cells at 400g for 5 minutes, re-
suspended in freezing medium (90%FCS, 10%DMSO), aliquoted into cryovials (NUNC)
and slowly frozen in a freezing chamber to -80°C. The cells were then transferred to
liquid nitrogen.
Cells were thawed rapidly in a 37°C water bath and the DMSO was diluted with growth
medium. The cells were centrifuged at 500g for 5 minutes, re-suspended in growth
medium and propagated as described.
2.6 Bacterial Manipulation
2.6.1 Gel electrophoresis
DNA fragments were visualised by loading on to a 0.8% - 1.5% agarose gel containing
0.5μg/mL ethidium bromide and separated by electrophoresis at 20 volts – 100 volts in 
1x TAE buffer (40mM Tris-acetate, 5mM EDTA) as indicated. Expected fragment length of
<1kb underwent electrophoresis for 30 minutes or 60 minutes for >1kb. The DNA was
visualised using ultra violet (UV) light.
2.6.2 Bacterial transformation
A frozen aliquot of 30-50µl of chemically competent E. coli was kept on ice, 10-50ng of
DNA was added and the cells were incubated on ice for 30 minutes. They then
underwent heat shock at 42°C for 30 seconds and put directly on ice. SOC medium was
added and the cells were incubated at 37°C for 1 hour, agitated at 250rpm. 50-500µl of
the transformed E.coli were then streaked onto LB agar plates containing the
appropriate antibiotic and incubated at 37°C overnight. Individual E.coli colonies were
then selected and grown in LB broth at 37°C, agitated at 250rpm. E.coli was stored long
term in 16% glycerol at -80°C.
2.6.3 Plasmid DNA preparation
E.coli expressing the plasmid of choice was grown for either small scale or large scale
plasmid DNA preparation. DNA was synthesised by E.coli and extracted using a Mini-
Prep kit (small scale) or a Maxi-prep kit (Large scale) carried out to the manufacturer’s
instructions.
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DNA concentration was measured using a Nano-Drop spectrophotometer. The
measurements were taken with a 0.2mm pathlength at a wavelength of 269nm (A260).
2.6.4 Restriction enzyme digests
For a 10µl reaction, miniprep DNA (1µg), restriction enzyme (10 units), corresponding
restriction enzyme buffer (1µl) and water to the volume of 10µl were incubated at
37°C for 1 hour. The products were then loaded alongside a 1Kb+ DNA ladder on a 1%
agarose gel containing ethidium bromide. After electrophoresis the gel was visualised
using UV light.
2.7 DNA cloning and analysis
2.7.1 Karyotype analysis
Cells were prepared for karyotype analysis as follows. 106 ED7R cells in 10ml of ED7R
growth medium (RPMI1640 with Glutamax, 20% FCS and 1% Antibiotic-Antimitotic)
were treated with 50μl Colcemid (KaryoMAX 10μg/ml) over night. Cells were 
centrifuged at 300g for 10 minutes. Cells were re-suspended in Potassium Chloride
(0.075M). Cells were centrifuged at 300g for 10 minutes and as much potassium
chloride was removed as possible. Freshly made (within 30 minutes) ice cold fix (30ml
methanol, 10ml acetic acid) was added drop wise for 10 drops with intermittent
flicking followed by 5ml. Cells were centrifuged at 300g for 10 minutes and re-
suspended in 5ml of fresh fix without slow re-suspension. Karyotype analysis was
carried out by Nikki Austin at Great Ormond Street Hospital.
2.7.2 PCR
DNA template (100ng) was used per reaction. Annealing temperatures and extension times
varied according to the primers and fragment length as indicated.
When 2x Go-Taq green mastermix was used the reaction was prepared to manufacturer’s
instruction and performed with an initial denaturation at 95°C for 2min followed by 35
amplification cycles consisting of denaturation at 95°C for 30s, primer annealing for 30s,
extension at 72°C for 1min/kb, and a final extension step at 72°C.
When 2x HF Taq mastermix was used the reaction was prepared to manufacturer’s instruction
and performed with an initial denaturation at 98°C for 2min followed by 35 amplification
cycles consisting of denaturation at 98°C for 30s, primer annealing for 30s, extension at 72°C
for 30 seconds/kb, and a final extension step at 72°C.
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2.7.3 Genotyping the humanised mouse strain
Mice were ear notched at 3 weeks of age for identification and genotyping. DNA was
released from the tissue using DNAreleasy to manufacturers instruction. The genomic
DNA was then amplified with the GoTaqGreen 2x mastermix containing forward (F)
primers to either human IL2RG:
5’TCTGGAATTTCTGGGCTCAC
or murine il2rg:
5’TTCATTCAACCCACCTGCGTCTC
and the reverse (R) primer to the region downstream of murine il2rg:
5’ CCACCCCTATAGATGCTGACAAC
Polymerase chain reaction (PCR) was performed with an annealing temperature of
54°C. Products were then run on a 1% agarose gel for 30 minutes at 100 volts and
visualised using UV light.
2.7.4 Site Directed mutagenesis
Complementary primers were designed using Stratagene’s primer design software.
F: 5’- GTTTCGTGTTCGGAGCCACTTTAACCCACTCTGTG and
R: 5’- CACAGAGTGGGTTAAAGTGGCTCCGAACACGAAAC
Site directed mutagenesis was then carried out to manufacturer’s instruction.
2.7.5 Modifying the ZFN binding site in the donor
Linker PCR was conducted in order to introduce the modified binding site MB17. HF-
Taq was used to amplify 2 fragments with the following primer pairs:
F:5’-GGAGCCGCACAATGGATTGAATCTTGATCTAACACGAAACGTGTAGCGTTTCTG
R:5’-TCACCCTTCTCCCAGTTGTC and
R5’-GGAGCCGCACAATGGATTGAATCTTGATCTAACACGAAACGTGTAGCGTTTCTG
F5’- GACAGAGCCTCACTCTGTTGC
respectively generated the 2 arms of the homology domain with a complimentary
overlapping section. These products were purified on Qiagen PCR purification columns
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(to manufacturer’s instructions). A second HF-Taq PCR using these two fragments plus
the flanking primers
F: 5’-TCACCCTTCTCCCAGTTGTC and R: 5’- GACAGAGCCTCACTCTGTTGC
generated the homology domain for the modified binding site donor. This blunt PCR
product was then cloned into pJet using the Fermentas clone jet system (performed to
manufacturer’s instruction).
2.7.6 Cloning the modified binding site (MBS) into the complete γc gene 
The MBS donor vector and the Wild type γc (WT γc) expression vector were digested 
with restriction enzymes NcoI and Bsu361 to create sticky ends. The correct bands
were excised from the gel and purified using the gel purification kit (Qiagen, to
manufacturer’s instruction). The fragments were then ligated at a 1:3 ratio of γc 
backbone:MBS donor insert with Promega T4 ligase to manufacturer’s instruction. The
modified γc expression vector was transfected into 293T cells, 48 hours later γc 
expression analysed by Flow cytometry.
2.7.7 DNA preparation
To assess the transgene copy number in the ED7RγcΔ and ED7RγcWT clonal cell lines, 
Chromosomal DNA was isolated by the salting out method of DNA extraction. 106 cells
were resuspended in 3mL of nuclear lysis buffer (10mM Tris-HCl pH8.2, 0.4M NaCl,
2mM Na2EDTA), 200µl 10% SDS and 537µl proteinase K solution (2mg/ml Proteinase K,
1% SDS, 2mM Na2EDTA) and incubated at 37 °C overnight. 1mL of 6M NaCl was added
and shaken to precipitate out the cellular debris which was then pelleted by
centrifugation at 1309g for 15 minutes. The DNA in the supernatant was isolated from
the debris and precipitated out with 10mL of ethanol. The chromosomal DNA was then
pelleted by centrifugation at 3351g for 30 minutes. The pellet was washed with 70%
ethanol, centrifuged again at 3351g for 15 minutes and dissolved in 500µl TE buffer
(10mM Tris, 1mM EDTA, pH8) at 37°C overnight.
10µg of chromosomal DNA was digested in 10 units of restriction enzyme to a
maximum volume of 20μl at 37°C overnight and the DNA products were separated on 
a 0.8% agarose gel at 30 volts overnight.
In a separate use of the Southern blot, utilised to quantify the rate of homologous
recombination in ZFN and repair donor DNA treated samples, template for the
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Southern blot was prepared by amplifying a 1,901bp product from the samples to be
quantified for targeted HR with primer pair 3
F: 5’-TGAACCACTGTTTGGAGCAC and R: 5’-AGGTTCTTCAGGGTGGGAAT
Following gel purification (Qiagen, to manufacturer’s instruction) 100ng of the PCR
product was digested with BsrBI with or without DraIII, to a total of 1µl per 10µl
digestion reaction, at 37°C for 1 hour. The digestion products were separated by
electrophoresis on a 1% agarose gel alongside a 1Kb plus ladder.
2.7.8 Southern blot
The DNA products were blotted onto a membrane (Amersham Hybond-N membrane)
overnight by capillary transfer in alkaline denaturing buffer (0.4M NaOH). The
membrane was washed in 2 x SSC (3M NaCl, 0.3M tri – sodium citrate dihydrate), dried
and stored at 4°C.
The membrane was pre-hybridised in 10ml of Church buffer (1% BSA, 7% SDS, 0.4M
Na2HPO4, 0.1M NaH2PO4) at 65°C for 1 hour.
To quantify the rate of HR, a radiolabelled probe was designed to bind the 5’ half of
the digested products and was produced by amplifying a 1002bp product from a γc 
expression plasmid with the primer pair 1:
F: 5’-CAAGATTCAATCCATTGTGCG and R: 5’-AGGTTCTTCAGGGTGGGAAT
Two probes were generated to detect the copy number of transgene by restriction
enzyme digest of the lentiviral construction plasmid.
Following gel purification (Qiagen, to manufacturer’s instruction), 25ng of the PCR
product was labelled with [α-P32]dCTP (Megaprime DNA Labelling System) to
manufacturer’s instructions. Unincorporated nucleotides were removed from the
probe by centrifugation through a microSpin –s-300 HR column (Amersham). Having
denatured the probe at 98°C for 5 minutes and cooling on ice, it was added to the
hybridisation tube containing the membrane and hybridisation was performed with
rotation at 68°C overnight.
The membrane underwent sequential washes with SDS (0.5%) and decreasing
concentrations of SSC (2x, 1x 0.5x, and 0.2x) at 65°C for 30 minutes/wash until no
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significant background signal (as determined by a Geiger counter) could be
determined. The membrane was then dried and sealed in cellophane and exposed for
a minimum of 10 minutes to a maximum of 2 weeks to a phosphor screen and was
processed using a Molecular Dynamics Typoon 9410 phosphorimager (GE Life Sciences,
Piscataway, NJ) and analysed using the ImageJ software.
2.7.9 Quantitative PCR (qPCR)
Genomic DNA (100ng) extracted using the Qiagen DNA extraction kit was used as a
template for each reaction. Each reaction consisted of primer (0.9 µM), fluorescent
probe (0.2 µM) and the Platinum qPCR SuperMix-UDG with ROX mastermix and was
performed in triplicate and real time PCR was carried out to manufacturers instruction
and quantified using an ABI Prism 7000 (Applied Biosystems, Foster City, CA). Primers
and probe designed to detect β-actin were designed in house and the primers and
probes to detect titin and WPRE were a kind gift from Anne Galy, Genathon. A plasmid
encoding the WPRE, β-actin and murine titin sequences, designed by Conrad Vink, was
titrated and used as a standard for DNA copy number
Primers to human β-actin
F: 5’-TCACCCACACTGTGCCCATCTACGA and
R: 5’-CAGCGGAACCGCTCATTGCCAATGG
Probe to detect human β-actin
F: 5’-FAM-ATGCCCTCCCCCATGCCATCCTGCGT-TAMRA
Primers to WPRE
5’-TTCTCCTCCTTGTATAAATCCTGGTT and R: 5’-CGCCACGTTGCCTGACA
Probe to detect WPRE
5’-FAM-CTGTCTCTTTATGAGGAGTTGTGGCCCG-TAMRA
Primers to detect murine titin
F: 5’-AAAACGAGCAGTGACGTGAGC and R: 5’-TTCAGTCATGCTGCTAGCGC
Probe to detect murine titin
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5’- FAM-TGCACGGAAGCGTCTCGTCTCAGTC-TAMRA
2.7.10 Detecting HR after transfection with ZFN and MBS donor
48 hours after transfection with plasmid, genomic DNA was harvested and a PCR
performed using the Primer pairs:
To detect the MB17 cassette:
1: F:5’-CAAGATTCAATCCATTGTGCG and R:5’-AGGTTCTTCAGGGTGGGAAT
2: F:5’-CGCACAATGGATTGAATCTTG and R:5’-TGAACCACTGTTTGGAGCAC
To detect the MB3 cassette:
1: F:5’-GGAGCCGCTTCAATCCG and R:5’-AGGTTCTTCAGGGTGGGAAT
2: F:5’-CGCACAATGGATTGAATCTTG and R:5’-CACTTCCACAGAGCGGATTG
To amplify the region outside of donor homology:
3: F:5’-TGAACCACTGTTTGGAGCAC and R:5’-AGGTTCTTCAGGGTGGGAAT
GoTaq 2x master mix was used to manufacturer’s instruction with an annealing
temperature of 60°C and an extension time of 90 seconds. The products then
underwent gel electrophoresis on a 1% agarose gel at 100V for 30 minutes.
2.7.11 Detecting insertions and deletions (Indels)
Genomic DNA that has undergone targeted NHEJ can be denatured and re-annealed to
give rise to areas of mismatched DNA which can subsequently be recognised and
digested by T7 endonuclease or Cel-1. 96 hours after 293T cells or ED7R cells were
transfected or transduced with ZFN encoding vectors, genomic DNA was extracted
(Qiagen DNeasy kit to manufacturer’s instruction). Genomic PCR was carried out with
High Fidelity (HF) Taq and primers which flank the ZFN target sequence on either side
F: 5’-TCAGTGAAGGGAGCAGTGTG and R: 5’-AACAACACGCTAACCCAACC
to amplify a 500bp template for the T7 endonuclease assay. To achieve a DNA
template with an area of mismatch 100ng of purified PCR product was incubated with
enzyme buffer 2 (NEB) at 98°C for 5minutes and allowed to cool. T7 endonuclease
(NEB) was then added and incubated at 37°C for 20 minutes. Alternatively the Cel-1
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surveyor assay was performed to manufacturer’s instruction. The cleavage product
was separated by gel electrophoresis on a 1.5% agarose gel at 90V for 30 minutes.
2.7.12 TnT lysate assay
500bp products were amplified from Wild type, mutant γc or the MBS donor with 
primers
F: 5’-TCAGTGAAGGGAGCAGTGTG and R: 5’-AACAACACGCTAACCCAACC
ZFN were translated in a microtube using the TnT rabbit lysate kit (to manufacturer’s
instruction). The product of translation was then incubated with 100ng of purified PCR
product NEB buffer 4, 0.1M NaCl, 1% BSA at 37°C for 1 hour 30 minutes. The digest
then underwent electrophoresis on a 1.5% agarose gel at 90V for 30 minutes.
2.8 Lentivirus production
The packaging cell line 293T cells were grown to 70-80% confluence in a 175cm2 flask
and washed with optimem before transfection. The Lentiviral vector DNA (40µg), VSV-
G plasmids pMDG.2 (10µg), packaging plasmid for integrating proficient lentivirus
pCMVRΔ8.74 (gag-pol) or integrating deficient lentivirus pCMVRΔ8.74 D64V (30µg) and 
OPTI-MEM (5mL) were filtered through a 0.22µl filter (Millipore). The transfection
reagent polyethylenimine (PEI) (1µl) and OPTI-MEM (5mL) was filtered separately
through a 0.22µm pore filter. The filtered vector and transfection reagent were mixed
and incubated together at room temperature for 20 minutes and added to the 293T
cells before incubating for 4 hours at 37°C and 5% CO2. At this point the supernatant
was replaced with fresh 293T growth medium and incubated at 37°C and 5%CO2 for 48
hours. The viral supernatant was then harvested, the cell debris was spun down at
3351g for 10 minutes in a table top centrifuge and the supernatant filtered through a
0.22µm pore filter. The virus was then concentrated by centrifugation at 98,000g for 2
hours. The pellets were re-suspended in OPTI-MEM (200μl) and stored at -80°C. Fresh 
293T growth medium replaced the viral supernatant on the same transfected 239T
cells which were again incubated at 37°C 5% CO2 and the viral supernatant was
harvested again as described 24 hours later.
2.8.1 Quantification of viral vector stocks
The titres of lentiviral vector stocks were quantified by either qPCR or flow cytometry.
5x105 ED7R cells in ED7R growth medium were plated in round bottomed 96 well
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plates (NUNC). A titration of virus (0.5, 1, 2.5, 5 or 7.5µl) was then added to the wells
with a final volume of 200µl. The cells were then incubated at 37°C and 5% CO2 for 2
days. On day 3 the cells were harvested and analysed. ED7R cells transduced with ZFN
and donor DNA constructs were analysed for integrated WPRE by qPCR. ED7R cells
transduced with IL2RG of GFP constructs were analysed for γc and GFP expression 
respectively by flow cytometry. Samples less than 30% positive for the viral construct
were used for the calculation of viral titre as positive cells should only have 1 copy of
vector. To calculate the amount of viral vector per mL, the following equation was
used: (percentage+/100) x number of ED7R cells transduced x (1000/μl of vector used). 
In subsequent transductions a multiplicity of infection (MOI) was calculated from these
values.
2.9 Nucleofection
Cells were centrifuged at 300g for 10 minutes, re-suspended in nucleofection solution
and pulsed per manufacturer’s instruction. Cells were then transferred to medium pre-
warmed to 37°C and incubated at 37°C and 5% CO2.
2.9.1 ED7R cells
2x106 ED7R cells were re-suspended in Lonza nucleofection solution V and DNA (2µg)
then pulsed with programme X-001. The cells were immediately transferred to ED7R
growth medium.
2.9.2 mES cells
2x106 mES cells were then re-suspended in Lonza nucleofection solution for murine ES
cells and 2µg of DNA and pulsed with programme A-30 as directed. The cells were
immediately transferred to ESGRO.
2.9.3 Lineage negative (lin-) cells
1x106 lin- cells were then re-suspended in Lonza nucleofection solution. 3
nucleofection kits were used (i) for macrophages and pulsed with the suggested
programmes for nucleofection (ii) for human CD34+ cells and pulsed with the
programme U-008 (iii) with solution V and pulsed with programme X-001. The cells
were immediately transferred to complete Stem-Span.
2.10 Flow cytometry
Cells were incubated with fluorophore conjugated antibodies, diluted to
manufacturer’s instruction in a volume of 100µl of FACS buffer (PBS with 1% FCS),
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incubated for 30 minutes at 4°C and washed twice with FACS buffer. The cells were
acquired on a Calibur (BD Biosciences) flow cytometer and the cell populations
analysed using FLOWJO software.
2.10.1 Episomal knockdown assay
1.3x105 293T cells were and seeded in to a 24 well plate and incubated at 37°C for 4-17
hours. The adhered cells were then transfected with a combination of plasmids
encoding ZFN EA, KV, γc-GFP fusion construct, mCherry, ∆Sce1 or mock (Appendix 3). A 
total of 2.5µg of DNA was incubated with 50µl PEI (0.1g PEI/L, 150nM NaCl, HCL to
pH5.5), incubated for 10 minutes at room temperature and transferred to the cells. 96
hours later the cells were harvested and acquired by a flow cytometer.
2.11 Western blot analysis
96 hours after 293T cells were transfected with ZFN encoding plasmids, the protein
lysate was harvested with Lysis buffer (20mM Tris pH 8.0, 100mM NaCl, 0.2% NP-40,
0.2% Triton X-100, 0.2% deoxycholate) plus protease inhibitor. Protein concentration
was determined with the BIORAD kit (carried out to manufacturer’s instruction) and
the absorbance read at 750nm. Equal amounts of protein lysate was loaded on to a
separating gel (1M Tris pH8.8, 30% AA/BAA, 20%SDS, 10%APS, TEMED) with stacking
gel (1M Tris pH 6.8, 30% AA/BAA, 20%SDS, 10%APS, TEMED) and underwent
electrophoresis at 175V for 70 minutes. The separated protein bands were transferred
on to a polyvinylidene fluoride (PVDF) membrane in transfer buffer (25mM Tris, 190
mM glycine, 20% methanol, 12g Tris, 57.6g glycine, H2O and MeOH) between 2
sponges. Transfer was performed at 100V for 1 hour at 4°C. The membrane was
removed from the transfer set up and incubated in blocking buffer (5% milk powder in
PBS, 0.5% tween) under gentle agitation overnight. The membrane was incubated with
primary antibody diluted to manufacturer’s instruction in PBS, 0.5% Tween, 2% BSA
and incubated for 1 hour at 25°C under agitation. The membrane was washed in PBS
0.5% tween 2x 5 minutes. The membrane was incubated with the appropriate
secondary antibody diluted to manufacturer’s instruction for 1 hour under gentle
agitation. When the membrane bound protein bands were detected with fluorescence
conjugated antibodies, the bands were detected by their fluorescence. Alternatively,
when protein bands were detected by HRP conjugated antibodies, they were visualised
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using enhanced chemiluminescence (ECL) using an UVIchemi (UVItec)
chemiluminescence documentation system and UVIsoft (UVItec) software.
2.12 The pSTAT-5 assay
1x105 nucleofected or non-nucleofected, ED7Rγc or ED7R γcm cells were incubated 
overnight in complete RPMI medium. The following day the cells were washed once in
PBS, pelleted by centrifugation in a table-top centrifuge at 400g for 5 minutes and re-
suspended in 200 µl of RPMI only. The cells were split between two FACS tubes and
human IL-2 was added to one of the tubes to a final concentration of 100 ng/µl. The
cells were incubated at 37°C with 5% CO2 for 10 minutes, pre-warmed (37°C) FACS
lyse/fix buffer (1:5 dilution) was added to each tube. The cells were then incubated for
a further 10 minutes at 37°C with 5% CO2. The cells were pelleted by centrifuging at
400g for 5 minutes, the supernatant was decanted and the cell pellets re-suspended in
1ml of cold Perm Buffer III. The cells were then incubated on ice for 30 minutes. The
cells were washed once with 1ml of FACS buffer. The cells were then stained with anti-
pSTAT5-PE and incubated on ice for 30 minutes. The cells were subsequently washed
twice with 1ml of FACS buffer and finally re-suspended in FACS buffer supplemented
with 1% (volume for volume) paraformaldehyde solution and analysed by flow
cytometry.
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2.13 Immunoglobulin ELISA assay
Capture
Antibody
FINAL CONC
Sample Serum
dilution
Detection
Antibody
Dilution
HRP
IgA 2µg/ml 1/100 1/250 yes
IgE 2µg/ml 1/10 1/250 yes
IgM 2µg/ml 1/250 1/250 yes
IgG 2µg/ml 1/81000 1/5000 yes
IgG1 2µg/ml 1/1000 1/250 no
IgG2a 2µg/ml 1/1000 1/500 no
IgG2b 2µg/ml 1/1000 1/250 yes
IgG3 2µg/ml 1/50 1/250 yes
Table 2.4 Antibody and Sample dilution for ELISA
Greiner flat bottom plates were coated with 50µl coating antibody in coating buffer
(0.5M carbonate-bicarbonate, pH9.6) and incubated at 4°C for 16 hours. The plates
were washed 3 times with 200µl wash buffer (1x PBS, 0.05% Tween). The wells were
then incubated for 2 hours at room temperature with 100µl of block buffer (1x PBS, 1%
BSA, 5% sucrose, 0.05% tween). Samples and standards were diluted in sample diluent
(1x PBS, 1% BSA, 5% sucrose), and 50µl/well incubated in duplicate at room
temperature for 2 hours followed by 3 washes in 200µl wash buffer. The diluted
detector antibody was added at 50µl per well and incubated at room temperature for
1 hour followed by 3 washes in 200µl wash buffer. 50µl of diluted Streptomycin-HRP
conjugated antibody was applied to samples detected with biotinytlated antibody and
incubated in the dark at room temperature for 30 minutes followed by 3 washes with
200µl of wash buffer. The TMB substrate (OptEIA BD) was applied per manufacturer’s
instruction and after incubation in the dark for 5-10 minutes the absorbance was read
using an Optima plate reader.
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3 Targeting the common gamma chain gene with IL2RG specific ZFN for
correction with a donor repair matrix designed to be resistant to ZFN
cleavage
3.1 Aims
 Confirm ZFN expression and cleavage of the desired target
 Design and construct a donor repair matrix resistant to ZFN cleavage
 Demonstrate targeted HR as a result of specific IL2RG cleavage by ZFN
3.2 Introduction
As gene therapy for SCID-X1 has shown, restoration of a functional immune system in
patients is possible with the introduction of functional IL2RG via integrating
retroviruses. Unfortunately, due to the insertional mutagenesis that can occur as a
result of vector insertion near a proto-oncogene, the incidence of cancer associated
has highlighted the necessity for safer gene therapy strategies to be developed.
A DSB can be repaired by NHEJ and, due to the error prone nature of this pathway, can
result in the disruption of the gene and therefore loss of protein expression.
Alternatively, the DSB may be repaired by HR which relies on homologous gene
sequence to be present and can be utilised to faithfully introduce predetermined gene
sequence. Both of these gene repair pathways have their uses in gene therapy In order
to harness the cell’s response to DNA damage for a therapeutic strategy, the DSB
stimulus can be directed to an exact point in the genome by ZFN.
The ZF designed by Sangamo Biosciences and described to confer specificity for IL2RG
were subsequently fused to an obligate Fok I heterodimer by T. Cathomen et al., which
has been modified from WT and installed with opposite charges at the dimer interface.
The Fok I subunit KV has amino acids K and V at positions 490 and 538 respectively and
confers a positive charge (Sollu, Pars et al. 2010). The partner subunit, EA has
increased negative charge at amino acids 486 and 499. The two variants EA and KV are
fused to the Left and Right ZF DNA recognition domain respectively (Figure 3.1). This
pair was shown to be a faithful heterodimer and capable of stimulating HR in an
episomal GFP targeting assay (Szczepek, Brondani et al. 2007).
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Correcting mutant IL2RG with ZFN remains to be seen. The strategy in this project is to
deliver the IL2RG ZFN pair alongside a donor DNA repair matrix and induce HR to
correct the common SCID-X1 mutation, G691A, in situ. To develop this strategy DSBs
and evidence of NHEJ and HR will be assayed to verify the possibility of gene targeted
correction.
Figure 3.1 The FokI obligate heterodimer
The charges of the amino acids at the Wild Type Fok1 dimer interface compared to the
charges engineered for the heterodimeric pair.
82
3.3 ZFN expression analysis
Due to the novel ZFN chimeric protein assembly of the Sangamo designed IL2RG
specific zinc finger sequences and the alternative FokI heterodimeric pair: EA-KV, it
was necessary to confirm whether this construct was capable of ZFN expression in
vitro. Furthermore, it was essential to confirm that such expression was capable of
cleaving the IL2RG target site.
3.3.1 Expression of the individual ZFN: EA and KV
In order to confirm that the Left and Right ZFN expression plasmids with EA or KV FokI
nuclease domain respectively were capable of the individual ZFN expression a Western
blot was carried out (Figure 3.2). 293T cells were transfected with the individual HA
tagged ZFN expression plasmids and a GFP expression plasmid was delivered alongside
as a transfection control. Protein lysate from the ZFN chimera treated cells was
isolated 48 hours post transfection and quantified in order to assess expression in
equal measure. The 40kDa Left or Right ZFN protein stained positive for HA. Likewise,
GFP was also present as confirmed by antibodies directed against GFP.
Figure 3.2 A Western blot to demonstrate ZFN expression.
293T cells were transfected with plasmids encoding either the Left or Right ZFN and the
protein lysate harvested 48 hours later. A western blot of the lysate was carried out. Red;
the HA tag. Green, the GFP positive control. Samples were run alongside an untransfected
293T control (U).
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3.3.2 Detecting NHEJ in DNA as a result of ZFN directed cleavage
The principal function of ZFNs is to induce a DSB at the target site for which the zinc
fingers were designed and assembled. Such a genetic modification can result in the
DNA repair process of error-prone NHEJ to re-ligate the DNA strands together,
frequently incorporating insertions or deletions (indels) in the process. Indels
incorporated at the ZFN target site provide evidence of NHEJ which in turn confirms
the functional expression of ZFN by their induction of a DSB.
Indels created as a result of ZFN treatment invariably result in a variety of different
DNA sequences which can be recognised and digested by T7 endonuclease when these
heterogenous DNA fragments are annealed at random. A schematic for the indel
detection assay is shown in Figure 3.3a. 293T cells were transfected with expression
plasmids for either the individual ZFN Left or Right or as a ZFN pair and incubated for
96 hours. The IL2RG target sequence was analysed for indel incorporation as follows:
the genomic DNA was isolated from the cells under each condition and PCR carried out
to achieve 500bp amplicons with the ZFN target site at the centre of the amplicon.
After denaturing and re-annealing of the PCR product, the DNA was incubated with T7
endonuclease. The 250bp product indicative of T7 endonuclease digestion was present
when the ZFN pair were administered together thus confirming IL2RG targeting (Figure
3.3b). Furthermore, the Left or Right ZFN alone did not result in the incorporation of
indels, at the ZFN target site in IL2RG. The presence of indels at the IL2RG target site in
the cells transfected with the ZFN pair but not in cells transfected with individual ZFN
expression plasmid alone confirms that this pair is capable of both target sequence
cleavage and appropriate heterodimerisation at the target site.
84
Figure 3.3 Detecting insertions and deletions (indels) as a result of ZFN induced double
strand breaks (DSB).
(a) A schematic of the T7 endonuclease assay. 293T cells are transfected with Left (L), Right
(R) or both ZFN expression plasmids. Genomic DNA isolated after 96 hours and the ZFN
target site is amplified by PCR. Indels incorporated as a result of ZFN induced NHEJ are
detected and cleaved by T7 endonuclease. (b) Results of the T7 endonuclease assay. 500bp
target templates produced by PCR from genomic DNA were incubated with T7
endonuclease. The 250bp digest products are separated by electrophoresis as shown.
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3.3.3 ZFN mediated cleavage assessed by an episomal GFP knockdown assay
To help quantify the rate of ZFN cleavage at the IL2RG locus, a GFP knockdown assay
was performed. An expression plasmid containing IL2RG cDNA upstream of the GFP
gene is transcribed into a γc-GFP fusion protein, on cleaving the IL2RG target site by
ZFN the plasmid will be disrupted and the expression of GFP will be prevented (Figure
3.4a). Considering both the γc-GFP and ZFN rely on the CMV promoter for expression, 
to account for any loss of GFP expression due the incorporation of the transcription
machinery at the ZFN’s promoter, plasmids containing CMV upstream of SceI were
transfected in place of ZFN in the GFP control. An mCherry expression plasmid was
included in all conditions as a transfection control. 293T cells were transfected with γc-
GFP expression plasmids and either ZFN or CMV control plasmids and analysed for GFP
expression 48 hours later by flow cytometry (Figure 3.4b). Transfection with the ZFN
pair reduced the mean fluorescence intensity (MFI) of GFP signal more than 4 fold
compared to the CMV control, and although the signal was not completely abolished,
the notable reduction in the fluorescence of GFP shows that the ZFN pair is capable of
episomal IL2RG disruption.
It was also considered that the mCherry positive cells may not have represented all of
the transfected GFP and control 293T cells. Further analysis of GFP expression in the
total live cells confirmed the same pattern of GFP knockdown as mCherry gated cells
(Appendix 3).
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Figure 3.4 GFP knockdown assay.
(a) A schematic for the process for episomal GFP knockdown. 293T cells are transfected with
γc-GFP expression plasmids alongside ZFN expression or CMV control plasmids. GFP 
expression is analysed by flow cytometry. (b) The results of the GFP knockdown assay. (i) Live
cells were gated positive for the transfection control, mCherry. (ii) The MFI and Geometric
mean (Geom mean) of GFP on mCherry+ cells is shown by a histogram for ZFN pair treated
(Left+Right), CMV promoter control and untransfected control (U).
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3.4 ZFN mediated cleavage of WT, Mutant and repair IL2RG DNA
It has been established so far that the IL2RG ZFN are capable of targeted cleavage of
the IL2RG locus as shown by the detection of DSB and the indels incorporated as a
result of NHEJ. Although techniques to detect NHEJ are useful to assess the
performance of the ZFN they cannot provide information regarding HR events which
are necessary to achieve gene correction.
In order to achieve targeted HR, together with delivering ZFN expression vectors to a
cell to attain a DSB, a donor molecule containing a sequence capable of correcting the
gene must also be provided. Due to the faithful DNA binding of sequence-specific ZFN
constructs to their target, certain considerations are necessary for the design of donor
DNA constructs for the correction of one base pair. There are three major concerns
concerning target sequence similarity. Firstly, cleavage of the donor fragment by ZFN
could hinder the efficiency of HR, secondly if the repair sequence is a target for the
ZFN, this would permit further cutting after recombination (Pruett-Miller, Connelly et
al. 2008) and finally, conversion of the point mutation G691A to WT will not introduce
a new restriction enzyme site and therefore would be difficult to detect during
genomic analysis. These concerns can be overcome by designing a donor DNA
containing ZFN blocking mutations which can subsequently be used to detect targeted
recombination.
The IL2RG ZFN pair has been shown to cut WT sequence at the site of a common SCID-
X1 associated point mutation: G691A located in exon 5 of the gene (Miller, Holmes et
al. 2007). As this missense mutation occurs in the zinc finger recognition site (Figure
3.5ai) it was necessary to confirm that the ZFN pair was capable of performing site
directed cleavage of the mutated target site. Furthermore the extent of base pair
diversity that is tolerated by the binding of this particular ZFN pair should be known to
construct suitable donor DNA repair constructs.
3.4.1 Design of donor DNA constructs with ZFN blocking mutations are capable of
restoring γc expression  
Using the degenerate nature of the codon code, the ZFN binding sequence of the
donor plasmid was modified to incorporate sequence disparity from WT by 1, 3 and
17bp whilst maintaining the same amino acid code. These proposed constructs were
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named MB1, MB3 and MB17 respectively (Figure 3.5aii). In all three designs, the
sequence modification resulted in a loss of a restriction site for DraIII and a gain of a
BsrBI site in all three plus an additional DpnII restriction site in the MB17 construct.
These modified binding cassettes were constructed as follows: A WT donor construct
was achieved by amplifying a 1,532bp fragment from WT IL2RG sequence from the full
length gene located in a γc expression plasmid (Appendix 1) with the ZFN target 
sequence located in the middle, flanked by left and right homology arms of 612bp and
889bp. The A-G modification in MB1 was introduced into the WT donor construct
consisting of the same homology arms flanking the ZFN target sequence by site
directed mutagenesis. The T-C, C-T and A-G modifications in MB3 were manufactured
by GeneArt and the synthesised cassette was subsequently cloned in the WT donor
construct. The MB17 cassette was constructed by linker mediated PCR whereby
primers were designed to incorporate the 17bp changes whilst maintaining the ability
to bind WT sequence (Figure 3.5b). The first round of PCR involved two PCR reactions
each generating a PCR product with the MB17 sequence overhangs at the 3’ or 5’ end.
The second round of PCR then relied on the modified overhangs to anneal and the PCR
was completed by the flanking primers used in the first round, achieving an amplicon
containing the 17bp modifications which replaced the WT ZFN target site. This
amplicon was purified from the PCR gel and cloned into the pJet backbone (Appendix
5).
To confirm that the modified region, when incorporated into IL2RG, would still be
capable of γc expression, the modified cassette from MB17, containing the maximum 
number of DNA base modifications used in this study, was cloned into a γc expression 
plasmid containing the complete endogenous IL2RG gene and transfected into 293T
cells. An increase in γc expression was observed 48 hours post transfection in cells 
treated with both WT IL2RG and IL2RG containing the MB17 cassette compared to
untransfected 293T cells (Figure 3.5c).
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Figure 3.5 Modifying the ZFN binding domain.
(a) The ZFN binding domain (yellow boxes) of IL2RG. (i) The G691A SCID-X1 associated
mutation is located within the ZFN binding site (ii) Designing a ZFN IL2RG donor with a
modified binding site. 3 different Donor DNA constructs, MB1, MB3 and MB17 were
designed based on the flexibility of the redundant amino acid code, changes in DNA
sequence from WT are shown in green and the corresponding restriction enzyme site for
each construct is labelled. (b) Construction of MB17 by linker mediated PCR. Primers
designed to incorporate the 17bp change (green) at the ZFN binding site (Yellow) undergo
1 round of PCR with flanking primers (Red) and generate an amplicon from WT template
(Blue) followed by a second round where the PCR amplicon becomes the template and
the cassette is completed by the flanking primers. (c) 293T cells were transfected with
either plasmid encoding the complete IL2RG gene with either the WT or MB17 modified
ZFN target sequence, untransfected 293T cells were included as a control. After 48 hours
the cells were stained with PE conjugated antibodies directed against γc and acquired by 
flow cytometry. The numbers shown indicate the percentage of γc positive cells. 
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3.4.2 ZFN translated in vitro is capable of targeted DNA cleavage of both WT and
SCID-X1 associated IL2RG mutation G691A but not donor constructs with ZFN
blocking mutations
Having established that the 17 DNA base modifications did not disrupt γc expression, it 
was necessary to confirm that these modifications abolished ZFN targeted cleavage.
ZFN protein was translated in vitro using rabbit reticulate lysate and incubated with
500bp target fragments generated by PCR from the WT, MB1, MB3 and MB17 donor
constructs. The digestion products were then separated by electrophoresis. In order to
confirm the correct product size and inclusion of a new restriction enzyme site, the WT
was also digested with DraIII and the modified donors were digested with BsrBI and
separated alongside the ZFN digestion products (Figure 3.6a). The WT template
digested with DraIII resulted in 250bp products. Likewise, all three modified donors
were digested by BsrBI to achieve nearly 100% digestion. A faint 250bp band indicates
the translated ZFN pair was able to cleave about 13% of WT template. There was
evidence of digestion of the MB3 template by the ZFN pair however at a lower rate of
3.5%. No other donor template showed any digestion product when treated with ZFN.
As the WT control rendered a weak digestion product I am unable to confirm that
these donors are resistant to ZFN cleavage from this assay. Furthermore, successful
ZFN translation was confirmed by Western blot (Appendix 6).
Considering the missense SCID-X1 mutation occurs in the ZFN binding domain of IL2RG,
the in vitro ZFN digestion assay was carried out to assess the ability of the ZFN pair to
target the SCID-X1 mutation. 500bp ZFN target templates from WT, G691A IL2RG
mutant and the MB17 donor construct were amplified by PCR and incubated with ZFN
translated by rabbit reticulate lysate in vitro (Figure 3.6b). Digestion with DraIII or
DpnII was included as a marker for cleavage product size. The results of the digestion
show that the ZFN pair was able to cleave both the WT and SCID-X1 target sequence at
67% and 61% respectively, however, the MB17 target remained uncut. Furthermore,
when the target was incubated with either ZFN individually, no cleavage occurred,
thereby confirming that the ZFN must be present as a heterologous pair in order to
introduce a DSB at their target site. Due to the clear result that the translated ZFN can
digest the WT and G691A mutant, the complete lack of MB17 digestion implies that
the MB17 modified binding site is resistant to cleavage by IL2RG ZFN.
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Figure 3.6 ZFN mediated cleavage of the WT, SCID-X1 and modified donor DNA
sequences.
Both the Left (L) and Right (R) ZFN were translated in vitro by rabbit reticulate lysate.
The translation products were then incubated with target template produced by PCR.
L or R ZFN were incubated as a control to confirm ZFN pair were obligate
heterodimers. Restriction enzyme digest of the target template confirmed inclusion of
the new restriction enzyme site and cleavage product size. (a) The results of the in
vitro ZFN digestion assay. Target template from WT, MB1, MB3 and MB17 were
digested with L, R or L+R alongside either BsrBI or DraIII. The products were separated
by electrophoresis. (b) 500bp DNA template from wild type, SCID-X1 mutation or
Modified binding site (MB17) were incubated with L, R or L+R ZFN. DNA digested with
DraIII and DpnII were used as a positive cleavage control. The numbers in white
denote the percentage of the 250bp digestion product of total 500bp DNA template
above background, calculated from the band intensity by ImageJ.
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3.5 IL2RG ZFN are capable of targeted HR as shown by HR specific PCR
It has been established that a donor DNA molecule containing the WT IL2RG sequence
and therefore the ZFN target, can be cut resulting in an incomplete repair matrix and
therefore theoretically unsuitable for HR. Modification of the ZFN target site in the
donor DNA, MB17, produced DNA resistant to ZFN cleavage and resulted in the
incorporation of a new restriction enzyme site. Furthermore, the disparity of 17bp
from WT, if incorporated into the endogenous IL2RG, will provide a new sequence at
the target site which may be exclusive for specific oligonucleotides. Utilising this in a
PCR reaction may offer the ability to rapidly detect targeted HR with less expense
compared to high throughput screening of recombination of the target site.
Another consideration for the donor DNA repair matrix is the size of the homology
domain (HD) between the donor and target gene. Donor DNA containing two sizes of
HD were compared, one of 978bp (short) and the other 1531bp (long) with the target
site for correction and detection, located in the middle.
The PCR strategy to detect targeted HR events is outlined in Figure 3.7 Primer pair 1
consists of a forward primer which anneals to the modified binding site (MBS) and a
reverse primer binding in exon 7 of the genomic DNA, outside of the homology domain
corresponding in the long donor DNA. Primer pair 2 is designed with the same principle
but with the forward primer targeted to exon 4, upstream of the long donor’s
homology domain and the reverse primer to the MBS. This strategy is employed to
detect HR in 293T cells, ED7R cells and finally mES cells over the course of this project.
Concatamers that may have been incorporated as a result of multiple HR events at the
target site can be detected by using the exon 4 forward primer and the exon 7 reverse
primer and a PCR elongation time suitable to amplify DNA regions in excess of the
endogenous size.
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Figure 3.7 A schematic of the primer strategy to amplify targeted HR.
A schematic of the primer strategy to amplify targeted HR. The long (1,531bp) or short
(978bp) homology domain (HD) of the donor DNA (Broken orange line) is incorporated into
the genomic DNA by HR. the modified binding site MB17 in exon 5 (orange rectangle) is
detected by primer pair 1 (green arrows) and results in an amplicon length of 1,002bp.
Primer pair 2 (red arrows) results in an amplicon length of 969bp.
94
3.5.1 Detecting ZFN induced HR in 293T cells
Two sets of transfections were carried out on 293T cells, with ZFN plasmids and donor
DNA constructs containing the MB17 cassette at ZFN:Donor ratios of 1:3, 1:1 and 3:1.
One set of transfections was carried out with the short (978bp) HD, the other with the
long (1,531bp) HD at a total of 2µg per transfection alongside an un-transfected
control. Transfected cells were incubated at 37°C for 96 hours at which point the
genomic DNA was isolated and analysed for targeted HR by PCR (Figure 3.8a). The
results show that on transfection with the short donor, the PCR product amplified by
primer pair 2 was present at a transfection ratio of 1:3 and 3:1 ZFN:Donor. However
there were no amplicons produced using primer pair 1. Cells transfected with the ZFN
plasmids and the long donor DNA construct resulted in positive PCR amplicons in all
three ZFN:Donor ratios detected using both primer pair 1 and 2. Regarding the
consistency of the long donor plasmid to achieve HR, this length of HD at 1,531bp was
chosen for all further donor DNA construct analysis. The positive control used in this
PCR is the IL2RG expression plasmid containing the MB17 modified binding cassette in
place of the WT ZFN target. Using this template, it appears that the band produced by
primer pair 1 is of a greater intensity than that produced by primer pair 2. It is worth
noting that there is no detectable background integration of long or short donor alone
in 293T cells at the IL2RG target site.
In order to verify that the targeted HR detected by PCR had resulted in a single
exchange of donor DNA with the endogenous locus, a PCR was performed to detect
any concatamers, similar to the head to tail repeats seen by Lombardo et al.
(Lombardo, Genovese et al. 2007) that may have resulted during the DNA repair
process (Figure 3.8b). The primers for exon 4 and exon 7 were utilised to detect any
genomic DNA in excess of the 1,901bp endogenous sequence by using a PCR
elongation time of 4 minutes. Using this technique, no evidence of concatamers was
seen.
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Figure 3.8 Targeted HR in 293T cells.
293T cells were transfected with ZFN expression plasmids or donor DNA constructs at
various ZFN:donor ratios as indicated. Genomic DNA was isolated 96 hours later. (a)
Results of the PCR to detect HR. Top, cells transfected with the short (978bp) HD domain.
Bottom, cells transfected with the long (1531bp) HD domain. (c) Results of the PCR using
primers to exon 4 and exon 7 to detect concatamers.
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3.6 Discussion
This section shows that the IL2RG-specific zinc finger fused to heterodimeric FokI
domains can be expressed in 293T cells. Furthermore, the ZFN pair is functional as they
are capable of inducing a DSB at the IL2RG target locus in 293T cells as shown by the
signature indels introduced as result of NHEJ. It was also shown that the IL2RG ZFN can
cleave both the WT sequence and a common SCID-X1 associated mutation (G691A).
Although ZFN exhibit excellent sequence specificity, there is a degree of flexibility in bp
recognition as observed previously between A and G in the middle finger of the murine
transcription factor Zif268 (Choo and Klug 1994).
Due to the extent of homology necessary between the donor DNA and the
endogenous sequence, the donor molecule was modified to render it resistant to ZFN
mediated cleavage. The ZFN recognition sequence was modified in 3 donor DNA
constructs by 1, 3 and 17bp. On assessing the cleavage resistant modifications, the
faint cleavage product from the MB3 template detected by band intensity analysis
maybe an artefact of unusually low background or the ZFN have a low affinity for the
new sequence. Furthermore, an inferior rate of digestion in the WT control at 13%
compared with 67% in the subsequent assay with the same indicates the cleavage
resistance should be re-assessed. The latter experiment did however provide evidence
that the MB17 donor construct is resistant to ZFN targeting. Furthermore, the 17bp
modifications from WT in this construct were shown not to disrupt γc expression 
making it a suitable candidate for IL2RG correction.
The advantages of such designs are that the donor molecule will remain intact during
ZFN treatment and will prevent subsequent cutting once incorporated into the
endogenous IL2RG. In addition, such a change in sequence is a marker for the
detection of HR events. Firstly, the introduction of the novel BsrBI restriction site can
be detected exclusively of the endogenous sequence as seen by Millar et al. (Miller,
Holmes et al. 2007). Furthermore, the incorporation of a new sequence with enough
sequence disparity from endogenous sequence can provide a target detectable by PCR.
This was shown in 293T cells transfected with ZFN expression plasmids and the MB17
donor. A possible disadvantage is that the decrease in homology between the donor
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and endogenous sequence could decrease the likelihood of HR events. Direct
comparison of the 3 modified donor DNA would be useful to investigate the effect
these modifications have on HR stimulated by ZFN induced DSB.
The length of HD between the donor DNA and endogenous target locus was briefly
investigated. Targeted HR in 293T cells was more consistent when an HD of 1531bp
was present in the donor DNA when compared to an HD of 978bp. Although
confounding evidence that homology arms >50bp are not necessary to exchange a
short region of sequence (Orlando, Santiago et al. 2010) this extent of homology was
also successful for the insertion of a 7,762bp sequence at the same IL2RG locus by
Moehle et al. (Moehle, Rock et al. 2007). Another observation when comparing these 2
HD lengths is the inconsistency in modified binding site detection. This is likely to be
due to differences in primer pair efficiency as observed in the positive control. Finally,
the ratio of ZFN to donor DNA was compared in transfected 293T cells. The ZFN:Donor
DNA ratios of 1:1 and 3:1 when using the Donor DNA with the long HD, resulted in a
PCR product of visibly more intensity.
To overcome the limitations of PCR to quantify targeted HR, it is possible to design a
fluorescent probe to bind the modified site for use in qPCR. Accompanying the
quantification of the modified binding site with a house keeping gene such as actin,
different conditions such ZFN to donor DNA ratios could be compared. This method
has been successful for Greenwald et al.(Greenwald, Cashman et al. 2010).
Having established functional expression of the ZFN pair, observing faithful
heterodimerisation at the IL2RG locus and having developed donor DNA constructs
which can undergo targeted HR, it remained to be assessed whether targeted gene
correction of IL2RG can result in functional γc expression which is explored in the 
following chapter.
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4 Developing a SCID-X1 cell line model for ZFN targeting analysis.
4.1 Aims
 To characterise the ED7R cell line
 To modify this cell line to contain 1 copy of either WT or G691A IL2RG
 To demonstrate ZFN mediated gene targeted knockdown of WT IL2RG
 To demonstrate ZFN mediated correction of the G691A mutation resulting in γc 
restoration and signalling
 To assess different ZFN and donor DNA delivery methods
 To assess the effect of sequence dissimilarity at the ZFN binding site on the donor
DNA
4.2 Introduction
As previously described, the IL2RG ZFN pair is capable of targeting IL2RG in an
episomal γc-GFP fusion construct and the endogenous locus in 293T cells, furthermore, 
this targeted DSB can be repaired by HR on the provision of a donor DNA construct in
these cells. In order to further examine this gene correction strategy, a cell line model
of SCID-X1 has been constructed that when corrected will restore γc expression. The 
common SCID-X1 mutation G691A was chosen to be included in the target locus for
ZFN due to its frequency in SCID-X1 cases and its location in the mutation hotspot of
exon 5. Due to the nature of base pair exchange during HR, extensive stretches of DNA
can be recombined >100bp from the cut site (Elliott, Richardson et al. 1998; Herrmann,
Garriga-Canut et al. 2011) which would suggest that a host of SCID-X1 mutations could
be corrected via HR stimulated by this ZFN pair.
The ED7R cell line is a model of SCID-X1 based on the characteristic that it does not
express γc resulting in incomplete IL2R, which doesn’t respond to IL-2 and is unable to 
phosphorylate the subsequent signalling steps of the Jak-Stat pathway. The cell line
was originally cultured from a patient with HTLV-1 associated T cell leukaemia and
lacked both γc and IL7Rα. Kumaki et al., re-introduced IL7Rα cDNA to the genome, 
hence the name ED7R, and on subsequent addition of the IL2RG cDNA, termed
EDγc7R, signalling via the receptors for IL-2, IL-4 and IL-7 was restored as shown by the 
tyrosine phosphorylation of Jak3 (Kumaki, Ishii et al. 1999). Lentiviral vectors (LV) have
been used to reintroduce IL2RG into ED7R cells with the promoters SFFV, UCOE,
(Zhang, Thornhill et al. 2007), PGK, LTR, WASP, Jak3 (Smyth, Ginn et al. 2007) and EF1α 
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(Smyth, Ginn et al. 2007; Throm, Ouma et al. 2009) and the subsequent γc expression 
proven functional by cytokine signalling resulting in the phosphorylation of Stat5.
Stat5a/b have been shown to be IL2RG specific as mice deficient in these proteins are
unable to undergo IL-2 induced cell cycle progression (Moriggl, Topham et al. 1999).
An LV vector was designed (W.Qasim) incorporating full length IL2RG in reverse
orientation to avoid intron splicing during lentiviral vector production and transgene
integration (Appendix 1). The IL2RG endogenous promoter, designed by S. Thornhill to
include binding sites for members of the Ets family of transcription factors,
(Markiewicz, Bosselut et al. 1996; Ohbo, Suda et al. 1996) and regulatory elements
conserved between human and mouse. This promoter, in conjunction with IL2RG cDNA
successfully restored γc expression in SC-1 fibroblasts and a SCID-X1 LCLs and IL2RG
downstream signalling in ED7R cells. This WT IL2RG LV is used to construct ED7R based
cell lines for ZFN gene targeting in this chapter.
Integrase deficient lentiviral vectors (IDLV) have been used to deliver targeting
endonucleases and donor DNA (Cornu and Cathomen 2007; Lombardo, Genovese et al.
2007) from which the transient endonuclease expression resulted in successful
targeted gene modification. ZFN delivery by LV, IDLV and nucleofection is attempted in
this chapter.
4.3 Characterising and constructing the ED7R cell line SCID-X1 model
Due to the unknown nature of the IL2RG locus in ED7R cells and why γc is not 
expressed, the cell line must be characterised to establish whether it is suitable model
for targeted for gene correction. The aim of this chapter is to characterise the cell line
and to incorporate a single copy of mutant IL2RG or WT IL2RG for control. These
modified cell lines will be used to optimise ZFN mediated gene targeting and
correction and to assess whether this gene correction strategy results in functional
IL2R signalling.
4.3.1 The ED7R Karyotype
The IL2RG locus is situated on the X-chromosome at Xq13.1. Karyotype analysis of the
male derived ED7R cell (Figure 4.1a) revealed gross chromosomal aberrations, most
importantly a duplication of the X-chromosome. Sequencing of the IL2RG locus from
207bp upstream of the promoter and regulatory elements to 350bp downstream of
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the polyA signal sequence revealed the deletion of a thymine (T) in the polypyrimidine
tract in intron 4 (Figure 4.1bi). As this deletion occurs in an intron it will not result in
frameshift of translated sequence, furthermore the affected polyT tract is not located
near the 3’ splice acceptor site which negates aberrant spicing. However, it is not
refuted that intron 4 may be involved in the regulation of γc expression.  
The sequence analysis also confirmed the presence of intact IL2RG ZFN target
sequence and clinical sequencing confirmed this sequence to be homologous which,
considering the duplication of the X-chromosome equates to two ZFN target
sequences per ED7R cell with the assumption that no recombination events have
occurred to incorporate the target external to the normal loci (Figure 4.1bii).
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Figure 4.1 IL2RG in ED7R cells.
(a) The ED7R karyotype. Top, chromosomes identified by G-banding. Bottom, the
location of the IL2RG locus in the X-chromosome. (b) Sequence analysis of ED7R
compared to the consensus sequence available from NCBI. (i) The ED7R IL2RG locus has a
deletion of a thymine (T) in the polyT tract of intron 3. (ii) The ED7R genome has an intact
IL2RG ZFN target sequence.
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4.3.2 WT or G691A IL2RG is incorporated as a transgene into the ED7R genome
Although the ED7R cell line contains the ZFN target site, subsequent genomic
modification at this site will not show translated evidence of IL2RG correction by ZFN.
The ED7R cells were transduced with LV encoding either WT or G691A IL2RG with the
endogenous IL2RG promoter. To accompany the SCID-X1 cell line, ED7R cells were also
modified with WT IL2RG to confirm that the lentiviral vector was capable of inserting a
transgene capable of functional γc expression and secondly, the ED7R cell line with WT 
sequence can be used to measure ZFN targeting as NHEJ of the DSB would result in the
knockdown of γc protein expression.  
The mutant IL2RG LV construct was engineered by incorporating the G691A mutation
via site directed mutagenesis of the plasmid vector containing the lentiviral backbone
and WT IL2RG by oligonucleotides containing the point mutation (Figure 4.2a).
Following a DpnI digest of un-mutated, methylated parental plasmid and amplification
in E. Coli, sequencing confirmed successful incorporation of this missense mutation
(Appendix 7). ED7R cells were transduced with a titration of either lentiviral vector
followed by limiting dilution of the transduced cells to create clonal cell lines.
ED7RγcWT clones were analysed for γc expression by flow cytometry in order to 
confirm successful insertion of the IL2RG transgene. As no γc expression was expected 
on the ED7RγcΔ clones, genomic DNA was isolated and analysed by PCR for WPRE to 
confirm insertion of the transgene. γc expression of a pooled population of ED7RγcΔ 
clones and a representative ED7RγcWT clone as compared to ED7R was analysed by 
flow cytometry (Figure 4.2b). As expected, γc expression was not detected on the cell 
surface of ED7RγcΔ cells as compared to the positive shift seen in the γc stained 
ED7RγcWT clone. To establish whether the γc mutation leads to a protein incapable of 
cell surface expression, intracellular γc staining was carried out, again the ED7RγcWT 
clone stained positive and the ED7RγcΔ were negative for γc confirming that the 
G691A mutation does not result in protein expression.
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Figure .4.2 Making the ED7RγcΔ and ED7RγcWT cell lines.
ED7R cells were transduced with lentiviral vectors encoding WT or mutant IL2RG. (a) Self
inactivating (SIN) lentiviral constructs used to introduce the G691A and WT IL2RG into
ED7R cells. Top, the WT vector sequence was mutated via site directed mutagenesis by
complementary primers (black) containing the G691A mutation (Red lollipop) resulting in
a lentivirus construct with mutated IL2RG. (b) Cell surface (top) and intracellular (bottom)
γc expression by pooled ED7RγcΔ clones, an ED7RγcWT clone and untransduced ED7R 
cells as detected by flow cytometry analysis of anti-γc antibody conjugated to PE. 
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4.3.3 Transcriptional and functional analysis of WT and mutant IL2RG
Having established that, like ED7R cells the ED7RγcΔ cells do not express γc and 
ED7RγcWT clones have γc expression restored, further analysis of these cell lines was 
carried out to investigate whether the ED7R or ED7RγcΔ cells express IL2RG mRNA and
also, whether the γc expression on ED7RγcWT is functional. 
Total RNA was extracted from ED7R, ED7RγcΔ and ED7RγcWT cells. The mRNA was 
reverse transcribed to cDNA by reverse transcriptase PCR (RT-PCR) and primers specific
for IL2RG mRNA were used to amplify a 78bp product and primers specific for GAPDH
mRNA was used as a template control (Figure 4.3a). A faint band represents the IL2RG
mRNA PCR product from un-transduced ED7R cells and a band of greater intensity can
be seen for both the ED7RγcΔ and ED7RγcWT clones. The intensity of GAPDH PCR
product suggests a suitable concentration of template was used for each sample. The
>300bp product seen in the NTC and ED7R was assumed to be an artefact of the IL2RG
mRNA specific primers and not mRNA contamination as no IL2RG mRNA product is
present.
In order to confirm that the WT IL2RG in the ED7RγcWT cells is functional and to 
confirm that no functional protein is translated in the ED7RγcΔ cells, the signalling 
molecule, pSTAT5 was analysed. On the binding of IL-2 at the cell surface by IL2R, the
intracellular cytoplasmic tails of the IL2Rαβγ complex recruit JAK kinases which 
phosphorylate STAT5 which dimerise and enter the nucleus to activate transcription
(Figure 4.3b). In order to prevent background phosphorylation of STAT5 by cross
reactivity with bovine IL-2 in the foetal calf serum (FCS), the cells were starved in
medium lacking FCS overnight. ED7R, ED7RγcΔ, ED7RγcWT and the previously 
published EDγc7R cells containing functional IL2RG cDNA were then pulsed with IL-2
and intracellular pSTAT5 was stained with antibodies and analysed by flow cytometry
(Figure 4.3c). The results of this assay clearly show that on pulsing the cells with IL-2,
~52% of ED7RγcWT and ED7Rγc7R positive control cells demonstrated STAT5 
phosphorylation, whereas the ED7R and ED7RγcΔ cells remained pSTAT5 negative. This 
confirms that the WT IL2RG transgene is functional and the G691A mutation renders
the IL2RG gene product non-functional.
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Figure 4.3 Further characterisation of IL2RG in ED7R cells.
(a) Reverse transcription PCR (RT-PCR) carried out on total RNA extract from ED7R, ED7RγcΔ 
and ED7RγcWT and amplified for IL2RG (78bp product) and GAPDH (107bp product) mRNA.
PCR products were separated by gel electrophoresis and visualised. (b+c) The pSTAT5 assay
of ED7R, ED7RγcΔ, ED7RγcWT and EDγc7R cells (b) a schematic of the downstream 
signalling events on IL-2 binding at the receptor resulting in the phosphorylated STAT5
(pSTAT5). (c) The results of IL-2 pulsing (bottom) or media alone (top) on starved cells as
detected by flow cytometry analysis of pSTAT5.
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4.3.4 qPCR of the transgene in ED7RγcΔ and ED7RγcWTclones  
In order for the cell lines to be suitable for ZFN targeting analysis, a single copy of the
transgene should be present in the genome. This will represent a more physiological
target and reduce the toxic effect of multiple DSB.
To determine the copy number of the transgene in the genomic DNA of each of the cell
lines, quantitative PCR (qPCR) was performed using fluorogenic FAM-TAMRA probes to
detect and quantify either the transgene’s WPRE or the housekeeping gene, β-Actin. 
The quantitative values from the qPCR was compared to the MFI of γc expression on 
transduced cell clones as shown in Figure 4.4a where each point on the graph
represents a clone. A positive linear association can be seen for WPRE copy number
and the MFI of γc measured flow cytometry for the ED7RγcWT clones demonstrating 
that multiple IL2RG transgenes result in greater γc expression with the greatest MFI 
expression seen in the ED7RγcWT clone with a transgene number quantified at 10, 
now referred to as ED7RγcWT high. Regression analysis did not confirm this correlation 
to be significant and no such pattern exists for the ED7RγcΔ cells as there is no γc 
expression on these cells. From these data it can be seen that no ED7RγcWT clones 
have a copy number of 1 whereas a WPRE copy number of less than 1 is seen in 2
ED7RγcΔ clones.  
In order to generate ED7RγcWT clones with a single copy number, the previous data 
were used to quantify the multiplicity of infection (MOI) of the IL2RG lentiviral vector
stock. ED7R cells were transduced with an MOI titration of 0.4, 0.8 and 1.2 viral
particles (vp) per cell and γc+ clones were isolated. The ED7RγcΔ clones with a WPRE 
copy number of <1 were also re-cloned by limited dilution to confirm there was no
contaminating un-transduced ED7R cells which would bring the ratio of WPRE to β-
Actin down.
A second round of qPCR was performed using TAMRA probes for WPRE and Albumin
on the genomic DNA from ED7RγcWT generated by low MOI (Figure 4.4b). The data 
from this qPCR analysis valued the WPRE copies per cell for the re-cloned ED7RγcΔ and 
WT cell lines at less than 1. The ED7Rγchigh cells consistently had a high copy number 
and as expected the un-transduced ED7R control had no transgene. The Albumin
housekeeping gene is normally located on chromosome 4 (Chr4) and the ED7R
karyotype analysis revealed that Chr4 is absent in these cells. The unknown quantity of
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this gene in ED7R cells may explain the low copy number in the freshly isolated ED7R
clones.
To verify the transgene copy number using the WPRE qPCR data, a further calculation
was possible with the karyotype analysis at hand, and calculated using the mass of the
ED7R genome. By using a database of normal human chromosome length in base pairs
the ED7R genome is valued at an estimated 6.71x109 bp (Table 4.1a). With the
assumption that a mole of nucleotides is 650g, the copy number of ED7R genome DNA
used in the qPCR reaction can be calculated using the amount of template in
nanograms and Avogadro’s number, 6.022x1023 (Table 4.1b). From these calculations it
can be seen that the copy number of transgene was close to 1 in 2/3rds of the clonal
cell lines for both ED7RγcΔ and γcWT and that the ED7RγcWThigh remained consistent 
at 10 copies.
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Figure 4.4 Quantitative analysis of the transgene
copy number in transduced ED7RγcWT and 
ED7RγcΔ clonal cell lines. 
The transgene copy number is calculated as
(WPRE value) / (Housekeeping gene value) x
copies of housekeeping gene (a) Geometric MFI
of γc expression quantified by flow cytometry 
compared to transgene copy number determined
by qPCR of WPRE and βActin. Each point 
represents clonal cell line of ED7RγcWT (green 
square) or ED7RγcΔ (black circle). (b) qPCR 
analysis of WPRE in ED7RγcΔ or γcWT clones 
compared to the controls ED7RγcWThigh and un-
transduced.
.Table 4.1 Quantitative analysis of the transgene
copy number in transduced ED7RγcWT and 
ED7RγcΔ clonal cell lines. 
(a) Estimate of the total number of base pairs in
a single ED7R genome based on karyotype
analysis (b) Determining the transgene copy
number based on the mass and amount of
template ED7R DNA in ng and Avogadro’s
number. (*) = (ng template x 6.022x10
23
)/(
6.71x10
9
bp x 1x10
9
x 650) and (~) = WPRE
/ED7R*
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4.3.5 Southern blot of the transgene in ED7RγcΔ and ED7RγcWTclones  
Southern blot analysis of the clones was carried out to verify the copy number values
generated by qPCR.
10μg of genomic DNA from the clonal cell lines was incubated with BamHI, EcoRI or 
XbaI alongside 100ng of IL2RG lentivirus plasmid vector for blotting and hybridisation
control. These restriction enzymes are estimated to cut 6x105 sites in the human
genome which results in an average of fragment size of 5kb. The digests (Appendix 8)
were blotted onto positively charged nitrocellulose membrane and hybridised with a
radioactive probe. Probes were made to detect either the rev response element (RRE)
or WPRE gene of the lentiviral backbone by digesting the IL2RG lentiviral construction
plasmid with either restriction enzyme NotI or ClaI respectively, separating the
digestion fragments by gel electrophoresis and isolating the correct size DNA of
1079bp (RRE) or 728bp (WPRE) with a gel extraction kit (Qiagen) (Figure 4.5a). The
plasmid control hybridised at the expected fragment length of 13351bp, 14131bp, and
1093bp for BamHI, EcoRI and XbaI respectively confirming that both the DNA to
membrane transfer and the radioactive probe were prepared successfully, this part of
the membrane was removed after an exposure time of 30 minutes to allow the more
extensive exposure time of 5 days for the genomic DNA. The RRE probe gave rise to
bands in the region of 11kb but as these bands appeared for all of the clones including
untransduced ED7R, this hybridisation is expected to be an artefact of background
recognition. The WPRE probe did not achieve any quantitative bands for any of the
DNA digests.
From the total data acquired to determine the transgene copy number in the clonal
cell lines it cannot be confirmed that a copy number of one has been achieved.
By using the clonal cell lines generated in this section, ZFN mediated gene knockdown
or correction can be assessed using the ED7RγcWT or ED7RγcΔ cell lines respectively 
and the ED7RγcWT and ED7RγcΔ clones which gave a copy number of <1 by qPCR are 
used in experiments where a cell line with a single transgene is required. Due to the
functional gene in ED7RγcWT and the mutation designed for ZFN mediated correction 
in ED7RγcΔ cells gene targeting can be observed both at the genomic and the 
proteomic level of expression. With these tools, different methods of delivery can be
assessed and compared.
110
Figure 4.5 Southern blot analysis of the transgene copy number in ED7R cell lines.
Genomic and plasmid DNA digested with restriction enzyme for Southern blot and
hybridised with radioactive probe. (a) The restriction enzyme and probe positions relative
to the IL2RG transgene. (b) Southern blots of clonal cell lines digested by restriction
enzyme and hybridised with radioactive probe as indicated.
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4.4 Knockdown of γc by ZFN induced NHEJ 
DBS which occur in protein coding sequence and are repaired by non-conservative
NHEJ will frequently result in a non-functional gene and protein knockdown can be
observed. In order to demonstrate IL2RG ZFN gene targeting, the ED7RγcWT clonal cell 
lines are used to ascertain the rate of knockdown by lentiviral delivery or nucleofection
of ZFN.
4.4.1 Knockdown by Lentivirus
The Left and Right ZFN genes were individually cloned into lentiviral constructs which
were subsequently used to produce either integrating proficient (LV) or integrating
deficient (IDLV) lentiviral vectors, the MOI for each vector stock was valued by qPCR of
the WPRE gene. It is important to note that constitutive ZFN expression achieved by LV
ZFN vectors is only useful to confirm ZFN activity as such expression is likely to be toxic
to the cell and gene targeting by transient ZFN expression provided by IDLV is far more
relevant to therapeutic strategies.
In order to confirm that these lentiviral vectors were functional the effects of
constitutive ZFN expression by the transgene integrated by LV was assessed.
ED7RγcWTlow clonal cells with a copy number of 3 as quantified by qPCR were 
transduced in triplicate with a total MOI of 0.5, 1, 2 and 4vp per cell of the ZFN pair
and for control the Left or Right ZFN at an MOI of 4. The γc expression was analysed by 
flow cytometry, 4 and 15 days post transduction (Figure 4.6a). It was seen 15 days post
transduction that an MOI of 4 appeared to knockdown γc expression and deplete γc+ 
cells, however the statistical power of this decrease in expression cannot be
distinguished when compared the cells treated with the L or R ZFN alone as there are
only two values for this negative control. Evidence of gene targeting at the genomic
level was assessed by analysis of indels detected by T7 endonuclease (Figure 4.6b).
Using the same primers that generate the target template from genomic DNA, an indel
positive control was generated by amplifying the 500bp target from a WT donor and
the MB17 donor and combined at a ratio of 1:1. On denaturing and reannealing, the
17bp dissimilarity from WT in the MB17 will be recognised by mismatch sensitive
endonuclease and digested, resulting in 250bp fragments. This 500bp target template
is hence forth known as the indel positive control. Unlike the flow cytometry analysis,
indels were detected 15 days post transduction in cells treated with an MOI of 4 or 2.
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There was also evidence of indel incorporation at an MOI of 0.5 but as no indels are
detected at an MOI of 1 this may be a false positive due to a DNA shearing.
The ZFN targeting which was observed by genomic analysis but not by change in γc 
expression at the cell surface could be explained by the multiple copies of IL2RG in the
cell line used where knockdown of a single copy would not be reflected by γc 
expression at the cell surface. To overcome this, cell lines with a single copy of the
transgene are used in subsequent experiments and denoted as ED7RγcWT. 
To achieve both viral transduction and transient expression, ZFN expression constructs
were delivered by IDLV to target IL2RG in ED7RγcWT cells. Transductions were carried 
out with a titration of the IDLV ZFN pair at 0, 100, 200 and 300vp per cell in total and
ZFN left only at an MOI of 300 for control. Flow cytometry analysis of γc expression 14 
days post transduction revealed a slight reduction in γc expression when cells were 
transduced with the ZFN pair at an MOI of 300 (Figure 4.6c) however this was not
confirmed by the Cel-1 surveyor assay as no indels were detected in any of the
transduced samples (Figure 4.6d).
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Figure 4.6 IL2RG targeting in ED7RγcWT cell lines by ZFN delivered by lentiviral vectors.
Knockdown of γc expression by ZFN expressing LV or IDLV was by analysed flow cytometry or 
indel incorporation detected by T7 endonuclease or Cel-1 alongside an uncut control. A
500bp indel positive control (+) which will be digested to 250bp fragments on exposure to
the endonucleases was also included. (a+b) 5x104 ED7RγcWTlow cells were transduced with 
LV at increasing MOIs of the ZFN pair or ZFN Left (L) or Right (R) alone at an MOI of 4. (a)
Expression analysed by flow cytometry at 4 and 15 days post transduction. Graphs show the
geometric mean of γc expression (MFI) and the percentage of γc+ cells (%). (b) Indel 
incorporation in the treated cells, detected by the T7 endonuclease 15 days post
transduction. The numbers in black denote the percentage of the 250bp digestion product of
total 500bp DNA template above background, calculated from the band intensity by ImageJ.
(c+d) 5x104 ED7RγcWT cells transduced with IDLV at increasing MOI of the ZFN pair or ZFN 
left only and analysed after 14 days. (c) Flow cytometry analysis of % γc expression, 14 days 
post transduction (d) Indel incorporation in the treated cells detected by the Cel-1 surveyor
assay 14 days post transduction.
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4.4.2 Knockdown by nucleofection of ZFN
To avoid the use of viral vectors altogether, transfection with plasmid DNA is a popular
method to introduce novel genetic material for transient expression. Nucleofection has
been developed to transfect virtually all cell types with various types of nucleic acid
including endotoxin free plasmid vector.
To assess the knockdown of γc expression by the IL2RG ZFN pair using this method,
2x106 ED7RγcWT cells were nucleofected with a titration of Left and Right ZFN 
expression plasmid together with a GFP control (pMax GFP) in order to consistently
use 2μg total DNA in each sample. The combined ZFN plasmid DNA increased from 0μg 
with 0.5μg intervals to 2μg and samples were run in triplicate. Flow cytometry analysis 
of γc expression was carried out 96hours post nucleofection (Figure 4.7a) and 
knockdown of expression was clearly demonstrated, from 60% γc+ cells in the GFP only 
control to 1.4% in cells treated with 2μg of total ZFN expression plasmid. Further 
analysis of these triplicate data (Figure 4.7b) revealed that nucleofection 2x106 cells
with 1.5μg of ZFN statistically reduces the percentage of γc+ cells however the 
reduction in the total level of γc expression as measured by MFI did not reach 
significance. Propidium Iodide (PI) uptake of dead cells was used to analyse cell
viability and a linear negative association observed between ZFN treatment and cell
viability where ≥1.5μg ZFN expression plasmid caused a significant drop in live cells. 
Interestingly, no indels were detected by the Cel-1 surveyor assay in the DNA pooled
from each triplicate (Figure 4.7c).
The consistently contradictory evidence of IL2RG targeting from the flow cytometry
analysis and indel detection prompted investigation into the sensitivity of the Cel-1
assay. In addition this enzyme was compared to the T7 nuclease which has also been
used for the same purpose in this study. As for the indel positive control, template was
prepared from plasmid containing the WT and MB17 donor plasmids and a total of
500ng per reaction was used with a decreasing percentage of template prepared from
MB17 thereby decreasing the potential template containing mismatches (Figure 4.7d).
The detection of indels using Cel-1 in this instance was more accurate than the T7
however the detection level of both the Cel-1 and T7 endonuclease could not be seen
above background when mismatch potential dropped to 2% and the drop off point
could be anywhere between 8% and 2%. This comparative analysis suggests that the
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Cel-1 surveyor assay is more sensitive than using the T7 endonuclease and from this
assessment it can be speculated that gene targeting events must reach a rate of ≥8% 
to be detected with this assay.
Flow cytometry analysis of the γc knockdown experiments in ED7RγcWT cells imply 
there is ZFN activity resulting in DSB. However the absence of indels in these samples
do not confirm that the DSB are repaired by NHEJ. This could be due to the sensitivity
of the indel surveyor assay or due to a deregulated DNA repair mechanism in ED7R
cells.
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Figure 4.7 IL2RG targeting in ED7RγcWT cell lines by ZFN delivered by nucleofection.
(a-c) ED7RγcWT cells nucleofected with increasing amounts of ZFN expression plasmid. (a) 
Flow cytometry analysis of γc expression detected on PI-ve cells. (b) The triplicate values 
of γc+ cells, the MFI of γc and the percentage of PI-ve (viable) cells as determined by flow 
cytometry, plotted against the ZFN titration and the significance calculated by a one way
analysis of variance (*= P-value<0.05) (**=P-value<0.01)(***=P<0.001). (c) Indels detected
by the Cel-1 surveyor assay in template prepared from nucleofected cells alongside uncut
template control and an indel positive control. (d) A decreasing percentage of DNA
capable of forming mismatched sequence (%) were digested by Cel-1 and T7
endonuclease and uncut template (UC) was included for control. The numbers in black
below the bands denote the percentage of the 250bp digestion product of total 500bp
DNA template above background, calculated from the band intensity by ImageJ.
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4.5 Gene targeted correction of IL2RG by ZFN induced HR
The ED7RγcΔ cell lines were made to assess the possibility that the DSB induced by ZFN 
can be repaired by HR from an endogenous donor fragment and in so doing, correct
the SCID-X1 associated G691A mutation. Again lentiviral vector delivery and
nucleofection of ZFN expression plasmids was performed but this time in unison with
donor DNA delivery. In addition to establishing an efficient method of delivery, the
most effective ratio of ZFN to donor DNA constructs was also considered in this
section.
When the MB17 donor is used for HR the MB17 sequence is incorporated and can be
distinguished from WT by an HR specific PCR as established in chapter 3. In addition,
the novel restriction enzyme site, BsrBI is introduced and the endogenous DraIII site is
lost. This exchange can be detected by RFLP analysis of 1,901bp template DNA
amplified from the treated cells using primers that anneal outside of the region of
donor homology and are therefore specific for unaltered genomic DNA (Figure 4.8a).
The digestion products can then be separated by gel electrophoresis and the band
intensity of cut and uncut bands can be determined (Figure 4.8bi). Subsequent blotting
of the DNA onto a membrane and hybridisation to radioactive probe can increase the
sensitivity of RFLP analysis as seen by the Southern blot analysis of a titration of BsrBI
containing fragments in total template DNA where the percentage of digested product
more accurately represented the percentage of BsrBI sites in the starting template
(Figure 4.8bii). As the HR specific PCR of the MB17 donor cassette is not quantitative,
this RFLP Sothern blot can be used to quantify the extent of HR in cells treated with
ZFN and Donor DNA.
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Figure 4.8 RFLP analysis of cells treated with ZFN expression vectors and Donor repair
DNA.
(a) A schematic of the RFLP analysis: genomic DNA is extracted from treated cells and the
target loci are amplified by primers (red and green) that anneal outside the region of
donor homology (Orange). The 2kb amplicons are purified and digested with BsrBI or
DraIII to achieve 1kb digestion products. (b) RFLP analysis of template DNA containing a
decreasing percentage of BsrBI (% BsrBI) containing fragments made up to 100ng with WT
template, digested with BsrBI or BsrBI plus DraIII. (i) Gel electrophoresis of the cut and
uncut fragments are visualised by UV. (ii) The separated fragments are blotted onto a
negatively charged membrane, hybridised with radioactive probe and visualised by
autoradiography. The numbers below the bands denote the percentage of the 250bp
digestion product of total 500bp DNA template above background, calculated from the
band intensity by ImageJ.
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4.5.1 Gene targeted correction of IL2RG by lentiviral vector delivery of ZFN and
donor DNA
To accompany the ZFN delivered by lentiviral vectors, the MB17 donor DNA was
cloned into a lentiviral backbone and IDLV was prepared. Donor DNA is always
delivered by integrase deficient vectors as randomly integrated donor constructs are
not readily available for HR.
To confirm the proof of principle of ZFN targeted correction and to establish an
effective ratio with donor DNA, 5x104 ED7RγcΔ cells were transduced with integrase 
proficient ZFN LV vectors and IDLV donor DNA at different ratios (Figure 4.9a). The
total MOI of ZFN LV pair was increased starting at an MOI of 5 in accordance with the
knockdown experiments where the most activity was observed at an MOI of 4. HR
specific PCR reveals that a ZFN:Donor DNA ratio of 3:1 consistently resulted in HR
positive amplicons. However, the smear from the PCR product, amplified by primer
pair 1, from cells treated with a 3:1 ratio and ZFN LV at an MOI of 10 (Figure 4.9a lower
gel) may or may not contain an HR positive product. HR occurred in 2/3rds of samples
treated with a ratio of 1:3 and the least effective ratio is 1:1 which only achieved HR
one in four times. In this assay the HR was frequently detected by primer pair 1 and
infrequently by primer pair 2 and the positive PCR control detected by both. It is also
important to note that the donor DNA integrated at the target locus without ZFN
activity when an MOI of 150 was used.
Subsequent analysis of ED7RγcΔ cells transduced with lentiviral vectors was performed 
with a titration of IDLV donor construct without ZFN vectors, and a ratio of 3:1,
ZFN:Donor DNA using either LV or IDLV ZFN vectors (Figure 4.9b). The HR specific PCR
performed on these transduced cells revealed that treatment with IDLV donor DNA
with MOI ranging from 1 to 100 viral particles per cell did not result in HR as no HR
specific band was detected at 1kb for primer pair 1 or 970bp for primer pair 2. When
donor DNA was combined with ZFN expression vector, targeted integration was only
observed when an MOI of 90 ZFN LV was combined with Donor DNA at an MOI of 30.
No HR was observed when ZFN IDLV constructs were used.
Cells treated with an MOI of 30:90 ZFN LV:Donor IDLV and the corresponding control
samples treated with either an MOI of 30 LV ZFN or 90 IDLV donor DNA and
untransduced control were analysed by RFLP (Figure 4.9c). Digestion product analysis
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revealed that 17% of target IL2RG had undergone HR and gene exchange was observed
in cells treated with donor alone. The positive control, prepared from full length IL2RG
containing the MB17 cassette was quantified at 150% digestion, this artefact may be
due to band saturation of the cut product or the background exceeding the remaining
uncut product. Double digest with both BsrBI and DraIII is incomplete so band intensity
was not calculated to determine whether there was a loss of the DraIII site by NHEJ in
ZFN treated samples.
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Figure 4.9 Targeted HR in ED7RγcΔ cells by ZFN and 
donor DNA delivered by lentiviral vectors.
5x10
4
ED7RγcΔ cells treated with ZFN delivered by 
increasing MOI of LV or IDLV ZFN construct with or
without IDLV donor at different ratios as indicated.
(a+b) HR specific PCR performed on genomic DNA
extracted from cells 15 days post transduction
alongside a plasmid containing full length IL2RG with
the MB17 cassette for control (+). (c) RFLP analysis by
Southern blot. BsrBI or BsrBI plus DraIII digest of
template from cells treated with either ZFN LV (Z) or
Donor IDLV DNA (D) at an MOI of 90 or 30 respectively,
or both (Z+D) alongside untransduced control (C) and
the BsrBI positive control (+). The numbers below the
bands denote the percentage of the 250bp digestion
product of total 500bp DNA template above
background, calculated from the band intensity by
ImageJ.
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4.5.2 Gene targeted correction of IL2RG by nucleofection with ZFN and donor DNA
plasmid vectors
Because the transient expression of ZFN by IDLV delivery did not result in any
detectable target HR, nucleofection was used to assess different ZFN to Donor DNA
ratios. Furthermore, different donor DNA constructs containing the WT, MB1, MB3
and MB17 cassette in the IL2RG homology domains were compared to establish
whether increasing the sequence disparity between the target and donor affects HR
and if WT homologous donor containing intact ZFN target hindered HR.
2x106 ED7RγcΔ cells were nucleofected with 1:3, 1:1 or 3:1 ZFN:Donor DNA constructs 
to a total of 2μg per sample. A titration of 0.5, 1 and 1.5μg of ZFN or donor construct 
were also nucleofected for control along with nucleofection solution alone. Flow
cytometry analysis 96 hours after nucleofection did not reveal correction resulting in
γc expression (Appendix 9) and HR specific PCR was carried out to determine whether 
any genomic modification had taken place. A set of primers specific for the MB3
cassette with the same binding position as the MB17 primers were used to detect HR
in MB3 donor treated cells (Figure 4.10a). HR was detected in cells treated with the
MB3 donor at all ratios tested and in the donor control with both primer pairs 1 and 2.
The absence of an HR specific product in the nucleofection solution alone and ZFN
treated cells confirmed that the primers can distinguish from WT. HR specific bands
were also detected in all the cells nucleofected with the MB17 donor. However no
BsrBI digestion was detected by RFLP analysis in cells treated with donor capable of
introducing the BsrBI restriction site (MB1, MB3 and MB17). Therefore it cannot be
determined whether cells treated with ZFN and donor DNA constructs had a greater
rate of HR than cells treated with donor alone (Figure 4.10b).
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Figure 4.10 Targeted HR in ED7RγcΔ cells treated with ZFN expression vectors and donor 
DNA delivered by nucleofection.
Genomic DNA analysis of targeted HR, 96 hours after nucleofection of 2x106 ED7RγcΔ with 
2μg of plasmid at different ZFN:Donor DNA or 1.5μg of ZFN or donor DNA constructs. (a) HR 
specific PCR to detect the MB3 or MB17 cassette at the IL2RG locus. (b) RFLP analysis of the
cells nucleofected with different ratios of ZFN to donor DNA capable of introducing a BsrBI
restriction site at the IL2RG locus alongside BsrBI positive control (+). The positive values of
DNA digested by BsrBI above background are noted as a percentage below the digested
bands. The number below the + band denotes the percentage of the 250bp digestion
product of total 500bp DNA template above background, calculated from the band intensity
by ImageJ.
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The nucleofection of ED7RγcΔ cells was repeated in order to monitor whether γc 
expression could be detected after a longer incubation period. The amount and type of ZFN
and Donor used remained the same however the Lonza GFP control was used to bring the total
DNA to 2μg for control samples. Flow cytometry analysis at day 12 showed γc expression in 
2.4% of cells receiving the WT donor at a ZFN to Donor DNA ratio of 3:1. Treatment with the
MB1 and MB3 donor constructs at the same ZFN:Donor ratio also achieved γc expression 
where no γc expression was detected in the other ratios or in the donor controls (Figure 
4.11a). These cells were kept in culture for a further 20 days and subsequent flow cytometry
analysis revealed a >15 fold increase of expression (Figure 4.11b). In addition to successful
gene targeted correction stimulated by ZFN, these results also suggest that γc expression 
conveys a selective advantage in vitro.
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Figure 4.11 Cell surface expression of γc in ZFN and donor DNA treated ED7RγcΔ cells.
2x10
6
 ED7RγcΔ nucleofected with 2μg of plasmid at different ZFN:Donor DNA. Or 1.5μg 
of ZFN or donor DNA constructs plus 0.5μg of GFP expression plasmid. 2μg GFP 
expression plasmid was used where no ZFN or donor DNA plasmid was used (0). Cells
were stained for γc expression, acquired by flow cytometry and gated on PI-ve live cells. 
(a) Flow cytometry analysis 12 days post nucleofection. (b) Flow cytometry analysis of
ED7RγcΔ receiving a ZFN:Donor ratio of 3:1 kept in culture for 32 days compared to 
untreated ED7RγcΔ control cells. 
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4.5.3 IL2 Receptor signalling in corrected cells
In order to determine whether the γc expression in the ED7RγcΔ cells treated with a 
ZFN:Donor ratio of 3:1 detected by flow cytometry restored IL2R signalling. The γc 
positive or negative cells were sorted by Fluorescence activated cell sorting (FACS) and
pSTAT5 was monitored following IL-2 stimulation (Figure 4.12). Medium alone did not
stimulate STAT5 phosphorylation in any of the sorted cells or the ED7RγcWT control 
(Appendix 10). The pronounced shift of pSTAT5 positive cells seen in the ED7RγcWT 
cells was not seen in any of the IL-2 stimulated cells. However a slight pSTAT5+ shift
was seen in the γc+ cells sorted after treatment with ZFN plus the WT, MB3 and MB17 
donor compared to the γc- sorted cells. Conversely, this pattern was reversed in the 
cells treated with the MB1 donor.
Figure 4.12 pSTAT-5 Signalling in treated ED7RγcΔ cells.
ED7RγcΔ cells treated by ZFN and donor ratio of 3:1 were cell sorted by FACS according to 
γc expression. Top, γc- . bottom γc+. After ON cell starvation of FCS, the cells were 
stimulated with IL2 and were analysed for pSTAT5 by flow cytometry.
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4.6 Discussion
In this chapter 2 cell lines, ED7RγcWT and ED7RγcΔ have been constructed, 
characterised and successfully used for ZFN mediated γc knockdown and correction 
respectively.
The data show that the ED7R cell line is capable of IL2RG transcription which follows
from the intact IL2RG locus. However, the lack of intracellular and cell surface γc 
expression suggests that there is a problem between translation and post-translational
processing of γc. The disproportionate, low intensity of the ED7R mRNA PCR product 
compared to the transduced controls could be speculated as (i) RNA instability,
possibly due to the loss of the T from the polyT tract in intron 4. (ii) The greater mRNA
product in transduced controls could be due to the transgene located in more active
chromatin leading to higher levels of expression. (iii) unequal concentrations of mRNA
in the sample. In order to resolve the latter 2 issues, a repeat RT-PCR of mRNA
expression should be compared between freshly isolated mRNA from the ED7R cells
and primary cells with endogenous levels of IL2RG and quantified with corresponding
RT-PCR amplicons generated from the housekeeping gene, GAPDH mRNA.
A point of consideration for the lack of γc expression in the ED7R cell line is the 
possible interference of IL-2 signalling by the original HTLV-1 infection. ED7R cells have
already been shown to be HTLV-1 protein tax negative (Hironaka, Mochida et al. 2004)
and the HTLV-1 protein p12I, capable of binding and stabilising γc in the pre-Golgi 
compartment (Mulloy, Crownley et al. 1996), is not suspected as ED7RγcWT cells are 
capable of cell surface γc expression. It would, however, be useful to investigate 
whether the HTLV-1 genome is located in proximity to the IL2RG locus and whether
cis-acting elements interfere with IL2RG expression.
The mRNA transcribed by ED7RγcΔ cells is a reflection of the nature of the G691A 
mutation which does not result in a stop codon or a splice site but the conversion of
arginine at codon position 226 to histidine (R226H) and mRNA was detected in a SCID-
X1 patient with this mutation by Northen blot (Puck, Pepper et al. 1997). This study
also observed a trace of cell surface expression of the mutant γc on the patient’s B 
cells however, this was not seen in a subsequent study by a different group on the
same mutation using the same monoclonal antibody, TugH4 (Kumaki, Ishii et al. 2000).
This residue is located in domain-2 of the extracellular region of γc (Stauber, Debler et 
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al. 2006) and is involved in binding IL-2. The location of this mutation could have
consequences in the recognition by antibodies raised to recognise WT γc, however 
over the course of this chapter, 2 different antibodies raised to recognise two different
epitopes of γc were used. Both the PE conjugated AG184 clone and the APC 
conjugated TuGH4 clone successfully discriminated between the γc-ve ED7R cells and 
the γc+ve ED7RγcWT and neither detected γc on the ED7RγcΔ cells, Furthermore, the 
AG184 clone recognises an epitope distinct from the IL-2 binding site of γc suggesting 
that this antibody would recognise the G691A mutation if the protein was expressed
on the cell surface. Justification for the lack of protein expression includes (i) the
protein is missfolded and promptly degraded, (ii) the protein is unable to traverse the
cell membrane and is degraded as a consequence. The latter is unlikely as no
intracellular protein was detected.
In trying to establish a cell line with a single copy of the WT or G691A IL2RG transgene,
3 qPCR analysis strategies gave consistent copy numbers which in turn justified the
copy number values used in subsequent experiments. The lack of supporting evidence
for these values by Southern blot analysis can neither confirm nor deny the qPCR
quantification. Limitations of the Southern blot analysis included the presence of large
>12kb fragments that were not separated by electrophoresis, this could be improved
by using a more extensive array of restriction enzymes used individually or in
combination to generate shorter fragments. It would also be of benefit to include a
probe that annealed to a known digested fragment length in the genomic DNA as this
would confirm successful digestion and DNA of suitable quality.
A limitation of introducing the ZFN target as a randomly integrated transgene means it
is unlikely that the chromatin infrastructure in and around the target site accurately
represent that of physiological conditions. Another drawback is due to the ED7R cell
line, despite the fact they were originally isolated from a human male, the karyotype
of the ED7R cell line contains two X chromosomes and therefore 2 copies of non-
functional IL2RG. These precursory, non-functioning copies of the IL2RG could “mop
up” the ZFN provided and the multiple DSB incurred could increase the toxicity
experienced by the cell. A solution to this latter problem would be to treat ED7R cells
with ZFN before introducing the transgene. By sequencing NHEJ events at the IL2RG
loci in ZFN treated cells, those which had both alleles disrupted by non-conservative
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repair would no longer have ZFN targets. This would ensure that any IL2RG target
sequence added to the cells would be the only target for ZFN and therefore decrease
toxicity and possibly increase the sensitivity of gene modification detection.
Gene targeting by flow cytometry analysis showed that γc gene knockdown was 
achieved by DSB mediated by ZFN however these data was not consistently supported
by the detection of indels which would evaluate DNA repair by NHEJ. As the level of
indel detection was determined to be sensitive enough for a dissimilarity of 8% of DNA
molecules, it is unlikely that the surveyor assay is not sensitive enough to detect IL2RG
modification where ZFN treatment resulted in a 59% drop of γc+ cells. It is well 
documented that over-expression of ZFN leads to toxicity due to off target cleavage
(Beumer, Bhattacharyya et al. 2006; Gupta, Meng et al. 2011) and ED7R cells may be
sensitive to the extent that the treated cells had undergone apoptosis and DNA
degradation before indel analysis was carried out. Contrary to this is the evidence of
indels in ED7RγcWTlow cells, containing an estimated 5 targets, undergoing 
constitutive ZFN expression. However the multiple copies may have resulted in enough
gene targets to be detected in surviving cells.
Genomic analysis detected targeted HR in the ED7RγcΔ cells 96 hours after ZFN and 
donor treatment, this is in accordance with the expected ZFN translation and activity
observed by Porteus et al. (Porteus and Baltimore 2003). The γc expression observed 
by flow cytometry after a longer incubation time of 12 days is corroborated by the 15
day incubations used by Lombardo et al. (Lombardo, Genovese et al. 2007). RFLP
analysis only detected targeted HR 15 days after transduction with ZFN LV and donor
IDLV. The 15 day time point was not analysed after nucleofection as γc expression was 
confirmed by flow cytometry but this analysis would be useful to corroborate the flow
cytometry data. The absence of targeted HR with the use of ZFN and donor DNA
delivered by IDLV is contradictory to the successful use of IDLV used by Lombardo et al.
It is not reasonable to compare the amount of IDLV vector used in either study as the
IDLV quantified by Lombardo et al. was in μg of p24/mL. This method of quantification 
is not in accordance with MOI calculations for vector stocks and does not exclude
empty vectors which may overestimate the quantity of complete viral vector.
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On transient expression of ZFN, HR was only successful by nucleofection where a 3:1
ZFN:Donor ratio was performed using 2μg of plasmid per 2x106 cells. Using Avogadro’s
number, this equates to 1.6x105 plasmids per cell. This is 180 fold greater than the
highest MOI of IDLV transfected and therefore a direct comparison cannot be made
with nucleofection. What is of interest is that by increasing the MOI of donor IDLV
alone led to HR at the IL2RG target when 150vp/cell was used but not ≤100vp/cell. It is 
of no surprise that ZFN independent HR occurred when nucleofected with 1.5x105
donor plasmids/cell.
Background HR of donor DNA at the target site in the absence of ZFN was frequently
observed in HR specific PCR but not in flow cytometry or RFLP analysis. As the HR
specific PCR cannot quantify the rate of HR but may be more sensitive than RFLP and
flow cytometry, it can only be assumed from the flow cytometry analysis which only
showed γc expression in cells that received both the ZFN pair and donor DNA, that the 
rate of recombination is increased when ZFN are administered to activate the
chromosomal target.
The comparison of different donor DNA constructs with increasing sequence
dissimilarity shed light on various aspects of correction in this model. Firstly, the PCR
method of detection is only possible in the donors with 3 or 17 base pair changes from
WT. Both of these donors were used for HR when DNA was delivered by nucleofection.
Using the quantifiable method of flow cytometry, after 12 days of culture post
nucleofection, it would seem that by increasing the base pair dissimilarity from the
mutant target, the rate of HR declines, from 2.38% with WT donor (1bp difference) to
none in MB17 (18bp difference). However, this pattern is not seen after a month of
culture where corrected γc was observed following treatment by all of the donors. 
Firstly this demonstrates that the PCR method of detection is more sensitive. Secondly,
the hypothesis that a donor containing the ZFN target site would inhibit HR is not
shown in this model. Thirdly, γc expression likely provides a growth advantage in ED7R 
cells in vitro, as the percentage of corrected cells increased over time.
The γc corrected cells did not convincingly demonstrate IL2R signalling by IL2 
stimulation. This may in part be due to the strenuous effects of cell sorting. It will be
necessary to repeat this assay to incorporate an extended recovery period for the
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sorted cells and to ensure that the inconsistent result observed after treatment with
the donor construct MB1, was not a result of sample exchange. It will also be optimal
to carry out RFLP and high throughput sequencing on the γc positive and negative 
sorted cells to ensure that the γc expression was the result of targeted IL2RG
correction.
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5 Characterising the humanised mouse model of SCID-X1
5.1 Aims
 To characterise the nature of human IL2RG in a new humanised SCID-X1 mouse
model
 To confirm the immune cell profile of the humanised mouse is deficient by
comparing it to WT and γc knockout mice 
 To reconstitute the immune system of the humanised mouse with IL2RG
expressing integrating lentivirus
5.2 Introduction
Studying ZFN in murine models is a prerequisite of human clinical trials. Variations of
γc knockout mice have so far been used as murine models of SCID-X1 and although 
gene transfer by retroviral vectors is successful in restoring the immune system in
these models, due to the lack of endogenous human IL2RG (hIL2RG), there is no
platform on which to perform IL2RG targeting with ZFN designed for hIL2RG.
Murine il2rg (mil2rg) like human, is expressed in blood cells rather than other tissue
and is located on the X chromosome where it shares 69% sequence homology with
hIL2RG at the cDNA level. It contains the conserved cysteine residues and WSXWS
motif and the greatest region of homology is in the cytoplasmic tail however not in the
SH2 subdomian (Cao, Kozak et al. 1993). In order to investigate whether a mouse
model devoid of il2rg expression would result in the same phenotype as SCID-X1
patients DiSanto et al. engineered a γc-/- mouse strain by excising exons 2-6 of murine
il2rg via cre-loxP recombination of intronic loxP (DiSanto, Muller et al. 1995) in parallel
Cao et al. developed another γc-/- mouse with a gene truncated from exon 3 (Cao,
Shores et al. 1995). These models have thymi that are markedly reduced in size and
cellularity with the same architecture as normal mice but their thymocytes are unable
to respond to mitogens in vitro. NK cells, intraepithelial lymphocytes and TCRγδ T cells 
are all absent and the population of B cells is decreased in the bone marrow with no
IgE in the sera and no immunoglobulin isotype switching in response to IL-4 in vitro.
The mice have smaller spleens than normal at age 3-4 weeks however further
observation by Cao et al. showed that at age 4-9 weeks the mice displayed
splenomegaly. Other observations by Cao et al. showed the lymph nodes lacked
germinal centres and that the CD4+:CD8+ T cell ratio in the periphery was increased
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due to the decreased population of CD8+ T cells. DiSanto et al. showed normal T cell
populations in the thymus, a 12-fold reduction of mature IgM+ IgD+ B cells and a 3 fold
reduction in IgM in the sera. In contrast Cao et al. observed no difference in IgM
compared to normal. No mutant γc mRNA was detected by Cao et al. and DiSanto et al.
confirmed the absence of γc by antibody detection but did not confirm whether any 
malformed protein was expressed. A third SCID-X1 mouse model was generated by
deleting the cytoplasmic domain of mil2rg (Ohbo, Suda et al. 1996). The observations
made in this mouse corroborated those made by both Cao et al. and DiSanto et al. and
the IgM+ B cells were 15-20 fold less than control littermates, however IgM in the sera
was increased in mice >8 weeks but was reduced at 10-11 weeks and the IgG levels
were lower than WT control mice. The conclusions that can be made from these SCID-
X1 animals are that they are hypothymic, have no NK cells, have reduced levels of
mature B cells and CD8+ T cells yet their CD4+ T cell numbers remain comparable with
WT.
The reduced B cell population in the γc-/- mice is unlike the non-functional B cell
population in human SCID-X1 patients. This is thought to be due to IL-7 in mice as B cell
development is blocked before transition to the Pro B cell phase in IL-7 Knockout (von
Freeden-Jeffry, Vieira et al. 1995) and IL7Rα knockout (Peschon, Morrissey et al. 1994) 
mice. In contrast, IL7Rα mutations in humans do not affect B cell development (Puel, 
Ziegler et al. 1998). However, T cell development is disrupted in both mouse and
human on the loss of IL-7 signalling.
The T cell population present in γc-/- mice does not reflect the T cell absence in SCID-X1
patients. When challenged with Toxoplasma Gondii, the depleted NK cells and CD8+ T
cells which are vital for protection against this opportunistic pathogen in humans,
where shown to be redundant in the γc-/- model and the CD4+ population produced
IFNγ in response to the infection (Scharton-Kersten, Nakajima et al. 1998). The 
enduring CD4+ T cells are also implicated in the occurrence of anaemia, splenomegaly
and colitis in γc-/- mice (Sharara, Andersson et al. 1997) and are likely to be due to the
loss of the immunomodulatory function of IL-2 (Sadlack, Merz et al. 1993). Colitis can
be resolved by keeping the animals in a pathogen free controlled environment which is
essential for the maintenance of SCID models.
134
The outcome of positive and negative selection of T cells in the thymus of γc-/- mice
crossed with mice expressing a TCR specific for male antigen demonstrated that
autoreactive CD8+ cells were negatively selected in the male mice negating the role of
γc in this process. Likewise positive selection of male antigen specific CD8+ cells in 
female mice was unaltered (DiSanto, Guy-Grand et al. 1996). The thymus of SCID-X1
patients is hypoplastic, lacks the cortico-medullary distinction and Hassall bodies seen
in normal thymus architecture and completely lacks CD3+ T cells (Hale, Buckley et al.
2004). The difference in T cell population between SCID-X1 humans and mouse models
can be explained by the role of the tyrosine kinase. Where Jak3 kinase is used in
humans, c-kit is used in murine thymocyte development as shown by the alymphoid
thymus in c-kit-/- γc-/- double knockouts (Rodewald, Ogawa et al. 1997).
Another alymphoid mouse model was generated by crossing the Rag2-/- mouse which
is incapable of V(D)J rearrangement and therefore unable to develop B and T cells
(Shinkai, Rathbun et al. 1992) with the γc-/- mouse of DiSanto et al. (Goldman, Blundell
et al. 1998). This genetic cross resolved the issue of splenomegaly and colitis observed
in the γc-/- mouse and the absent innate immunity in these mice makes them suitable
recipients for HSC transplants from different animal origins.
In light of the requisite for a new animal model of SCID-X1, a humanised mouse model
was engineered by InGenious (figure 5.1a). Briefly, the full length mil2rg with its
promoter and enhancer elements was replaced by full length hIL2RG with the G691A
point mutation (figure 5.1b). This humanised mouse model of SCID-X1 not only
provides the mutant IL2RG target for site specific endonucleases, but due to the
location of the novel human loci, it also takes into account the chromatin structure and
epigenetic factors that can affect gene targeting which may be applicable to the
human location of IL2RG.
This chapter determines whether this SCID-X1 mouse model, hγcmut, results in a SCID 
phenotype by comparing it to a γc-/- mouse. Subsequently, lineage negative (lin-) HSC
from this mouse are enriched and transduced with lentiviral constructs in order to
introduce hIL2RG as a transgene and assess whether these transformed multipotent
cells are capable of restoring a fully functional immune system. The 2 constructs used
to demonstrate immune cell reconstitution by restoring γc expression were, the 
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IL2RGp-IL2RG lentiviral vector used in the previous chapter or an SFFVp-IL2RG lentiviral
vector construct, comprising the U3 region of the spleen focus forming virus as a
promoter (SFFV) and IL2RG cDNA. Both the IL2RG and SFFV promoters contain an Ets
binding site (EBS) (Markiewicz, Bosselut et al. 1996), (Baum, Itoh et al. 1997). The Ets
family of transcription factors regulate hematopoietic cell development including T
cell, B cell and NK cell differentiation (Anderson, Hernandez-Hoyos et al. 1999) and the
EBS in the IL2RG promoter is involved in the regulation of γc expression in various cell 
types (Markiewicz, Bosselut et al. 1996).
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Figure 5.1 Engineering the humanised mouse model of SCID-X1.
(a) The human IL2RG was subcloned into a shuttle vector and the G691A point mutation
introduced by site directed mutagenesis. The murine il2rg was also subcloned and both the
human and murine il2rg loci were flanked by MluI sites which allowed for gene exchange. Now
the mutated human gene was flanked by murine homology arms, the shuttle vector was
electroporated into murine ES cells and successful homologous recombination was selected for
by Neomycin resistance (NeoR). Following selection the LoxP flanked NeoR was excised by Cre
resulting in humanised mouse (hγcmut) ES cell lines ready for implantation. (b) The hγcmut loci 
containing the G691A mutation in the selected ES cell line was amplified by PCR which
underwent high throughput sequencing. The read out is aligned with the known WT sequence
to confirm the mutation as present seen at base pair 220 of the read out.
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5.3 Characterisation of the humanised γc mutant mouse 
InGenious provided 2 γcΔ/Y homozygous males and one γcΔ/+ heterozygous female. A
pure strain of hγcmut mouse was bred whereby the females were homozygous for the 
mutated human γc gene. To genotype the mice, a PCR strategy was designed to 
generate a 623bp or 206bp product if the human or mouse gene were present,
respectively (Figure 5.2a). Figure 5.2b shows the PCR products that relate to the
genotype of the mice received from InGenious as compared to a BL6 WT mouse. Only
PCR products generated from murine specific primers were seen in the BL6 wild type
mouse and the heterozygous female. The PCR products generated by human specific
primers were only seen in both of the knock in males and the heterozygous female but
not in the WT sample. A combination of mouse and human specific primers were
successful in amplifying both mil2rg and hIL2RG targets in the heterozygous female,
this combination was therefore used as the method of screening for litters up to and
including the founding litter as seen in Figure 5.2c. The founding litter contained only
human mutant IL2RG (hIL2RGΔ) and there was no evidence of mil2rg as compared to a
heterozygous control, confirming a pure strain had been bred.
Having confirmed the presence of hIL2RGΔ in the hγcmut mouse, it was then 
investigated whether the missense mutation resulted in lack of transcript expression.
Total mRNA was isolated from hγcmut and WT mice and human peripheral blood and 
cDNA generated by RT-PCR (Figure 5.2d). The 76bp amplicon generated by the primers
recognising the exon 6 and 7 boundary of the cDNA template was seen exclusively in
the hγcmut mouse and human control samples. An amplicon was detected in the WT 
sample, but as its size was at least 3 fold greater than the 76bp specific product, it was
more likely to be due to non-specific binding. Amplicons generated by human GAPDH
and murine gapdh cDNA detecting primers verified the presence of human and murine
RNA respectively. It can be confirmed that the hγcmut mice are capable of transcribing 
the hIL2RGΔ gene mRNA.
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Figure 5.2 Genotyping the hγcmut mouse model.
(a)The PCR strategy for detecting the human IL2RG or murine il2rg in the mouse model,
blue arrows represent murine specific primers and the red arrow is human specific. The
PCR products amplified from transgenic mice by primer pair combinations 1-5. Human
forward (hF) and mouse reverse (mR) or mouse forward (mF) and mouse reverse (mR)
confirm the heterozygous female and 2 knock-in males in (b). (c) The homozygous founding
litter genotype as amplified by the mouse and human forward with mouse reverse is
shown alongside a heterozygous control. (d) cDNA was generated from total mRNA from
human, hγcmut and WT blood cells. The 76bp IL2RG amplicon was seen in human and
hγcmut samples. GAPDH was amplified for control with primers specific for human GAPDH
or murine gapdh.
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5.3.1 Immune cells in the peripheral blood
It is not possible to differentiate hγc in murine immune cells using the current 
antibodies available. Further analysis of the hγcmut mouse was carried out to ratify 
this model as immunodeficient by comparing the immune cell profile to WT BL6 mice
and the pre-existing γc knockout (γc-/-) mouse model (DiSanto, Muller et al. 1995).
Immune cell populations were acquired from the following tissues: Blood, spleen,
thymus, lymph node and bone marrow. Specific immune cell subsets were determined
using fluorophore conjugated antibodies specific for lymphocyte markers and
quantified using flow cytometry. The lymphocyte subsets analysed included T cells,
defined by their CD4+ and CD8+ cell surface markers, NK1.1+ CD3- NK cells and IgM+
B220+ B cells. Representative flow cytometry plots of the proportion of immune cell
types in the peripheral blood are shown as a percentage of the total live gate,
determined by forward and side scatter (FSc and SSc respectively) (Figure 5.3a) and the
total data accumulated from analysed mice are shown in figure 5.3b. Here it is clearly
demonstrated that the peripheral blood of the γc-/- and the hγcmut mouse model have 
significantly fewer CD8+ cells, NK cells and IgM+ B cells than WT (P< 0.001). A well-
established CD4+ cell population was seen in all three mouse models. Because the
immune cell populations were calculated as a proportion of total cells, this method of
analysis does not consider the total number of immune cells in circulation. Due to the
nature of pathogenic IL2RG deficiency, it is possible that there are fewer immune cells
circulating the peripheral blood and tissues as compared to wild type. As a result, it is
possible that the proportions of immune cells found in each tissue don’t accurately
represent the insufficient immune repertoire of the SCID-X1 models. In order to
address this observation, the absolute number of cells analysed by flow cytometry
were calculated using a known number of absolute counting beads (Figure 5.3c).
Again, there is a CD4+ cell population in the hγcmut mouse similar to WT, and in this 
instance, the decrease in CD8+ cells does not reach significance, possibly due to a
smaller sample number. In support of the proportional data, the IgM+ B cells and NK
cells are consistently reduced, as compared to WT. Taking both the proportional data
from the various tissues examined and the absolute cell counts from the blood, it can
be concluded that the hγcmut mice, like the γc-/- mice, do not have the full repertoire
of immune cells and are therefore immunodeficient.
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Figure 5.3 Immune cells in the blood of hγcmut, WT and γc-/- mice.
(a) Representative flow cytometry plots from the analysis of immune cell isolation from the
peripheral blood of WT, hγcmut and γc-/- mouse model. The live cells were established by
the FSc, SSc plot. T cells are established by CD4 or CD8 expression, NK cells determined by
CD3- NK1.1+ expression and Mature B cells by IgM and B220 expression. (b) Vertical
scatter plots of the immune cell percentage in the peripheral blood, of WT (blue), hγcmut 
(green) and γc-/- (red) mice, as analysed by flow cytometry. (c) Scatter plots of the absolute
cells count per mL of immune cells in a known volume of peripheral blood as analysed by
flow cytometry. The comparison of CD4+ or CD8+ T cells, NK cells and IgM+ B cells did not
have a normal distribution and were analysed using the Kruskal Wallis extension of the
Mann-Whitney test and the P values generated by comparing the hγcmut mouse to WT or 
γc-/- mice are indicated by star ratings: *** : P=<0.001; ** : P=<0.01, * : P=<0.05.
141
5.3.2 Thymic development in SCID-X1 mice
Characterising the phenotype of the hγcmut mouse continued with a more in-depth 
analysis of particular tissues that may be affected by aberrant γc expression. As it has 
been observed that mice lacking γc cannot develop a normal bi-lobular thymus and 
only a rudimentary thymus is seen, thymi of hγcmut and γc-/- mice were compared to
WT mice (Figure 5.4a). Example thymi are shown in situ and isolated. The WT thymus
example was clearly bi-lobular with a width of at least 8mm. Conversely, thymi
dissected from mature hγcmut and γc-/- mice were smaller and a bi-lobular structure
was not present. Although it can be seen that a thymus is unable to fully develop in the
hγcmut mouse, T cells can develop in this rudimentary thymus. The flow cytometry 
plots (Figure 5.4b). demonstrated that the CD4+ and CD8+ single positive populations
and the CD4+ CD8+ double positive population were found in the hγcmut mouse and 
the γc-/- mouse. This corroborates with the CD4+ cell populations found in the
periphery of the hγcmut and γc-/- mouse. However, the CD8+ cell population was
greater in the WT mouse compared to the hγcmut and γc-/- mice. On analysing the
immune cell populations of a greater sample size (Figure 5.4c), there was no difference
in the CD4+ or CD8+ cells between the WT and hγcmut thymi. The contrasting 
decrease of T cells seen in the γc-/- mouse may be due to the larger number of hγcmut 
mice analysed compared to γc-/- mice. The populations of NK cells and IgM+ B cells in
WT were not seen in the hγcmut and γc-/- counterparts. To summarise, when the
mutated human IL2RG is present in place of the functional murine il2rg locus, only
rudimentary thymus develops.
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Figure 5.4 Immune cells in the hγcmut, WT and γc-/- thymi.
(a) examples of mature murine thymi from hγcmut WT and γc-/- aged over 10 weeks. Left,
thymi (1) heart (2) and lung (3) in situ. Right, isolated thymi with a corresponding scale bar.
(b) Representative flow cytometry plots of of CD4+ and CD8+ single and positive T cells
analysed by FACS, 100,000 events were acquired with a minimum of 40,000 events in the
live gate. (c) Vertical scatter plots of the collective data of all the immune cells analysed in
the thymus did not have a normal distribution and was analysed using the Kruskal Wallis
extension of the Mann-Whitney test and the P values generated by comparing the hγcmut 
mouse to WT or γc-/- mice are indicated by star ratings: ** : P=<0.01; * : P=<0.05.
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5.3.3 Immune cells in the spleen, bone marrow and lymph node
It has also been observed in γc-/- mice that there is a propensity for splenomegaly.
Spleens from WT, hγcmut and γc-/- mice over 9 weeks of age were compared.
Representative spleens isolated from each mouse type demonstrated that the spleen
size from the SCID-X1 mouse is greater than WT (Figure 5.5a). The scatter graph of
splenic mass from the different mouse groups shows an increased spleen mass in the
SCID-X1 mouse models (Figure 5.5b). Analysis of the immune cell populations reveals
immune cell distribution similar to the observations made from peripheral blood
(Figure 4.5c) and taking into account the splenic mass and size, it can be concluded
that like the γc-/- mouse, the hγcmut mouse also exhibits signs of splenomegaly.  
To complete the comparison of the immune cells of the mouse models, the immune
cells of the bone marrow and lymph node were also analysed by flow cytometry
(Figure 4.5d). The bone marrow showed a similar immune cell distribution to the blood
with a decrease in NK cells and IgM+ B cells however a significant decrease in CD8+
cells was not well defined. The immune cell populations of the lymph nodes were not
significantly different between the mouse models which is possibly due to the low cell
numbers retrieved from the isolation of the tissue.
Overall, the immune cell populations from the hγcmut mouse reflect that of the γc-/-
mouse and also have the same rudimentary thymus associated with a lack of γc 
expression. Furthermore, the existing CD4+ cell population observed in the SCID
mouse models can be implicated in the occurrence of splenomegaly observed in these
mouse models.
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Figure 5.5 Immune cells and mass of the hγcmut, WT and γc-/- spleen.
(a) representative age matched spleens from >9 week old WT, hγcmut mice and γc-/-
with scale bar. (b) scatter plots of the splenic mass of mice >9 weeks of age. (c+d)
vertical scatter plot of the percentage of immune cell populations in WT (blue), hγcmut 
(green) and γc-/- (red) mice. (c) spleens (d) bone marrow and lymph node. Data were
analysed using the Kruskal Wallis extension of the Mann-Whitney test and the P values
generated by comparing the hγcmut mouse to WT or γc-/- mice indicated by star ratings:
*** : P=<0.001; ** : P=<0.01; * : P=<0.05.
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5.4 Reconstitution of the immune system by introducing human IL2RG
In order for the hγcmut mouse to be a suitable model for gene targeting of the hIL2RG
locus, it must be possible to reverse the disease phenotype in this model of SCID-X1 by
introducing hIL2RG. The ability of functional human γc to complete interleukin 
receptors missing the murine γc and develop a functional immune cell repertoire was 
assessed in this model by transducing progenitor cells from the hγcmut model with a 
hIL2RG gene and observing the possibility of restoring a functional immune system
when transplanted into a Rag2-/-γc-/- immunodeficient mouse of the same, C57BL/6
genetic background. This strategy has proven successful as Rag2-/-γc-/-c5-/- are suitable
recipients as they have no immune cells to compete with, or reject the transplant
(Thornhill, Schambach et al. 2008). As haematopoietic progenitors capable of long
term engraftment are resting in the G0 phase of the cell cycle immediately after
isolation from the donor (Reems and Torok-Storb 1995), the lin- cells from the donor
mice were stimulated with Stem cell factor (SCF), murine Flt3 ligand (mFlt3) and
human thrombopoietin (hTPO) as these factors aid self-renewal of lin- cells in vitro
with limited multipotency (Hennemann, Conneally et al. 1999; Oostendorp, Audet et
al. 2000) and progression from the G0 phase of the cell cycle enhances lentiviral vector
transduction (Sutton, Reitsma et al. 1999).
5.4.1 The reconstitution assay
A reconstitution assay was carried out whereby lin- cells were enriched from the bone
marrow of hγcmut mice, transduced with lentiviral vector overnight in StemSpan 
supplemented with SCF, mFlt3 and hTPO. The cells were then re-suspended in RPMI
and injected intravenously into lethally irradiated Rag2-/-γc-/- mice. (Figure 5.6a), Three
integrating lentiviral vectors were each used at an MOI of 10 as calculated by flow
cytometry analysis of either GFP or cell surface γc in the case of GFP or hIL2RG
constructs respectively. 3 mice were treated with cells transduced with the full length
hIL2RG with its promoter and regulatory elements (IL2RGp-IL2RG). 3 with hIL2RG cDNA
regulated by an SFFV promoter (SFFVp-IL2RG) and 2 with an SFFVp-GFP construct for
control (Figure 5.6b). Untransduced lin- cells from WT mice were also injected into 2
additional lethally irradiated mice at this point for positive control. Flow cytometry
analysis of the lin- cells selected by magnetic activated cell sorting (MACS) from either
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WT or hγcmut bone marrow confirms that the NK cells and IgM+ B cells were 
successfully depleted however some T cells were still present (Figure 5.6c). The extent
of lentiviral transduction was assessed at the pre-injection stage by incubating the cells
in complete StemSpan at 37°C for 72 hours, extracting the genomic DNA and
quantifying the copy number of transgene by qPCR (Figure 5.6d). Primers and probe
specific for the WPRE detected the integrated viral backbone and primers and probe
for the murine housekeeping gene, titin, quantified the cell number. The proviral copy
number was calculated by dividing the WPRE copy number by the titin copy number
and multiplied by two, to account for the 2 copies of titin. From the copy number
observed in these cells it was seen that the IL2RGp-IL2RG and the SFFVp-GFP
constructs achieved a greater copy number than the SFFVp-IL2RG. The transplanted
animals were maintained for 16 weeks in an environment suitable for
immunodeficient animals.
147
Figure 5.6 The reconstitution experiment.
(a) a schematic of the ex vivo protocol of transduced
lineage negative (lin-) HSC transplant. lin- enriched
bone marrow from hγcmut mice was transduced 
overnight (ON) with integrating lentiviral vector and
subsequently injected intravenously into lethally
irradiated Rag-/-γc-/- mice. (b), the lentiviral vector
constructs IL2RGp-IL2RG, SFFVp-IL2RG cDNA or
SFFVp-GFP were used to transduce lin-ve enriched
bone marrow. (c) The lin- cells were assessed for
purity by flow cytometry, the cells were stained with
antibodies to CD4, CD8, NK1.1, CD3, B220, IgM and
compared to unstained and the efficiency of
magnetic selection verified by streptavidin detection
of biotin labelled cells. (c) Copy number analysis by
qPCR of WPRE compared to the house keeping gene
titin in lin- cells, 72 hours post transduction
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5.4.2 Reconstitution at 12 weeks
The presence of immune cells reconstituted by the transduced donor hγcmut bone 
marrow cells was analysed by flow cytometry. Peripheral blood was extracted from the
mice 12 weeks post-transplant and stained with antibodies to detect mature cell
lineages (Figure 5.7a). Example flow cytometry plots reveal CD4+ cells, CD8+ cells. NK
cells and IgM+ B cells in all the mice treated with cells transduced with functional
IL2RG constructs and in mice receiving WT lin- cells. The mice transplanted with lin-
cells transduced with SFFVp-GFP did not show any reconstitution of the immune cells
analysed. The ratio of CD4+ to CD8+ cells was 1.9 in mice transplanted with WT and 2.3
and 3.3 in mice treated with cells transduced with IL2RGp-IL2RG and SFFVp-IL2RG
respectively. In the previous characterisation data this ratio in an untreated WT mouse
was seen to be 2.3 (Figure 5.3a). The greatest reconstitution of NK cells was observed
in the WT reconstitution control and second greatest in the SFFVp-IL2RG treated
example. Interestingly, the IgM+ B cells were more frequent in the recipients of IL2RG
transduced donor cells than the WT control. The total immune cell data retrieved from
all 10 of the transplanted mice (Figure 5.7 b) showed an increase in CD4+, CD8+ and
IgM B cells in the mice treated with either WT or IL2RG transduced lin- cells compared
to the GFP control. No significant conclusions could be drawn as only 2 GFP control
mice were analysed.
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Figure 5.7 Tail bleed 12 weeks post
injection
Representative flow cytometry plots of
the immune cell reconstitution at 12
weeks. Mice were tail bled and the
peripheral blood cells stained with
antibodies to detect CD4+ and CD8+
cells, CD3-NK1.1+ cells and IgM+
B220+ cells. (b) A scatter plot of the
percentages of the reconstituted
immune cells 12 weeks after
transplant.
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5.4.3 Reconstitution at sacrifice
Due to the successful reconstitution of immune cells analysed in the periphery at 12
weeks post-transplant, further analysis of the tissue in the recipient mice was carried
out. Apart from one SFFVp-IL2RG treated mouse that died at week 12 due to an
unrelated circumstance, the remaining mice were sacrificed at week 16 plus 3
untreated Rag2-/-γc-/- mice for comparison. Cells from all the mice were isolated from
the blood, bone marrow, spleen, and thymus. Immune cells were stained with
lymphoid specific antibodies and acquired by flow cytometry. The populations, as a
percentage of the total live cells, (Figure 5.8a) confirmed that all of the immune cell
types analysed were increased in both the IL2RG treated hγcmut lin- cells and the WT
positive control mice. However, due to small sample sizes, the clear trend is not
supported by statistical analysis. The increase is most notable in the percentage of T
cells in the blood, bone marrow and spleen when the IL2RGp-IL2RG lentiviral vector
was used and the increase of IgM+ B cells in the blood and spleen when the SFFVp-
IL2RG vector was used. The SFFVp-IL2RG lentiviral vector did appear to reconstitute
CD4+, NK and IgM+ B cells but the difference was less striking concerning the CD8+
cells. The GFP control recipients showed a moderate presence of T cells in the spleen
yet fewer than untreated hγcmut mice (Figure 5.5c) and a remarkable disparity of 
these cells in the thymus between the 2 animals analysed. Conversely there is no
evidence of NK or IgM+ B cells in the treated negative control. There are no values for
immune cell populations in Rag2-/-γc-/- thymi due to the absence of this tissue in these
animals.
The overall pattern of immune cell repertoire in the treated mice is that IL2RG treated
hγcmut lin- cells are capable of restoring immune cell populations similar to the WT
positive control than the GFP negative control which displays immune cell populations
with a similar pattern to untreated Rag2-/-γc-/- mice.
To determine the engraftment capacity of the transduced donor cells, the proviral
copy number was assessed in the various tissues of the treated mice by quantitative
PCR (qPCR) (Figure 5.8b). Genomic DNA was extracted from the peripheral blood, bone
marrow, spleen and thymus of mice sacrificed at week 16. Primers and probe specific
for the WPRE detected integrated viral backbone. Likewise, primers and probe for the
murine housekeeping gene, titin, quantified the cell number. The proviral copy number
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was calculated by dividing the WPRE copy number by the titin copy number. Unlike the
transduction efficiency at 72 hours where the quantity of transgene achieved by the
IL2RGp-IL2RG construct was greater than the SFFVp-IL2RG construct after
transplantation, the SFFV promoter constructs now exceed the IL2RGp-IL2RG
construct’s copy number. This could be in part due to the higher transduction
efficiency resulting in cell morbidity or it may be due to regulatory elements which
allow physiological control of the haematopoietic stem cell differentiation.
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Figure 5.8 Immune cell reconstitution at sacrifice and transgene copy number at 16
weeks
(a) Scatter plots of the flow cytometry analysis of the immune cells from the spleen, bone
marrow, thymus and peripheral blood in mice transplanted with lin- cells from either WT
mice or hγcmut mice transduced with IL2RGp-IL2RG, SFFVp-IL2RG or SFFVp-GFP and
Rag2-/-γc-/- non-transplanted control. The small sample sizes do not warrant a one way
analysis of variance. (b) Proviral copy number at 16 weeks detected by qPCR in the
spleen, bone marrow, thymus and peripheral blood mice transplanted with lin- from WT
(n=2), or hγcmut transduced with IL2RGp-IL2RG (n=3), SFFVp-IL2RG (n=2), SFFVp-GFP
(n=2) and calculated by the WPRE copy divide by the copy number of titin housekeeping
gene.
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5.4.4 Thymic development in reconstituted mice
The Rag2-/-γc-/- mouse is incapable of developing a thymus and a sign of successful
immune system reconstitution is the development of thymic tissue after treatment. In
all of treated mice thymic tissue was present at sacrifice, including the GFP control
(Figure 5.9a). From the examples of thymi in situ and isolated from the treated mice
and untreated WT and Rag2-/-γc-/- controls it can be seen that the thymi are smaller
than those dissected from WT mice. Example thymi from mice treated with lin- cells
from hγcmut mice incorporating an IL2RG transgene and the WT reconstitution control
more closely resembled the bi-lobular structure of the untreated WT positive control
than the SFFVp-GFP treated control. Furthermore the CD4+/CD8+ single positive and
double positive T cells of the mice reconstituted with functional IL2RG containing lin-
cells had a consistent pattern of distribution whereas the thymic tissue isolated as a
result of SFFVp-GFP treatment was uni-lobular like the thymi seen in hγcmut mice and 
had an aberrant distribution of CD4+/CD8+ single and double positive T cells (Figure
5.9b). The second SFFVp-GFP treated mouse did not have any CD4 or CD8 staining
(Appendix 12) accounting for the large variation of the CD4+ and CD8+ cells observed
in the 4 organ comparison flow cytometry data in the thymi of SFFVp-GFP treated
mice. The untreated WT positive control displayed a unique CD4+/CD8+ distribution,
most likely due to a greater amount of cells isolated from the tissue resulting in fewer
antibodies per cell and therefore a dimmer stain. The tissue extracted from the Rag2-/-
γc-/- mouse for control contains no cells with either the CD4 or CD8 T cell marker is
unlikely to be thymic tissue. The immune cells of the thymi were analysed by flow
cytometry and it was clearly demonstrated that the CD4+, CD8+ single and double
positive populations of T cells are present the mice which received lin- cells capable of
γc expression.  
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Figure 5.9 Thymic reconstitution.
(a) Examples of thymi dissected from Rag2-/-γc-/- mice treated with IL2RGp-IL2RG , SFFpV-
IL2RG and SFFVp-GFP transduced hγcmut lin- cells or WT lin- cells for reconstitution control
compared to untreated WT and Rag2-/-γc-/- control mice, in situ (Left) thymi (1) heart (2),
and isolated with a scale bar (Right). (b) The flow cytometry analysis of the CD4+ and CD8+
single and double positive T cells from these thymi.
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5.4.5 Splenic observations in the reconstituted mice
The Rag2-/-γc-/- mouse has a hypocellular spleen due to a lack of lymphocytic infiltrate,
therefore an increase in splenic mass and cellularity after treatment will be indicative
of a recovered immune system. Spleens were removed from the treated and control
groups of mice. Examples of dissected spleens from the test and control mice
demonstrated an increase in splenic size (Figure 5.10a) and mass (Figure 5.10b) in all
the mice that received donor cells compared to the Rag2-/-γc-/- control. However, the
splenic mass of the IL2RGp-IL2RG treated mice is not significantly greater than the
Rag2-/-γc-/- control.
To assess the proliferative capacity of the engrafted immune cells in response to
stimuli, splenocytes were isolated from the spleens of Rag2-/-γc-/- mice treated with lin-
cells from either WT mice or hγcmut mice, transduced with IL2RGp-IL2RG or SFFVp-
GFP. Untreated WT and Rag2-/-γc-/- control murine splenocytes were also included. The
splenocytes were incubated with cytokines IL-2 or IL-7 with or without Concanavalin A
(ConA) which is a T cell mitogen (Figure 5.10c). The proliferation index, a measure of
proliferation in response to cytokines divided by medium alone, demonstrated that
providing functional IL2RG results in a response to ConA which was increased with the
further addition of IL-2 or IL-7. No proliferative cytokine response was observed in the
SFFVp-GFP or Rag2-/-γc-/- control splenocytes.
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Figure 5.10 Splenic reconstitution.
(a) Examples of spleens dissected from Rag2-/-γc-/- mice treated with WT or IL2RGp-IL2RG ,
SFFVp-IL2RG and SFFVp-GFP transduced hγcmut lin- cells and untreated Rag2-/-γc-/- mice with
a scale bar. (b) The splenic weight of all the treated and control mice are compared in a
scatter plot. (c) Splenocytes from Rag2-/-γc-/- mice treated with WT or IL2RGp-IL2RG and
SFFVp-GFP transduced hγcmut lin- cells and untreated Rag2-/-γc-/- controls at the sample
number indicated (n) were incubated with mitogens IL-2 (20μg/ml) or IL-7 (20μg/ml) with or 
without Concanavalin A (1μg/ml). Proliferation index values above 1 denote splenocyte 
proliferation above that of media alone measured as counts per minute.
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5.4.6 Serum immunoglobulin levels in reconstituted mice
The final analysis performed on the all of the reconstituted mice at sacrifice measured
the immunoglobulin (Ig) levels in the serum as a measure of the functionality of the B
cells (Figure 5.11). It has already been described that mature IgM+ B cells developed in
the mice reconstituted with lin- cells containing a functional IL2RG gene whereas no
IgM+ B cells developed in SFFVp-GFP control mice. To assess whether there was an
increase in Ig types compared to untreated hγcmut mice, serum from these animals 
were also included as a control. From the data it can clearly be seen that all Ig types
were detected at normal WT levels in mice treated with WT lin-  cells and hγcmut lin-
cells treated with either IL2RGp-IL2RG or SFFVp-IL2RG. With the exception of IgG2a,
there was an increase in Ig levels in IL2RG treated mice compared to control and the
increase of the total Ig analysed across the sample conditions revealed that this
increase is significant. Not only does this imply successful B cell development, it also
reveals the presence of functional T helper cells.
Figure 5.11 Serum immunoglobulin levels in reconstituted mice.
Serum immunoglobulin levels in Rag2-/-γc-/- mice treated with WT or IL2RGp-IL2RG, SFFVp-
IL2RG or SFFVp-GFP transduced hγcmut lin- cells and untreated WT, hγcmut and Rag-/-γc-/-
controls were run in triplicate and analysed by ELISA. The data have a normal distribution
according to the Kolmogorov-Smirnov test and analysed by one way analysis of variance with
a Bonferroni post-test (*= P-value<0.05) (**=P-value<0.01).(*** : P=<0.001).
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5.5 Discussion
The hγcmut mouse has the same distribution of CD4+, CD8+, NK and IgM+ B cells as 
the γc-/- mouse. The CD4+ cells are of normal levels as seen in the previous SCID-X1
mouse models (Cao, Shores et al. 1995; DiSanto, Muller et al. 1995; Ohbo, Suda et al.
1996) and are likely to cause the splenomegaly observed in these mice. The
rudimentary thymi and the associated T cell maturation are also common to both the
hγcmut mouse and the γc-/- SCID-X1 mouse.
Although a direct comparison of Ig was not performed with the γc-/- mouse, the similar
distribution of Ig in the hγcmut mouse and the Rag2-/-γc-/- mouse highlights the B cell
deficiency in the new model, contributing to its SCID phenotype.
Concerning the ability to reconstitute a Rag2-/-γc-/- mouse, these data imply that stem
cells from the hγcmut mouse are not able to generate a functional immune system 
without the addition of IL2RG to the genome. However, of the 2 thymi extracted from
the GFP treated control group, one did demonstrate that the stem cells of the hγcmut 
mouse can support the development of a rudimentary thymus as seen in the SCID-X1
models however, the pattern of T cell distribution was unlike that seen in the mice
receiving IL2RG expressing cells. In the other control, the thymus did not have any
CD4+ or CD8+ cells present. Furthermore, neither GFP control mice were able to
generate CD4+ or CD8+ cells to reach normal levels in the peripheral blood, bone
marrow or the spleen. Together with the Ig data, demonstrating no significant
difference between untreated Rag2-/-γc-/- mice and those receiving GFP treated hγcmut 
stem cells, it can be speculated that hγcmut stem cells alone are not able to 
reconstitute a functional immune system. However a greater number of GFP negative
control mice should be included to confirm this finding as significant.
The overall observations from mice receiving hγcmut cells treated with IL2RG
expressing lentiviral vectors clearly demonstrate that this reconstitution strategy was
successful when using both constructs. It is however interesting to note that the
IL2RGp-IL2RG vector appears to be more effective in generating CD8+ cells and the
SFFVp-IL2RG vector better at generating NK cells although normal levels of NK cells
were not achieved in any of the tissues analysed, this is in accordance with a study
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using SIN gammaretroviral vectors expressing IL2RG treated γc-/- progenitor cells to
reconstitute Rag2-/-γc-/-c5-/- mice (Thornhill, Schambach et al. 2008) where NK cells
constituted 1.8% of bone marrow in mice treated with an SFFVp-IL2RG vector, almost
2 fold less than that of normal. It is also important to note that a greater sample
number would be required to determine a significant different between these vectors.
It is of interest that the level of viral transduction was at least 10 fold greater in the
cells treated with the IL2RGp-IL2RG construct compared to SFFVp-IL2RG at 72 hours,
and after 16 weeks of animal maintenance, the copy number of IL2RGp-IL2RG in all
tissues analysed was both lower than the SFFVp-IL2RG copy number and consistent in
each tissue. It is possible that this reduction in IL2RGp-IL2RG transgene was due to a
high degree of mortality as a result of the high transduction rate. Another explanation
could be that the IL2RG promoter was methylated more readily than the SFFV
promoter, leading to the loss of IL2RG gene expression and moderating the survival
advantage provided by γc. The SFFVp-IL2RG transgene however was found at variable
levels in each tissue, the greatest in the blood and the lowest in the bone marrow. This
may be a result of the regulatory elements additional to the EBS included within the
promoter or intronic regions of IL2RG not included in the SFFVp-IL2RG construct.
Alternatively, the divergent copy numbers in different tissues seen in cells treated with
SFFV containing constructs may be due to clonal dominance as a result of activating
growth promoting genes by the SFFV promoter which is capable of far reaching
promoter activity (Ott, Schmidt et al. 2006).
The results from this chapter clearly demonstrate that the hγcmut mouse mirrors the 
phenotype of the γc-/- mouse and like the γc-/- mouse, hγc expression can be restored 
with integrating hIL2RG encoding lentiviral vectors. Importantly, it is also
demonstrated in this chapter that the hIL2RG promoter and regulatory elements are
effective at providing the transcription control of IL2RG in mice which is vital for the
use of this model in gene targeting studies as the mutant human gene, if corrected in
situ, will provide γc capable of reconstituting this SCID-X1 mouse model’s immune 
system.
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6 Correcting the humanised mouse model of SCID-X1 by ZFN mediated
HR
6.1 Aims
 To optimise the efficiency of ZFN gene delivery to lineage negative cells by
nucleofection
 To attempt ZFN mediated targeted HR in stem cells
6.2 Introduction
Having established that the IL2RG ZFN pair is capable of targeting the G691A mutation
and thereby stimulating HR at this target site with extragenous donor, it is possible to
apply this strategy to correct the novel humanised mouse model, hγcmut. This mouse 
model has been confirmed to contain the hIL2RG with the common SCID-X1 mutation
G691A in replace of mil2rg and is immunodeficient. Furthermore, full length hIL2RG
with its corresponding promoter and regulatory elements are capable of restoring γc 
expression as seen by the reconstitution of the immune cells on treatment of lin- bone
marrow cells from these animals with hIL2RG expressing lentiviral vectors.
IL2RG targeting in published work has been limited to the WT gene in human cell lines
K-562 and LCLs (Urnov, Miller et al. 2005; Lombardo, Genovese et al. 2007; Moehle,
Rock et al. 2007). The hγcmut mouse model provides an opportunity to correct mutant 
hIL2RG in situ and to assess the efficiency of ZFN mediated corrected HSC to
repopulate the immune system with fully functional immune cells.
For such a therapeutic strategy to develop, it is necessary to correct lin- HSC in order to
provide the multipotent properties for haematological reconstitution. ZFN mediated
gene targeting has been shown not to disrupt the pluripotent quality of stem cells in
vitro (Soldner, Laganiere et al. 2011; Hoher, Wallace et al. 2012), and ZFN mediated HR
in one cell rat and mouse embryos has resulted in heritable transgene (Cui, Ji et al.
2011), further providing evidence for the efficacy of this method regarding the
correction of stem cells. It is also an important consideration that haematopoietic
progenitors are resting in the G0 phase of the cell cycle (Reems and Torok-Storb 1995)
and HR occurs in the S/G2 phase. To aid cell cycle progression and the conditions for
HR in the this set of experiments, the cytokines used in the reconstitution experiment,
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SCF, mFlt3 and hTPO were included in the medium for the lin- bone marrow cells after
the ZFN and donor constructs were introduced.
An important factor to consider at this juncture is the method of ZFN gene and donor
DNA delivery. As has been shown in this work, integrating lentiviral vector delivery has
proven successful in both the delivery of a transgene to lin- cells and of ZFN genes to
cell lines. However, as the purpose of ZFN mediated gene correction is to avoid the
risks associated with integrating viral vectors and because constitutive ZFN expression
could result in unwanted DSB events, this method of delivery is not included in this
section. Furthermore, the alternative, IDLV ZFN vector did not provide detectable
targeted HR in the ED7R cell line. Considering nucleofection meets the integration
deficient criteria and was proven successful in the delivery of donor DNA and IL2RG
ZFN expression plasmids to the ED7RγcΔ cell line as seen by targeted HR events at the 
IL2RG locus, this chapter explores the use of this method to achieve the correction of
murine stem cells.
6.3 Nucleofection optimisation of lin- bone marrow cells.
To remain consistent with the reconstitution strategy of SCID-X1 mouse models,
nucleofection was optimised for lin- bone marrow cells. However, murine lin- cells are
not included in the primary cell repertoire optimised for nucleofection by Lonza.
Lonza’s technical support advised testing the murine macrophage nucleofection kit, in
addition to this, the human CD34+ cell kit and the murine T cell kit were also included
for optimisation.
Lin- cells were enriched from the bone marrow of the hγcmut mice by MACS, any 
biotin labelled differentiated cells remaining in the selection were analysed by flow
cytometry by staining with Cy5 conjugated streptavidin (Appendix 13). 1x106 of the lin-
enriched bone marrow cells were nucleofected according to the pulse programme
recommended for each kit, with 2μg of the GFP expression vector, pMax GFP or were 
resuspended in the nucleofection solution without a pulse to establish the toxicity of
the solution. The cells were incubated for 72 hours then analysed by flow cytometry
for cell viability, as measured by the resistance to uptake of PI, and GFP expression
(Figure 6.1). Nucleofection with the murine macrophage kit was performed using 3
different pulse programmes and the viability of the cells decreased in all of the pulsed
cells compared to the no pulse control (Figure 6.1a). The greatest cell survival was seen
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using the pulse programme A-023 resulting in GFP expression of 5.65%, however, this
programme resulted in a >2 fold decrease in cell survival compared to no pulse. The
greatest GFP expression observed for this kit was with the pulse programme Y-001
however, this programme also resulted in the most cell death.
The human CD34+ cell nucleofection kit had a greater cell survival compared to the
murine macrophage kit and achieved 4.2% GFP positive cells (Figure 6.1b). The lin-
enriched cells used for this nucleofection included 43% biotin labelled cells (Appendix
13), indicating a poor purity of the MACS selection. The murine T cell nucleofection kit
appeared to have the least toxic nucleofection solution, where 62.1% of the cells
survived compared to 23.2% for the murine macrophage kit and 57.5% for the human
CD34+ cell kit when no pulse was applied (Figure 6.1c). The pulse resulted in a 2.4 fold
reduction in cell survival however the kit did result in the greatest GFP expression at
14% GFP positive cells. However, the lin- cells prepared for this assay contained 53%
biotin labelled differentiated cells.
It is important to consider the purity of the lin- cells used in the nucleofection
optimisation and whether the differentiated cells, such as T cells, were nucleofected at
a greater rate than the lin- cells. To overcome the low level of purity seen in these
experiments it is possible to apply the MACS effluent to a second magnetic column.
This can decrease the yield of lin- cells yet increase the purity.
Considering the overall cell survival and GFP expression across the nucleofection kits
tested, the murine T cell nucleofection kit was used for subsequent gene delivery to
lin- enriched bone marrow. The low rate of GFP+ cells seen in the nucleofected cells
may have been due to loss of expression plasmids as the cells divided over the
extensive incubation time of 72 hours. This incubation time was chosen due to the
high cell morbidity of nucleofection and the personal observation that cell recovery is
enhanced if left to rest for this time in replenished medium.
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Figure 6.1 Optimising nucleofection of murine bone marrow cells.
1x10
6
lin- enriched bone marrow from hgcmut mice was nucleofected with 2μg pMAX GFP 
expression plasmid and analysed by flow cytometry 72 hours post nucleofection for the
viability stain Propidium Iodide (PI) and GFP expression in PI-ve cells. (a) Optimisation of the
macrophage nucleofection kit with the voltage programme indicated. (b) Nucleofection
with the human CD34+ cell kit. (c) Nucleofection with the T cell line kit.
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6.4 ZFN mediated targeted HR in murine stem cells
Having established a nucleofection kit capable of delivering expression plasmids to lin-
enriched bone marrow cells, gene targeting by ZFN was assessed in these cells. A
second source of stem cells was available from the hγcmut mice in the form of a 
murine embryonic stem (mES) cell line established during the development of the
mouse (Appendix 14).
1x106 lin- enriched bone marrow cells, obtained by MACS or 2x106 mES cells were
nucleofected per sample, with the murine T cell and mES nucleofection kit
respectively. Both cell types were nucleofected with a total of 2μg of plasmid of the 
ZFN pair in equal measure, the donor DNA MB17 or the ZFN pair plus the donor DNA at
a ratio of 3:1, a no pulse control was also included for both cell types. The ZFN to
donor DNA ratio of 3:1 was chosen for this assay due to the observation that this ratio
resulted in the most consistent target HR in ED7R cells, observed in chapter 4. The lin-
cells were incubated in StemSpan supplemented with SCF, mFlt3 and hTPO and the
mES cells were incubated in ESGRO.
96 hours post nucleofection the genomic DNA was extracted and analysed by HR
specific PCR (Figure 3.7) for the presence of the MB17 sequence by using primer pairs
1 or 2. A template control was also included whereby the forward and reverse primers
which recognise exons 4 and 7 respectively and bind outside the region of donor DNA
homology were used as a primer pair (primer pair 3) in a further PCR reaction (Figure
6.2a). The PCR did not detect targeted HR in lin- enriched bone marrow cells
nucleofected with the ZFN expression plasmids and donor DNA. The full length IL2RG
expression plasmid containing the MB17 cassette, included as a positive control, did
confirm correct PCR conditions as a faint 1,002bp band was seen for primer pair 1 and
a more intense 969bp band present for primer pair 2. The DNA template for all
conditions was also shown to be suitable by the 1.9kb band amplified by primer pair 3.
Targetted HR was observed in the mES cells when the cells were nucleofected with
both the ZFN pair and donor DNA plasmids as demonstrated by the 1,002bp and 969bp
bands for primer pair 1 and 2 respectively (Figure 6.2b). Again, primer pair 3 confirmed
the presence of DNA template for all the nucleofection conditions, although the faint
band for donor DNA may indicate a lower concentration of this template or the
presence PCR inhibitors.
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Having established the targeted HR events in the mES cells, RFLP analysis by Southern
blot was carried out to determine the rate of HR in the cells treated with ZFN
expression plasmids and donor DNA alongside the nucleofection controls and a
positive control (Figure 6.2c). 100ng of purified template DNA, amplified from the
genomic DNA by primer pair 3 was incubated with either BsrBI to detect the inclusion
of this novel restriction enzyme site by target recombination with the donor plasmid
MB17, or BsrBI and DraIII as a template control. Template prepared from the full
length IL2RG expression plasmid containing the MB17 cassette was included as a
positive control. No inclusion of the BsrBI restriction site was detected by RFLP analysis
in any of the nucleofected samples and the assay conditions were shown to be suitable
by the 78% digestion detected for the BsrBI positive control.
The RFLP analysis has been shown to be sensitive enough to detect HR events when
BsrBI is present in >5% of total DNA template. Therefore it maybe speculated that the
HR events detected by HR specific PCR did not reach the rate necessary for
quantification by RFLP.
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Figure 6.2 Targeted correction of human IL2RG in murine pluripotent cells.
 96 hours after nucleofection with 2μg of ZFN and Donor constructs at a ratio of 3:1 and 
untreated, ZFN or donor DNA constructs alone for control. (a,b) HR specific PCR to detect
the MB17 cassette at the genomic IL2RG locus was carried out with primer pairs 1 and 2.
A full length IL2RG expression construct containing MB17 was included as a PCR control,
A PCR with primer pair 3, designed to recognise exon 4 and 7 was also carried out to
verify the template suitability. (a) 1x106 lin- enriched bone marrow. (b) 2x106 ES. (c) RFLP
analysis of the cells nucleofected with different ratios of ZFN to donor DNA capable of
introducing a BsrBI restriction site at the IL2RG locus alongside BsrBI positive control (+)
and BsrBI+DraIII template control. The numbers below the bands denote the percentage
of the 250bp digestion product of total 500bp DNA template above background,
calculated from the band intensity by ImageJ.
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6.5 Discussion
The observations in this chapter have demonstrated the requirement for further
optimisation of the delivery of ZFN expression vectors and donor DNA to stem cells. It
has been demonstrated that targeted HR is possible in hγcmut mES cells however, in 
order for this correction strategy to progress it is necessary to demonstrate the
correction of primary HSC ex vivo for the subsequent re-infusion of autologous cells.
More stringent methods must be employed to yield a pure fraction of lin- cells. This will
ensure that the gene targeting events do occur in multipotent cells. Another
consideration for gene delivery to lin- cells is the potential loss of mulipotency. It has
been demonstrated that mES cells (Capecchi 2001) and ZFN treated human primary
CD34+ HSC (Holt, Wang et al. 2010) retain pluripotency after nucleofection. However,
it will be advantageous to culture colonies from treated lin- cells to determine their
stem cell properties and to assess the rate of target HR by high throughput
sequencing.
Nucleofection was chosen as the mechanism for gene delivery to murine ES cells in this
chapter and has proven successful for ZFN mediated targeted gene insertion in human
ES cells, human iPS cells (Sebastiano, Maeder et al. 2011; Zou, Sweeney et al. 2011)
and gene disruption in primary human CD34+ cells (Holt, Wang et al. 2010), this
technique is not established for murine lin- cells. In order to achieve an appropriate
rate of gene delivery to these cells, other methods must be identified and optimised.
The potential of other gene delivery methods is overviewed in the final discussion.
The ZFN:Donor DNA ratio that provided the most consistent evidence of targeted HR in
293T cells and ED7R cells was 3:1, as compared to 1:3 and 1:1. The most pronounced
evidence for this observed in the nucleofection of ED7RγcΔ cells where γc+ cells were 
detected 12 days post nucleofection at this ratio in 3 of 4 of the treatment conditions
whereas no evidence of correction was detected in the other ratios. Whether this
method of gene delivery or ratio is optimal for murine lin- cells is yet to be discerned.
Future attempts at gene targeting in primary mouse cells would also benefit from a
titration of ZFN vs Donor vectors as increasing dosage of ZFN can inhibit HR (Connelly,
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Barker et al. 2010; Handel, Gellhaus et al. 2012) and observations from the ED7R cell
line may not be applicable in the murine lin- cells.
The data in this chapter confirms that the IL2RG ZFN are capable of targeted HR in
hγcmut mES cells, thereby confirming the utility of these animals in the future of gene 
targeting therapeutic strategies for SCID-X1. And in addition to the optimisation of the
ZFN:Donor ratio and delivery strategy, future experiments should also compare the
WT, MB1 and MB3 donor constructs designed for IL2RG correction. It is possible to
regenerate multilineage hematopoietic engraftment in mice with mES cells modified to
ectopically express the Homeodomain gene HoxB4 and the Homeobox domain
transcription factor Cdx4 which modulates Hox expression (Wang, Yates et al. 2005).
Therefore it could be possible to utilise this method of regeneration to investigate the
principal that the corrected hγcmut mES cells are capable of reconstituting the 
immune system of an immunodeficient mouse.
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7 Final discussion
In the case of SCID-X1, when a suitably matched donor is not available for a bone
marrow transplant, it is possible to cure the disease by the addition of IL2RG via a
retroviral vector into the genome of the patient’s haematopoietic stem cells. This gene
addition strategy results in integration of IL2RG and its promoter with limited
predictability. This may result in insertional mutagenesis due to off target gene
regulation and gene disruption. An alternative strategy for SCID-X1 treatment is to
correct the gene at the site of the mutation. In situ resolution will permit endogenous
expression and reduce the risk associated with retroviral vector therapy. Gene
correction can be instigated by stimulating HR with a DSB introduced by a ZFN pair.
Previous reports have demonstrated that the ZFN designed to target IL2RG can
mediate targeting of WT IL2RG in K-562 cells and a lymphoblastic cell line. This project
has observed IL2RG ZFN sequence specific activity in additional cell lines, 293T cells,
ED7R cells and mES cells. Furthermore, the IL2RG ZFN pair has been shown to target a
common SCID-X1 mutation. This mutation is included in a humanised mouse model
designed for in situ correction studies and this work has confirmed the SCID-X1 mouse
model to have an immunodeficient phenotype which can be resolved by the addition
of full length human IL2RG with its endogenous promoter to their lin- bone marrow
cells.
This study has shown that the ZFN pair designed to target IL2RG is capable of cleaving
both WT IL2RG and the SCID-X1 mutation hotspot, G691A. Due to the nature of HR and
the potential to convert DNA sequence up to 511bp from the initiation site (Elliott,
Richardson et al. 1998), this IL2RG ZFN pair could, in theory, correct a host of
mutations within this distance from the target providing the mutation does not occur
within the ZFN binding site. Such a mutation is the G691A neighbouring mutation,
C690T, which is also common (Puck, Pepper et al. 1997). It has not yet been
demonstrated whether this ZFN pair can target this mutation and it would be of
interest to investigate whether the IL2RG ZFN is capable of binding and cutting
sequence containing this mutation. A further genome editing strategy could be
employed, regardless of SCID-X1 associated mutation, which would be to introduce the
IL2RG gene at the safe harbour sites CCR5 or AAVS1 using the corresponding ZFN pairs.
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However, the potential to correct the SCID-X1 mutation in situ would have the benefits
of physiological expression and no unforeseen consequences of disruption at the CCR5
and AAVS1 locus would be challenged.
During this study, the detection of HR was limited in the majority of cases to targeted
HR specific PCR which could detect recombination events that remained undetectable
by RFLP and flow cytometry. Unfortunately this method does not provide a means to
quantify the rate of recombination. Furthermore, the PCR product generated by
primer pair 1 and 2 did not result in consistent band intensity. This could be due to the
efficiency of the individual primer pair however, the primer pair generating the band of
greater intensity alternated from the more intense band seen in the 293T cells and
ED7RγcΔ cells to the less intense band observed in mES cells treated with ZFN and or 
Donor. A possible explanation for this is the presence of contaminants in the PCR
reaction that inhibited the efficiency of the reaction. It would be beneficial to
overcome the limitations for sensitive quantification by analysing clones from the
treated cells by high throughput sequencing as not only would this quantify the rate of
correction, it would also identify the mechanism of correction, including unilateral
SDSA or bilateral DSBR mechanism of HR and allow for the comparison with NHEJ
events at the DSB. This may also serve an explanation for the variable primer binding
efficiency for if the unilateral SDSA mechanism of HR was employed, and half of the
primer binding site was recombined, the target site may have been recognised, but at
a decreased efficiency.
The comparison of 4 donor DNA constructs designed to correct the G691A mutation
which differed in sequence from the target site by an increasing number of base pairs
did not confirm the hypothesis that divergent sequence at the site of HR initiation
would inhibit strand invasion. Nor was it shown that the WT donor, with an intact ZFN
target site, would be cleaved by ZFN and therefore unsuitable, as this donor DNA
generated the greatest percentage of corrected ED7RγcΔ cells as observed by flow 
cytometry. However, these data have not been repeated or verified by another form of
quantifiable analysis.
Over the course of this study, targeted HR was demonstrated in 293T cells, ED7RγcΔ 
cells and mES cells. All of these examples are cell lines, which are liable to accrue
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transformation events during extensive periods of cell culture in vitro including mES
cells which can accumulate copy number variations (Liang, Conte et al. 2008) and other
chromosomal abnormalities reviewed by Rebuzzini et al. (Rebuzzini, Neri et al. 2008).
In order for the optimal assessment of gene targeting strategies, the target locus
should be representative of the physiological genome. In this study, the ED7R genome
was shown to contain at least 2 copies of the IL2RG locus which does not represent the
male SCID-X1 patient. Furthermore, the necessary addition of the hIL2RGΔ transgene 
increased the number of ZFN target sites at unknown locations in the genome. These
conditions are not ideal for accurate assessment of ZFN targeting efficiency as multiple
target sites could cause multiple DSB events thereby unnecessarily increasing these
toxic events experienced by the cell. Furthermore, the analysis of gene correction is
hindered by the presence of ZFN targets that will not result in functional protein as a
result of targeted HR. Such an obstacle has been overcome with the development of
the hγcmut mouse which provides a single copy of the ZFN target in male cells and also 
provides a source of mulipotent stem cells.
The long term goal of this project is to correct haematopoietic stem cells from disease
patients ex vivo and return the corrected progenitor cells to re-populate the immune-
system with fully functioning cells.  The humanised hγcmut mouse has been confirmed 
to contain the hIL2RGΔ gene in place of mil2rg and has been characterised as
immunodeficient in this study. Furthermore, an immunodeficient phenotype can be
reversed in lin- cells from these mice following transduction with vectors carrying the
full length hIL2RG with its endogenous promoter. This novel SCID-X1 mouse model will
be a major source of information on whether targeted gene correction strategies for
IL2RG can restore healthy phenotypes. Initial observations pertaining to the IL2RG ZFN
stimulated HR events at the target locus in hγcmut mES cells further support the 
advances that can be made with this model concerning genome editing of IL2RG in
murine stem cells.
An outstanding problem still remains in that no targeted HR has been observed in the
lin- bone marrow cells which model the HSC used in autologous BMT in SCID-X1
patients. This study has begun initial gene delivery strategies in the form of
nucleofection, but poor lin- purity, high cell mortality, low transduction efficiency and
the absence of targeted HR highlight the need for optimisation of this strategy.
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Firstly, the most suitable gene delivery mechanism for lin- cells must be established. As
previously discussed in chapter 6, it is not justified to use integrating proficient
lentiviral vectors. Although nucleofection is a popular method of DNA delivery to mES
cells (Capecchi 2001) a comparative study demonstrated that lipofection achieved a
greater rate of transfection in these cells (Osiak, Radecke et al. 2011). Integrase
deficient viral vectors can also be utilised to deliver ZFN and donor DNA to stem cells
as observed by the targeted gene integration of 6% of human neural stem cells
(Lombardo, Cesana et al. 2011). Adenoviral vector (Ad), Ad5/35, which is naturally non-
integrating, has successfully delivered ZFN to primary T lymphocytes (Perez, Wang et
al. 2008; Lombardo, Cesana et al. 2011) and the CCR5 safe harbour in human
Mesenchymal stromal cells, achieving stable expression of the transgene in 40% of
cells without affecting the plasticity of the cell (Benabdallah, Allard et al. 2010).
However this delivery method has not been directly compared to IDLV.
AAV vectors have been developed by deleting the gene for the rep protein which
mediates HR at the AAVS1 site. An AAV vector was developed to target hepatocytes
and successfully delivered both ZFN and donor DNA to the liver of f9 deficient mice via
I.P. injection resulting in long term targeted correction (Li, Haurigot et al. 2011). An
AAV integration profile was then carried out, revealing genome wide integration
events had occurred in genes claimed not to be oncogenic. This is in contrast to
hepatocellular carcinoma that has been observed in mice due to insertional
mutagenesis caused by the integration of AAV vectors via regions of microhomology
(Li, Haurigot et al. 2011). However, an AAV associated risk of insertional mutagenesis
has not been observed in human cells.
An advantage to using AAV vectors is their ability to recombine with host chromatin.
Two independent studies of the hypoxanthine-guanine phosphoribosyltransferase
locus in the HT1080 cell line estimated targeted HR at a rate of 10-6 for Ad viral vectors,
similar to plasmid DNA (Stephen, Sivanandam et al. 2008) and 10-3 for AAV vectors
(Russell and Hirata 1998). However both vectors have shown a rate of heterologous
integration up to 10 fold more than HR. It has been observed that ZFN mediated DSB
can increase the rate of targeted HR by AAV donor DNA in hES cells up to 15 fold and it
was estimated that background integration occurred at 1 AAV genome per 100 cells
(Asuri, Bartel et al. 2012). Background integration has also been reported in
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approximately 0.04% human CD34+ cells by IDLV (Lombardo, Genovese et al. 2007)
and remains a concern regarding the safety issues surrounding genome modification.
Other limitations of AAV delivery include the inefficiency of multipotent cell
transduction (Liu, Yan et al. 2004) and the high MOI needed to achieve transduction
which can inhibit HR events (Handel, Gellhaus et al. 2012). This can, in part, be
overcome by combining the ZFN pair in one vector (Sollu, Pars et al. 2010) or by
combining the a ZFN and the donor DNA as previously described for IDLV (Lombardo,
Genovese et al. 2007). The benefit of this is the reduced transduction events
experienced by a cell. Possible drawbacks include the possibility of unequal ZFN
expression and in the case of ZFN-Donor constructs, less flexibility in optimising the
most appropriate ratio of ZFN to donor. However, a viral vector could be designed for
clinical use once these conditions are proved optimal.
The problem of background integration of episomal DNA could prove deleterious if
either the ZFN vector is randomly integrated resulting in constitutive ZFN expression or
whether elements of either the ZFN or donor DNA vector were introduced to sites that
could cause insertional mutagenesis. To avoid the risk of ZFN vector integration, it is
possible to deliver ZFN mRNA via nucleofection which has proven effective in gene
insertion at the AAVS1 safe harbour site in human iPS cells (Zou, Sweeney et al. 2011),
this transient expression also avoids the risk of background integration of the ZFN
expression vector in to the host genome which would be deleterious as over
expression of ZFN increases the risk of off target DSB. Another promising method of
transient ZFN delivery which demonstrates a decrease in off-site ZFN activity is by
cellular uptake of the ZFN protein itself which has proven successful in targeted gene
disruption in primary human dermal fibroblasts and CD4+ T cells. This method of
delivery was shown to be comparable to plasmid transfection of ZFN at the CCR5 loci in
HEK293 cells with targeting frequencies of 13% for direct protein and 15% for plasmid
transfection but resulted in fewer events at predicted off target sites (Gaj, Guo et al.
2012).
Although direct application of ZFN protein to cells can result in gene targeting, in order
to achieve HR, donor DNA must be provided. Furthermore, this strategy is optimal
following repeated treatment over 3 days and at hypothermic, 30°C conditions, where
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ZFN activity is increased. This extensive “cold shock” could prove deleterious to
primary cells treated ex vivo. The activity of ZFN at 37°C has been increased by
selecting an obligate heterodimer FokI nuclese pair with the greatest performance at
37°C (Doyon, Vo et al. 2011) and by the development of the more enzymatically active
Sharkey FokI catalytic domain (Guo, Gaj et al. 2010).
To limit the the possible integration of unwanted elements from the donor DNA
construct, it is possible to create plasmid DNA with no bacterial backbone by
generating minicircles whereby the bacterial features of a plasmid are excised by
intramolecular recombination (Chen 2003). These minicircles can be transfected into
cells and could provide the correction template for HR. Another donor DNA design
which avoids the presence of superfluose DNA are single stranded
oligodeoxynucleotides (ssODN). Gene correction via ZFN induced DSB and ssODN
donor DNA has achieved gene conversion in 22-23% of K-562 cells (Chen, Pruett-Miller
et al. 2011). However another study observed unfaithful DNA repair whereby the
ssODN was added between the DSB termini rather than acting as the template for HR
(Radecke, Radecke et al. 2010) thus limiting their use for gene correction strategies. HR
can be enhanced by tethering a dsDNA molecule to a triplex-forming oligonucleotide
(TFO) (Chan, Lin et al. 1999). TFOs form a triplex with dsDNA by forming Hoogsteen
hydrogen bonds with polypurine or polypyramidine tracts in the genome in a sequence
specific manner. These could potentially serve to aid the localisation of donor DNA to a
targeted DSB. Although the TFO site would be outside of the donor DNA homology
region, a potential drawback to this approach could be interference of the TFO with
the formation of the Holliday junction at the DSB site.
Although the focus of this study has been on gene targeting by ZFN, these are not the
only reagent capable of mediating a sequence specific DSB. As breifly mentioned in the
introduction, TALENs are a promising alternative to ZFN and due to their simple
assembly, researchers can construct their own custom TALENs which has aided their
populatrity. TALENs have successfully achieved gene targeting in human ES cell with a
similar rate of efficiency to their ZFN counterparts and a high degree of specificity yet
they are also capable of off target activity (Hockemeyer, Wang et al. 2011). TALENs
have not, as yet, superseded ZFN in IL2RG targeting efficiency (Mussolino, Morbitzer et
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al. 2011). A more recent development for mediating a sequence specific DSB is by
clustered regularly interspaced short pallendromic repeats (CRISPR). CRISPR
technology is based on an RNA directed Cas9 nuclease from Streptococcus pyogenes.
The nuclease guiding sequences in the non-coding RNA can be modified to correspond
to a target gene in eukaryotes with the same specificity as TALENs, as observed for the
EMX1 locus (Cong, Ran et al. 2013). However, constraints due to RNA processing and
stability limit the range of possible targets. The Cas9 nuclease can also be modified to
cut a single strand rather than introduce a DBS, and so called a nickase.
The single stranded nick achieved by nickases can be repaired seamlessly and rarely
results in NHEJ however the with a lower rate of HR (Certo, Ryu et al. 2011). The FokI
nuclease domain of a ZFN or TALEN can also be engineered to become a nickase. In a
direct comparison ZFN ahieved targeted HR at a rate 3-10 fold higher than its
ZFNickase counterpart (Ramirez, Certo et al. 2012).
Considering the progress made in genome engineering, the IL2RG ZFN is the most
efficient reagent for IL2RG targeting so far. This leaves and structure of donor DNA and
the method of delivery currently remaining for optimisation. The safest method of
delivery would, in theory, avoid the end use of any promoter/ enhancer elements, viral
or otherwise, that could randomly integrate at unpredictable sites in the genome.
Circular DNA ensures the donor DNA will not be wholly integrated by DSB end capture
which can occur with linear DNA. The ZFN expression must be well tolerated by the
host cell to allow DSB repair to progress rather than cell death in response to the toxic
nature of DSB. The greatest way to achieve this is by the administration of ZFN protein
itself, thus ensuring transient expression with no risk of ZFN gene integration.
In developing an IL2RG correction strategy the method and dosage of reagent delivery
must be optimised. In the face of the challenges involved in gene targeting it is
important to note that different cells respond differently to DSB, resulting in variable
rates of DNA repair and it would be advisable to use the most relevant source of cell
for optimisation. As the purpose of developing such a multifaceted gene therapy
strategy is to improve the safety of gene manipulation it is also necessary to monitor
off target integration of the delivery vectors and employ a method that minimises
these events. Off target IL2RG ZFN activity has been observed in K-562 cells (Gabriel,
Lombardo et al. 2011). However, it is important to consider the state of the chromatin
profile and therefore the accessibility of sequence specific endonucleases to their
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target sequences which may differ between a human derived cell line and primary
human multipotent cells. A limitation of the hγcmut murine model, due to their 
murine genome, is the prediction of off target integration and DSB activity that may
occur as result of targeted gene correction treatment in humans. Therefore it would be
beneficial to monitor off site activity in human haematopoietic progenitor cells. An
additional measure of the safety of this strategy could include transformation assays
adapted from those used to assess retroviral gene insertion (Modlich, Bohne et al.
2006) to help predict whether ZFN/Donor constructs are potentially oncogenic. Proof
of safety combined with efficient targeted HR will make ZFN mediated gene correction
a viable therapy strategy for the future.
In addition to the efficiency of ZFN mediated HR and the safety profile of this reagent,
additional features learnt from the retroviral treatment of SCID-X1 must be
considered.
The clinical trials of SCID-X1 with retroviral vectors inluded the ex vivo treatment of
HSC over 4 days to stimulate the progression of the cell cycle in order to achieve
gammaretroviral transduction (Cavazzana-Calvo 2000; Gaspar, Parsley et al. 2004). Due
to the nature of HR which occures in the S/G2 phase of the cell cycle, it will be
necessary to stimulate cell cycle progression during the ex vivo treatment of the cells
for targeted correction by HR. Although detectable HR events did not occure in the lin-
cells stimulated with SCF, mFlt3 and hTPO, this may have been due to the gene
delivery technique yet optimisation of cell cycle progression for HR should be
considered in future HSC correction strategies. A drawback in promoting stem cell
progression is the relationship seen between lineage committed cells and the rate of
cycling where cells in the S/G2 and M phase of the cell cycle are often committed
progenitors (Gothot, Pyatt et al. 1997).
Another observation made in a clinical trial for the treatment of SCID-X1 is the age at
which gene therapy will prove effective at regenerating a functional immune system. 2
patients aged 15 and 20 years old underwent retroviral gene therapy with the same
protocol for the infants in the SCID-X1 therapy clinical trials however the T cell
compartment remained lymphopenic (Thrasher, Hacein-Bey-Abina et al. 2005). This
was likely to be due to the inability to regenerate a functional thymus as has been seen
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in adult mice which were unable to reverse the disturbed architecture of the thymic
tissue that had developed without the appropriate signalling by thymocytes (van Ewijk,
Hollander et al. 2000). It is therefore of great importance that long-term SCID-X1
therapy is administered as soon as viably possible after diagnosis and this includes
gene correction strategies.
Even though the rate of HR stimulated by ZFN remains lower than gene addition
mediated by retroviral transduction, with advances in stem cell therapy, a small
number of stem cells can theoretically repopulate the missing popultaions on immune
cells as seen in the T cell progenitor revertent which repopulated the T cells of a SCID-
X1 patient (Stephan, Wahn et al. 1996). Considering the survival advantage confered
by γc expression by corrected cells in a SCID-X1 patient, ZFN mediated correction of 
stem cells holds great potential for this disease. Once the correction of IL2RG in human
multipotent haematopoetic stem cells has been optimised with a diminished
associated risk confirmed, the gene correction strategy for SCID-X1 will be a suitable
candidate for therapy.
This project has continued the assessment of IL2RG ZFN and has confirmed their
cleavage of a SCID-X1 associated mutation. A SCID-X1 mouse model has also been
described which is suitable for ZFN mediated correction of IL2RG and will provide a
platform for the assessment of ZFN treatment of primary stem cells and subsequent in
vivo studies necessary to confirm the suitability of in situ correction of IL2RG for use in
clinical trials.
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9 Appendices
Appendix 1: Full length IL2RG expression vectors. Top, IL2RG in a plasmid expression vector
deigned by W. Qasim (WQ) incorporating the IL2RG promoter region isolated by S. Thornhill (ST).
Bottom, the IL2RG in reverse orientation in a lentiviral packaging vector. The donor DNA homology
arms are marked on the lentiviral vector to demonstrate their position in regards to the
endogenous gene.
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Appendix 2: Expression vectors representing either ZFN, EA or KV. The ZFN gene was cloned
from a plasmid expression vector (Top) in to a Self-inactivating lentiviral packaging vector
(SINLV) (Bottom). The ZFN expression plasmid was digested with restriction enzymes ApaI and
XhoI and the ZFN fragment isolated and purified. Corresponding sticky ends were generated by
linearising the lentiviral backbone with BspeI and XbaI. The ZFN containing insert was ligated
into the lentiviral backbone and confirmed by a restriction enzyme digest and DNA sequencing.
On ligation of the insert the BspeI site is lost and the XbaI site remains, as shown.
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Appendix 3: Representative Donor DNA constructs. (Top) The 1531bp homology domain
for WT IL2RG was amplified by PCR and ligated into pJET1.2 by blunt-end ligation The
MB1, MB3 and MB17 donor DNA cassettes were subsequently cloned to replace the ZFN
binding domain. The MB17 donor DNA variant was cloned into a self-inactivating
lentiviral packaging vector (SINLV) (Bottom). The 1531bp homology domain with the
MB1 cassette was digested from the pJet1.2 plasmid with restriction enzymes ClaI and
HpaII and the donor DNA fragment isolated and purified. Complementary sticky ends
were generated by digesting the lentiviral backbone with ClaI (ClaI has compatible sticky
ends with HpaII) followed by dephosphorylation. The donor DNA insert was ligated into
the lentiviral backbone and confirmed by a restriction enzyme digest and DNA
sequencing. On ligation of the insert the HpaII site on the insert is lost and the ClaI site
remains, as shown.
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Appendix 4: The episomal GFP knockdown assay. 293T cells were transfected with
IL2RG-GFP expression plasmids (top) alongside ZFN expression or CMV control
plasmids. GFP expression was analysed by flow cytometry. (bottom) The MFI and
Geometric mean (Geom mean) of GFP on live cells is shown by a histogram for ZFN
pair treated (L+R), CMV promoter control and untransfected (U).
198
Appendix 5. Construction of the long and short MB17 donor DNA plasmids. (a) the linker
PCR strategy. (b) the first round of PCR, using primers designed to make short, 470 and
548bp and long, 642 and 919bp product. pMK-IL2RG WQ was used for template Non
template controls were included for each primer pair, as indicated. (c) the second round
of PCR was carried out to combine the short and long PCR products from (b) resulting in
1018bp and long 1561bp MB17 donor DNA cassettes. (d) The 1018bp Long and 1561bp
Short PCR bands were purified by gel extraction and cloned into pJet. Plasmid DNA was
extracted from clones 1-5 and digested with BglII (Cut) which cleaves on either site of the
pJet multiple cloning site. Uncut (UC) was included for control.
199
Appendix 6: Western blot to detect ZFN protein production in the Sp6 rabbit reticulate
lysate assay. Left (L) and right (R) ZFN expression plasmids were incubated with Rabbit
reticulate. A no plasmid control (C) was also included. The lysate was run on an SDS page
gel, the protein bands were then transferred to a membrane and Anti-HA antibody,
conjugated to HRP, was applied to the membrane at a 1:1000 dilution in 5% milk powder,
0.1% Tween in PBS, to detect the HA tag on the 40KDa ZFN protein.
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Appendix 7: Sequencing results of the site directed mutagenesis. Chromatographs (A-
G) of the G691A point mutation and the surrounding DNA sequence from 7 plasmid
samples isolated from 7 E. Coli clones as a result of site directed mutagenesis
compared to the wild type (WT) sequence (Top).
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Appendix 8: Copy number Southern blot hybridisation accompanying gel. Genomic
DNA was extracted from the cell lines indicated and was digested with restriction
enzyme as indicated alongside plasmid control DNA. Digestion fragments were
separated on a 0.8% agarose gel by gel electrophoresis at 20V for 24 hours and
ethidium bromide intercalation was visualised by UV light.
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Appendix 9: Flow cytometry analysis of γc correction by nucleofection at 96 hours. 
2x10
6
 ED7RγcΔ was nucleofected with 2μg of plasmid at different ZFN:Donor DNA 
ratios. Or 1.5μg of ZFN or donor DNA constructs. 2μg GFP expression plasmid was 
used instead of ZFN or donor DNA plasmid for negative control (0). Cells were stained
for γc expression, acquired by flow cytometry and gated on PI-ve live cells. 
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Appendix 10: Detection of pSTAT5 without IL-2 stimulation. ED7RγcΔ nucleofected with 
ZFN expression plasmids and donor DNA at a 3:1 ratio were cell sorted as either γc+ or γc- 
by FACS. Cells were starved overnight to prevent STAT5 phosphorylation and the cells
were analysed for intracellular pSTAT5 without IL-2 stimulation by flow cytometry
analysis.
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Appendix 11: Self inactivating lentiviral (SINLV) expression vector. Top, an enhanced GFP
(eGFP) gene with an Spleen Focus Forming Virus (SFFV) promoter. Bottom, IL2RG cDNA
with SFFV promoter (SF gc). Excerpt from the Thesis of Suzy Bailey.
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Appendix 12: The thymus and associated T cells of a control Rag2-/-γc-/- mouse
treated with hγcmut lin- cells treated with the integrating lentiviral vector SFFV-GFP.  
Left, the thymus in situ. Middle, the isolated thymus with a scale bar. Right, the CD4+
and CD8+ immune cell populations analysed by flow cytometry.
206
Appendix 13: The purity of lin- cells enriched from the bone marrow of hγcmut 
mice in preparation for the nucleofection indicated. Murine bone marrow was
stained with biotin labelled antibodies directed against differentiated blood cell
markers and captured on a magnetic column by magnetic activated cell separation
(MACS). The non-magnetic effluent was stained with Cy5-conjugated streptavidin to
assess the contaminating, biotin labelled cells. Flow cytometry analysis of the
stained cells compared to unstained was carried out for the cells prepared for
nucleofection for the kits indicated.
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Appendix 14: An mES embryoid body from the hγcmut mouse mES cell line. Alkaline
phosphatase staining in blue.
